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RESUMO 
 
De acordo com a organização mundial de saúde, muitas pessoas em todo mundo sofrem de 
doenças mentais e psicológicas, incluindo depressão e esquizofrenia. O tratamento destas 
doenças muitas vezes é auxiliado pelo uso de antidepressivos e antipsicóticos. Em 2009, houve 
um aumento de 52% no uso deste tipo de fármacos psicotrópicos. Devido ao aumento do seu 
uso e o seu envolvimento em situações de intoxicações e suicídio, a sua detecção em amostras 
biológicas torna-se cada vez mais uma necessidade. Assim o desenvolvimento de uma 
metodologia analítica para a identificação e quantificação de fármacos psicotrópicos 
(citalopram, clozapina e haloperidol) em plasma e pêlo foi o principal objectivo deste trabalho. 
As amostras de plasma foram processadas com metanol por precipitação de proteínas e as 
amostras de pêlo foram incubadas com metanol a 45 °C, seguindo-se um passo de limpeza com 
extração fase sólida. Todas as amostras foram analisadas por cromatografia líquida acoplada a 
espectrometria de massa sequencial (LC-MS/MS) em modo MRM1 com um tempo analitico de 9 
minutos. 
Para garantir a fiabilidade dos resultados analíticos foram definidos parâmetros de validação 
para este método: selectividade, limites de detecção e quantificação, linearidade, 
arrastamento2, precisão intermédia, repetibilidade, exactidão, recuperação e efeito matriz. 
O método provou ser selectivo para todos os compostos, com um limite de quantificação de 
0,012; 0,014 e 0,015 pmol/μL para o citalopram, clozapine e haloperidol, respectivamente. 
Também a linearidade do método foi demonstrada para os intervalos: 0,05 a 5 pmol/μl para o 
haloperidol; 0,05 a 3 pmol/μl para o citalopram e 0,05 a 2 pmol/μl para a clozapina, com 
coeficientes determinação (R2) maiores do que 0,998 para todos os compostos. Os limites de 
quantificação foram: 0,037; 0,044 e 0,045 pmol/μL para o citalopram, clozapina e haloperidol, 
respectivamente. 
A precisão intermédia do método apresentou alguns valores altos, 13,7-31,3 %. Contudo na 
exactidão e repetibilidade, os resultados obtidos encontram-se dentro dos critérios 
estabelecidos. 
                                                          
1
 Do inglês, Multiple Reaction Monitoring 
2
 Do inglês, carry-over 
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Na recuperação do método, a diferentes níveis de concentração, os valores obtidos para o 
plasma foram de 68,9 a 115,5% e para o pêlo de 8,9 a 45,5%.  
Em relação ao efeito de matriz foram obtidos valores negativos para o plasma, indicando 
supressão iónica. E para o pêlo foram obtidos valores positivos, indicando um aumento do sinal 
da substância analisada. 
O método desenvolvido foi aplicado em amostras de plasma e pêlo que foram recolhidas de 
ratinhos (5 réplicas independentes por dia) que foram submetidos a um tratamento com 
fármacos psicotrópicos (citalopram, clozapina e haloperidol) por diferentes períodos de tempo: 
1, 2, 4, 8, 15 e 30 dias. A análise da evolução temporal da quantificação dos três compostos no 
pêlo revela um aumento na concentração ao longo dos dias com um aumento acentuado no dia 
15. A evolução temporal da quantificação do citalopram, clozapina e haloperidol para o plasma 
foi diferente para cada composto, com um pico máximo no dia 8, dias 1 e 2 e dias 4 e 8 para o 
citalopram, clozapina e haloperidol, respectivamente. 
 
Palavras-chave: fármacos psicotrópicos; plasma; pêlo; LC-MS/MS; quantificação; validação. 
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ABSTRACT 
 
According to World Health Organization, many people worldwide have mental and psychosocial 
disabilities, including depression and schizophrenia. The treatment of these diseases is 
performed with the use of antidepressants and antipsychotics. In 2009 there was a 52% increase 
in the use of these types of psychotropic drugs. Due to their increased use and their involvement 
in intoxications and suicide, the ability to reliably detect this class of drugs in biological 
specimens is a necessity. Thus, the development of an analytical methodology for the 
identification and quantification of psychotropic drugs (citalopram, clozapine and haloperidol) in 
biological fluids (plasma and hair) was the main goal of this project. 
The plasma samples were processed with methanol, by protein precipitation and the hair 
samples were incubated overnight with methanol at 45 °C followed by solid phase extraction. All 
samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 
MRM mode and with a running time of 9min. 
To guarantee reliability in the analytical results validation different parameters were defined for 
this method: were define for this method: selectivity, limits of detection and quantification, 
linearity, carry-over, intermediate precision, repeatability, accuracy, recovery and matrix effects. 
The method proved to be selective for all compounds with limit of detection of 0.012, 0.014 and 
0.015 pmol/μL for citalopram, clozapine and haloperidol, respectively. 
Linearity was demonstrated for the intervals: 0.05 to 5 pmol/μl for haloperidol, 0.05 to 3 
pmol/μl for citalopram and 0.05 to 2 pmol/μl for clozapine, with determination coefficients (R2) 
higher than 0.998 for all compounds. The limits of quantification were: 0.037, 0.044 and 0.045 
pmol/μL for citalopram, clozapine and haloperidol, respectively. 
The intermediate precision of the method presented some high values (13.7 to 31.3 %). 
However, for the accuracy and repeatability the results obtained are within the established 
criteria. 
In the recovery of the method, at different concentration levels, the values obtained for plasma 
were 68.9 to 115.5% and for hair were 8.9 to 45.5%.  
In the matrix effects were obtained negatives values for plasma, indicating ion suppression. And 
for hair were obtained positive values, indicating enhancement of the analyte.  
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The developed method was applied in plasma and hair samples that were collected from mice (5 
independent replicates per day) that were submitted to a treatment with psychotropic drugs 
(citalopram, clozapine and haloperidol) for different periods of time: 1, 2, 4, 8, 15 and 30 days. 
The analysis of the time evolution of the quantification for the three compounds in hair reveals 
an increase in the concentration over the days with a marked increase on day 15. In the time 
evolution of the quantification in plasma for the citalopram, clozapine and haloperidol, it was 
different for each compound, with a maximum peak on days 8, 1-2 and 4-8, for citalopram, 
clozapine and haloperidol, respectively. 
 
Keywords: psychotropic drugs; plasma; hair; LC-MS/MS; quantification; validation. 
 
 
 
CONTENTS| v 
 
CONTENTS 
 
RESUMO ................................................................................................................................. I 
ABSTRACT ............................................................................................................................. III 
ABBREVIATIONS .................................................................................................................. IX 
1. JUSTIFICATION OF THE THEME ...................................................................................... 1 
2. INTRODUCTION ............................................................................................................. 5 
2.1. PSYCHOTROPIC DRUG .................................................................................................................. 5 
2.1.1. ANTIDEPRESSANTS ........................................................................................................... 7 
2.1.1.1. SELECTIVE SEROTONIN REUPTAKE INHIBITORS .................................................................... 7 
2.1.2. ANTIPSYCHOTICS ............................................................................................................. 9 
2.1.2.1. FIRST-GENERATION ANTIPSYCHOTICS ................................................................................ 9 
2.1.2.2. SECOND-GENERATION ANTIPSYCHOTICS .......................................................................... 10 
2.2. DRUGS INTOXICATION ............................................................................................................... 12 
2.2.1. MANNER OF DEATH BY THE USE OF DRUGS ......................................................................... 14 
2.2.1.1. INTOXICATIONS BY PSYCHOTROPIC DRUGS ....................................................................... 15 
2.3. BIOLOGICAL MATRICES ............................................................................................................... 18 
2.3.1. PLASMA ...................................................................................................................... 19 
2.3.2. HAIR .......................................................................................................................... 20 
3. ANALYTICAL METHODOLOGIES FOR PSYCHOTROPIC DRUG ANALYSIS ........................ 25 
3.1. ANALYTICAL METHODOLOGIES FOR SAMPLE PREPARATION ................................................................ 25 
3.1.1. SAMPLE PREPARATION OF PLASMA .................................................................................... 26 
3.1.1.1. PROTEIN PRECIPITATION ............................................................................................. 26 
3.1.2. SAMPLE PREPARATION OF HAIR ........................................................................................ 26 
3.2. LIQUID CHROMATOGRAPHY COUPLED TO MASS SPECTROMETRY (LC-MS) .............................................. 28 
3.2.1. LIQUID CHROMATOGRAPHY .............................................................................................. 29 
3.2.2. MASS SPECTROMETRY .................................................................................................... 32 
3.2.2.1. MODES OF IONIZATION ............................................................................................... 33 
3.2.2.2. QUADRUPOLE ANALYZER ............................................................................................. 35 
3.2.2.3. MULTIPLE REACTION MONITORING (MRM) .................................................................... 38 
3.2.2.4. ISOTOPIC ABUNDANCES .............................................................................................. 39 
3.3. ANALYTICAL METHOD VALIDATION ................................................................................................ 40 
vi |CONTENTS 
 
4. MATERIALS AND METHODS ......................................................................................... 43 
4.1. EQUIPMENTS ........................................................................................................................... 43 
4.2. MATERIAL ............................................................................................................................... 43 
4.3. STANDARDS AND REAGENTS ........................................................................................................ 44 
4.4. ANIMAL PROTOCOL ................................................................................................................... 44 
4.4.1. ANIMALS AND DRUG ADMINISTRATION ............................................................................... 44 
4.4.2. PLASMA AND HAIR COLLECTION ........................................................................................ 45 
4.5. METHOD DEVELOPMENT ............................................................................................................ 45 
4.6. INSTRUMENTAL CONDITIONS ....................................................................................................... 46 
4.6.1. LIQUID CHROMATOGRAPHY .............................................................................................. 46 
4.6.2. MASS SPECTROMETRY ..................................................................................................... 47 
4.7. EXTRACTION PROCEDURE FOR PLASMA SAMPLES ............................................................................. 48 
4.7.1. PROTEIN PRECIPITATION .................................................................................................. 48 
4.8. EXTRACTION PROCEDURE FOR HAIR SAMPLES ................................................................................. 48 
4.8.1. DECONTAMINATION AND SEPARATION OF DRUGS FROM THE HAIR MATRIX ................................... 48 
4.8.1.1. OMIX TIP C18 CLEAN UP ........................................................................................... 48 
4.9. ANALYTICAL METHOD VALIDATION ............................................................................................... 49 
4.9.1. SELECTIVITY .................................................................................................................. 50 
4.9.2. LINEARITY .................................................................................................................... 51 
4.9.2.1. MANDEL TEST ........................................................................................................... 52 
4.9.3. WORKING RANGE ........................................................................................................... 54 
4.9.3.1. WEIGHTED LEAST SQUARES LINEAR REGRESSION ............................................................... 55 
4.9.4. LIMITS: LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION .................................................. 57 
4.9.5. PRECISION .................................................................................................................... 58 
4.9.6. ACCURACY.................................................................................................................... 60 
4.9.7. CARRY-OVER ................................................................................................................ 60 
4.9.8. RECOVERY .................................................................................................................... 61 
4.9.9. MATRIX EFFECTS ............................................................................................................ 62 
4.10. APPLICATION OF THE ANALYTICAL METHOD DEVELOPED IN REAL SAMPLES ............................................... 64 
5. RESULTS AND DISCUSSION .......................................................................................... 69 
5.1. METHOD DEVELOPMENT ............................................................................................................. 69 
5.1.1. ISOTOPIC IDENTIFICATION ................................................................................................ 75 
5.2. COMPOUND IDENTIFICATION ....................................................................................................... 77 
5.3. ANALYTICAL METHOD VALIDATION ............................................................................................... 78 
5.3.1. SELECTIVITY .................................................................................................................. 78 
5.3.2. LINEARITY .................................................................................................................... 84 
CONTENTS| vii 
 
5.3.2.1. MANDEL TEST .......................................................................................................... 86 
5.3.3. WORKING RANGE .......................................................................................................... 87 
5.3.3.1. WEIGHTED LEAST SQUARES LINEAR REGRESSION ............................................................... 88 
5.3.4. LIMITS: LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION .................................................. 91 
5.3.5. PRECISION AND ACCURACY .............................................................................................. 92 
5.3.6. CARRY-OVER ................................................................................................................ 93 
5.3.7. RECOVERY ................................................................................................................... 94 
5.3.8. MATRIX EFFECTS ........................................................................................................... 96 
5.4. APPLICATION OF THE DEVELOPED ANALYTICAL METHOD IN REAL SAMPLES .............................................. 98 
6. CONCLUSION AND FUTURE PERSPECTIVES ................................................................ 111 
7. REFERENCES .............................................................................................................. 115 
8. APPENDIX .................................................................................................................. 125 
 
 
 
 
ABBREVIATIONS| ix 
 
ABBREVIATIONS 
  
ACN Acetonitrile 
ANOVA Analysis of variance 
CE Collision Energy 
     Estimated concentration in the sample 
CID Collision Induced Dissociation 
CNS Central Nervous System 
CUR Curtain Gas 
CV Coefficient of Variation 
CXP Collision Cell Exit Potential 
DC Direct Current 
DP Declustering Potential 
EMA European Medicines Agency 
EP Entrance Potential 
ESI Electrospray Ionization 
eV Electronvolt 
FA Formic Acid 
Fcrit tabulated F value 
Fcal calculated F value 
FDA Food and Drug Administration 
FGAs First-generation antipsychotics 
HPLC High-performance liquid chromatography 
IS Internal standard 
ISO International Organization for Standardization 
IUPAC International Union of Pure and Applied Chemistry 
LC Liquid Chromatography 
LC-MS Liquid Chromatography - Mass Spectrometry 
LC-MS/MS Liquid Chromatography - Tandem Mass Spectrometry 
LLE Liquid–liquid extraction 
LOD Limit Of Detection 
LOQ Limit Of Quantification 
m/z Mass-to-Charge ratio 
x |ABBREVIATIONS 
 
MAOIs Monoamine oxidase inhibitors 
MeOH Methanol 
ME Matrix Effects 
MRM Multiple Reaction Monitoring 
MS Mass Spectrometry 
MS/MS Tandem Mass Spectrometry 
PD Psychotropic drugs 
PP Protein precipitation 
Q1 First Quadrupole 
q2 Second Quadrupole (Collision Cell) 
Q3 Third Quadrupole 
QCs Quality Controls 
R Coefficient of correlation 
R2 Coefficient of determination 
RF Radiofrequency 
∆RTratio Retention time ratio 
RT Retention Time 
SGAs Second-generation antipsychotics 
S/N Signal to noise 
SPE Solid-phase extraction 
SSRIs Selective serotonin reuptake inhibitors 
S2 Variance 
Sy/x Standard error of the linear regression 
Sb Standard deviation the y-intercept 
TCAs Tricyclic antidepressants 
   Weighting Factor 
WADA World Anti-Doping Agency 
        Sum of the relative errors 
 
  
 
 
 
 
 
 
JUSTIFICATION OF THE THEME| 1 
 
1. JUSTIFICATION OF THE THEME 
 
 
According to World Health Organization, many people worldwide have mental and psychosocial 
disabilities, including depression and schizophrenia [1]. Mental disorders are on the rise in the 
European Union. It is estimated that, about 11% of the population has experienced mental 
disorders [2]. Portugal is the European country with the highest prevalence of mental illness in 
population, according to the first National Epidemiological Study of Mental Health  [3]. Last year, 
one in five Portuguese suffered from a psychiatric illness (23%) and almost half (43%) already 
had one of these disorders during life [3]. 
Depression is already the most prevalent health problem in many European Union-Member 
States [2] and suicide is very associated with mental illness. Almost one million people die due to 
suicide every year [1]. Also Schizophrenia is placed among the top causes of disability due to 
health‐related conditions in all countries [1,2]. 
The treatment of these diseases is performed with the use of antidepressants and 
antipsychotics. In 2009 there was a 52% increase in the use of psychotropic drugs (PD), 
especially antidepressants and antipsychotics. An analysis of the total market for medicines, 
made by the National Epidemiological Study of Mental Health, revealed that drugs belonging to 
the therapeutic group central nervous system (CNS) therapeutic constitute the second group 
with more weight on spending, with particularly weight of PD, including antipsychotics and 
antidepressants [3]. 
The increased use of antidepressants and antipsychotics may be due to many reasons, such as 
prevalence of psychotic disorders, increased duration of treatment, drug accessibility, expansion 
of approved indications for second-generation antipsychotics [3]. The relation between 
substance abuse and psychiatric disorders is a matter of great concern, both conditions are 
reportedly linked to increased suicide risk [4]. 
The pharmacological and toxicological information obtained from the drug distribution in tissues 
and cells is important for understanding and predicting both drug reaction and toxicity [5]. 
Analysis of these drugs could be also necessary in forensic cases such as driving under the 
influence of drugs, cases of violent crimes, cases of drug-facilitated sexual assault and cases of 
unknown cause of death [6]. 
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Determining the presence of various drugs in samples is an important facet of forensic science 
[7]. Liquid Chromatography - Mass Spectrometry (LC–MS) has established itself as the clear 
leader in the quantification of psychotropic drugs in biological samples, such as plasma and hair 
[5]. The pharmacologic effects of most drugs have a direct correlation with their concentrations 
in plasma, fact that serves as a basis for therapeutic drug monitoring [8,9]. Therefore the plasma 
is preferred for quantitative analysis when interpretation of concentrations and effects are 
required [8]. However, hair has become an important matrix for drug analysis, complementing 
other specimens like blood [10], since it provides evidence of longer term exposure of drugs and 
can provide important information as to the time course of drug use [8,11]. Also, it can be used 
in cases of extreme putrefaction of the body and when there is no longer any matrix available 
[11]. 
Whereby stated above, intervention is necessary in terms of therapeutic drug monitoring. Only 
this way unnecessary consumption associated with therapy can be reduced. Moreover, 
detection of these drugs in these biological samples is necessary to establish their use and 
possible contribution to the cause of death. So its detection may be relevant in different 
situations, presenting indisputable forensic interest. 
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2. INTRODUCTION 
2.1. PSYCHOTROPIC DRUG 
 
Many prescription drugs are widely available today, more developed and marketed every year. 
Each has the potential for adverse effects and many of them may cause death by overdose [12]. 
A drug must act on a site of action that is physiologically relevant to the effect. The activation or 
inhibition of that specific site is termed the drug’s mechanism of action. A given drug may affect 
one or more sites over its clinically relevant dosing range and may produce multiple and 
different clinical effects [13]. 
The PD are compounds that affect the functioning of the mind through pharmacological action 
on the CNS, by other words they have effects on psychological function [7,12]. This category of 
drugs is widespread in today’s society and include both prescribed psychiatric medications and 
illegal narcotics [7]. It can be divided in four main psychotropic drug categories: antidepressants, 
antipsychotics, anxiolytics, antiepileptics [7,14]. 
Due to their abuse potential and their involvement in intoxications and suicides [15], the PD 
have rapidly gained importance in both clinical and forensic setting [16,17], which makes the 
ability to reliably detect this class in human biological specimens a necessity [16]. In a clinical 
environment, the analysis of PD in blood (and/or plasma) is necessary in order to monitor 
patient compliance and to maintain drug concentrations within the recommended therapeutic 
range of the respective drug [16]. On the other hand, in a forensic setting, the detection of PD is 
crucial in determining whether these drugs played a role in the cause of death [16]. 
The pharmacological treatment of schizophrenia is often performed with the simultaneous use 
of two or more psychotropic agents to achieve the desired control of psychotic symptoms [5,17]. 
They are also prescribed to use in the treatment of depression [17].  
Most PD are similar in chemical properties such as high lipophilicity, relative molecular weight 
between 200 and 500 and basicity [18]. In the following pages the main physicochemical 
characteristics of the compounds that will be studied in this project will be presented (Table 2.1) 
along with some aspects associated to the mechanism of action, adverse effects and 
pharmacokinetics properties. 
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2.1.1. ANTIDEPRESSANTS 
 
The antidepressants are currently among the most frequently prescribed therapeutic agents in 
medicine [12-14], mainly because of their efficacy and good profile of side effects [14]. This type 
of drug is a therapeutic indicator for the treatment of depression, anxiety disorders, including 
obsessive-compulsive disorder, bulimia nervosa and psychosomatic disorders [14].  
Despite advances in research there is no full explanation of the proper functioning of 
antidepressants [19]. But it is known that these drugs act on depressive illness through the 
action on various neurotransmitter systems: serotonine, noradrenaline and dopamine. They 
produce an increase in the concentration of neurotransmitters in the synaptic gap by inhibiting 
the metabolism, blocking reuptake of neuronal activity or in the action on presynaptic receptors 
[19]. 
The newer antidepressants are much less toxic, safer and more tolerable than the tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) [12,20], but may still be 
involved in overdose deaths, particularly when combined with other drugs [12]. 
Antidepressants can be classified according to the chemical structure or pharmacological action. 
Because the new-generation antidepressants do not share common structures, the 
pharmacological action is currently more used [19]. In past years, TCAs and MAOIs were the 
most commonly used antidepressants [12,14], however the selective serotonin reuptake 
inhibitors (SSRIs) have emerged as a major therapeutic advance in psychopharmacology [13].  
 
2.1.1.1. SELECTIVE SEROTONIN REUPTAKE INHIBITORS 
 
The SSRIs were all developed to have a similar mechanism of action: block the serotonin 
reuptake. The inhibition of the serotonin reuptake carrier raises the level of this 
neurotransmitter in the synapse [13,14,21,22], enhancing serotonin neurotransmission, which 
results in their antidepressant effects [21]. 
Serotonin binds to serotonin receptors located in the central and peripheral nervous system and 
affects various functions such as: sleep, pain perception, blood vessel regulation, anxiety, mood, 
and depression. The SSRIs have lower binding affinities for other neurotransmitter receptors (for 
example dopaminergic receptors), providing another reason to be considered better tolerated 
than TCAs and MAOIs [22]. 
8 |INTRODUCTION 
 
Although they have a common mechanism of action in this class, each SSRI has a slightly 
different pharmacologic profile that leads to its distinct clinical activity, side effects and drug 
interactions [19-21].  
After oral administration, SSRIs are well-absorbed, suffer less effect of first-pass metabolism and 
bind strongly to plasma proteins. SSRIs are metabolized primarily by the liver and their 
metabolites are mainly eliminated in the urine [19,22]. 
Overall, the most frequently reported side effects are gastrointestinal (nausea, vomiting, 
abdominal pain, diarrhea), psychiatric (agitation, anxiety, insomnia, mania, nervousness), sleep 
disturbances, fatigue, loss or weight gain, sexual dysfunction and skin reactions [19,21,22]. In 
general, SSRIs have milder adverse effects than older antidepressants, and their adverse effects 
are often dose related [22]. 
 
 
CITALOPRAM 
 
Citalopram (consult Table 2.1) is a selective and potent serotonin reuptake inhibitor that is used 
for the treatment of depression [23] and offers an efficient alternative treatment of depression 
to the TCAs [24]. 
The main metabolite of citalopram, measurable in plasma, is N-desmethylcitalopram, which is 
also an SSRI [13,25]. However, the pharmacological activity of the metabolite is weaker when 
compared to the parent drug [13,25].  
As for other lipophilic drugs, the absorption of citalopram from the gastrointestinal tract is 
almost complete [13,24,25]. The first pass effect of citalopram seems to be of minor importance, 
since it has an absolute bioavailability of about 80%. [13,25]. As only 50% of the dose is excreted 
in urine, a significant fecal elimination is suggested [25], with the peak plasma concentrations 
being reached after 2–4 hours [24].   
A linear relationship between citalopram dosage and plasma concentration has been reported, 
but the interindividual variability increases with dose, which might be due to saturation of an 
elimination pathway [13]. 
Citalopram, has been associated with low rates of insomnia, anxiety, and other activating side 
effects. Nausea is the most common early side effect [21] and it was also associated with weight 
gain [19]. 
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2.1.2. ANTIPSYCHOTICS 
 
Since their introduction, antipsychotic drugs are medications that have been extensively 
prescribed and are the primary intervention for the stabilization of acute psychotic episodes, 
including schizophrenia, bipolar disorder, mania and depression [14,26-28]. Some of these drugs 
are also used for the palliative treatment of some movement disorders [14]. 
Dopamine has a central role in excitement, motivation, attention, the extrapyramidal motor 
system and other pathways. Although the exact etiology is uncertain, dopamine dysregulation 
plays a role in a number of symptoms. In psychosis, its overactivity leads to excessive 
information throughput, resulting in hallucinations and delusions [29]. Since the antipsychotic 
block dopamine D2 receptors [30], they help to correct this overactivity and improve the 
symptoms [29]. 
Two primary classes referred in the literature are the typical and atypical antipsychotics. The 
term atypical originated from the idea that these medications reduce the risk of extrapyramidal 
side effects. Most recently the classification of these medications has been changed based on 
pharmacology. The terms first-generation antipsychotics (FGAs) and second-generation 
antipsychotics (SGAs) have replaced the terms “typical” and “atypical” [18]. 
The different groups of antipsychotic drugs have slightly different pharmacological profiles, 
however all of them block the dopamine D2 receptor with different degrees [18,31]. 
 
2.1.2.1. FIRST-GENERATION ANTIPSYCHOTICS 
 
The first-generation antipsychotics, include the commonly used butyrophenones (such as 
droperidol and haloperidol) and phenothiazines (such as chlorpromazine, promethazine and 
thioridazine) [30]. 
Their clinical efficacy is strongly correlated with their binding affinities for the receptor subtype 
[32]. These FGAs were categorized based on their affinity for the dopamine D2 receptor as low 
potency, such as chlorpromazine, or high potency, such as haloperidol [30]. So, the blocking of 
dopamine is responsible for the therapeutic effect, with reduction of delusions and 
hallucinations [14,32-35]. 
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The FGAs are well absorbed orally, have great solubility, easily cross the blood-brain barrier and 
also the placental barrier. They show a great affinity for plasma proteins (85-90%), which 
involves risk of toxicity when other drugs that also bind to proteins are available in the plasma 
simultaneously [14]. Due to their lipophilic properties, antipsychotic are stored in the peripheral 
fat. FGAs drugs are metabolized in the liver, being removed primarily by urine and feces, through 
bile, but also by the saliva, tears, sweat, and breast milk. The elimination half-life varies between 
18-40 hours [14]. 
 
 
HALOPERIDOL 
 
Haloperidol is a butyrophenone (consult Table 2.1)and is the most used drug for the 
symptomatic management of psychotic disorders [36]. 
After oral administration, haloperidol has significant first-pass metabolism in the liver, 
decreasing oral bioavailability. There is wide inter individual variation in plasma concentrations, 
so no strong correlation between plasma concentration and therapeutic effect has been found. 
It was reported to have half-lives between 12 and 38 hours after oral administration. Also 92% of 
this drug is bound to plasma proteins and is widely distributed throughout the body, including 
breast milk [37]. 
 
 
2.1.2.2. SECOND-GENERATION ANTIPSYCHOTICS 
 
The SGAs drugs introduced in recent years, besides being dopamine receptor antagonists 
[27,32], comprise a more heterogeneous pharmacological profile involving actions on multiple 
neurotransmitter systems [32,33]. The difference between these and the FGA medications is the 
specificity of the dopamine antagonism at recommended dosages and also the serotonin activity 
[35]. These agents functionally antagonize dopamine (D2) receptors and antagonize serotonin 
(5-HT2A) receptors [35]. When compared to phenothiazines and butyrophenones, SGAs  have a 
greater binding affinity for the 5-HT2 receptors than for D2 receptors [38]. 
They are defined clinically as having minimal or no extrapyramidal symptoms at clinically 
appropriate doses [30]. Moreover, over the past decade, they have become the treatment of 
choice for schizophrenia in many countries, due to the perception of a more favourable 
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tolerability profile, thus raising major hopes of superior effects in a number of areas such as 
compliance, cognitive functioning, movement disorders, and quality of life [27].  
In the case of an overdose, these drugs produce a range of manifestations that affect multiple 
organ systems. The most serious toxicity involves the cardiovascular system and the CNS, with 
the most common cardiovascular effects being tachycardia and mild hypotension. [30]. 
 
CLOZAPINE 
Clozapine is a dibenzodiazepine derivative (consult Table 2.1) that was the first of the atypical 
antipsychotics to be developed [24,30]. 
Properties of clozapine are due to the combination of a low affinity for the D2 receptors along 
with strong affinity to serotonergic, adrenergic and cholinergic receptors. This property is 
present in many SGAs, so these drugs cause fewer movement disorders as side effects [14]. 
This drug is efficient in treating the delusions, hallucinations, and disorganization of 
schizophrenic patients. It has also been demonstrated that clozapine can improve the negative 
symptoms of schizophrenia, such as lack of emotion [30,39]. It has been shown to have other 
clinical advantages over FGAs drugs, most notably the ability to improve some aspects of the 
cognitive dysfunction of schizophrenia, such as attention, verbal fluency (semantic memory) and 
recall [39]. 
Clozapine is rapidly and completely absorbed with the peak serum concentration occurring 
1h30–2h30 after a single dose [38] and its main metabolite is desmethylclozapine [40]. 
The most common adverse effects include orthostatic hypotension, gastrointestinal symptoms, 
and sedation. Seizures may be observed in higher therapeutic doses and in overdose [30].  
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2.2. DRUGS INTOXICATION 
 
In many countries, intoxication with therapeutic substances exceeds deaths from other types of 
toxic agents, especially in suicidal and accidental intoxications. Overprescribing or the supply of 
large a quantities of drugs at one time allows excessive stocks of drugs to be easily available to 
the public [41]. 
Deliberate and accidental cases of self-poisoning with psychiatric drugs have become a major 
medical problem because of their widespread use and the severity of their toxic actions. This 
fact has led to the development of reliable analytical methods for their analysis [17]. The 
analysis of these drugs could be also necessary in forensic cases such as driving under the 
influence of drugs, cases of violent crime, cases of drug-facilitated sexual assault and cases of 
unknown cause of death [6].  
Since forensic science is often concerned with determining the basis of death, investigations are 
frequently concerned with the influence and effects of toxins. Results of the laboratory 
procedures must be interpreted and are often used as evidence in legal cases [7]. Thus, the 
detection of drugs in biological samples is very important and useful in ante-mortem and post-
mortem toxicology. Ante-mortem forensic toxicology implies an understanding of drug before 
the death and the interpretation of result [42]. While, post-mortem forensic toxicology involves 
analyzing body fluids and organs from death cases and interpreting that information [43].  
These toxicological studies are now recognized as an integral part of the proper investigation 
and evaluation of most medical examiner cases [44]. In sudden unexpected and/or unexplained 
deaths toxicology studies are useful and necessary for the final decision regarding the cause and 
manner of death [43]. For example, in many cases, the drug or toxic agent is the direct cause of 
death, such as by overdose, or may explain the actions of the deceased leading to his death [44]. 
Also, it is important to investigate a crime scene in order to provide to the toxicology laboratory 
an idea of what substances might be present in the body, guiding the research and adapting the 
methodology used for their detection[12]. 
Intoxication can be understood as the set of disorders that derive from the presence of a 
substance in the body. There are two forms of intoxication according to the early-onset, severity 
and symptomatology, which is usually related to the absorption speed of compounds [45]. Acute 
intoxication is due to short-term exposures, with rapid absorption of compound. Concerns a 
single dose or multiple doses, but for a brief period, which may be at approximately 24 hours 
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and the clinical manifestations of poisoning are fast [45]. On the other hand, chronic intoxication 
is due to a repeated exposure to the compound, during a long period of time. The mechanism 
may occur due to the following causes: first, the compound accumulates in the body as the 
elimination rate is less than the absorption. Secondly, effects generated by exposures are added 
[45]. 
It is important to clarify that there is a difference between drug, poison and toxic substance. A 
drug is a substance or composition, characterized by having properties, that is used to treat or 
prevent a disease or to treat symptoms of a disease or injury [45,46]. Poison is a substance  that 
has an inherent ability to produce adverse effects on the body, whether it is an illness, injury, or 
death [45,46]. While toxic is any chemical agent that after entering the body, change 
biochemical elements essential to life [45]. However, it is important to keep in mind that any 
substance can be harmful and produce balance disorders in the biological cell. Only the amount 
and time over which the substance is administered will allow to determine how harmful it will be 
[7,45,46].  
Thus, the main issue of the toxicity of a compound is its dose [7,45], which makes it necessary to 
introduce some concepts related to levels of drug ingested. Therapeutic levels are the steady 
state concentrations that need to be reached for the drug to exert a significant clinical benefit 
without causing unacceptable side effects [47]. So the use of the word therapeutic implies a 
concentration at which a useful response is obtained free from any toxicity [48].  And toxic levels 
are concentrations above which unacceptable (concentration dependent) side or toxic effects 
might appear. [47]. However, if a concentration is in the fatal range then it is capable of causing 
death [48].  
In the Table 2.2 are the Therapeutic, Toxic and Lethal Concentrations for each drug that is 
subject of the study in this project. The drugs that are used for the treatment of psychiatric 
illness can be misused (for suicide attempts, as an example), so it is important that the physician 
balances the benefit of pharmacotherapy against the risk of drug overdose. 
So, it can be said that another common applications of post-mortem toxicology data is its use to 
define therapeutic, toxic and fatal doses for drugs. This is useful when establishing a possible 
role of a drug in a case [48]. 
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Table 2.2- Toxic concentrations, Lethal concentrations and recommended therapeutic range for 
psychotropic drugs [47]. 
Psychotropic drug 
Therapeutic Concentration 
(mg/L) 
Toxic Concentration 
(mg/L) 
Lethal Concentration 
(mg/L) 
Citalopram 
1
 0.02-0.2 _ 0.5 
Clozapine 
2
 0.1-0.6 0.8-1.3 3 
Haloperidol 
2
 0.005- 0.015 0.05-0.1 0.5 
1
 Matrice: plasma 
2
 Matrice: serum 
 
Control of dosage is the basis of almost all safety assessment in the use of chemicals [49]. There 
are drugs that are difficult to define safe and toxic concentrations in the post-mortem setting 
[48]. Because, although dosage and time are the main factors determining whether or not a 
particular substance will produce a given effect, there are other factors that influence response, 
including route of exposure, species and individual differences, sex, age, nutrition, and disease 
[49]. 
 
2.2.1. MANNER OF DEATH BY THE USE OF DRUGS 
 
The manner of death is the category that describes the circumstances that led to infliction of the 
cause of death [7]. Cases related to therapeutic drugs can involve a variety of special 
considerations [12]. It can be divided in natural or violent, where the first one involves disease or 
can be due to the effects of a drug, considered also natural deaths [7,12]. The second one is 
subdivided in accidental, homicidal, or suicidal. In other words involve some form of physical 
trauma [7]. 
Accidental intoxications is the most common type of intoxications and can result from several 
circumstances [45]. It can occur in a casual way despite the right indication, dose and route of 
administration. In other situations, it results from self-medication, lack of knowledge about side 
effects of drugs and possible actions resulting from simultaneous administration with other 
drugs [45]. It can also be caused by mistakes in the administration of the drug, like medication 
error or dosing error [12,45]. On the other hand, it may result from an automated action, which 
occurs in chronic treatments. For example, when an individual, by negligence, takes an amount 
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of the drug prescribed higher than the normal, leading to overdosing [45]. Drug intoxication 
occurring in children, are mostly accidental, depending on circumstances such as the attractive 
appearance and accessibility of drug [12,45]. Another example is the recreational use of drugs, 
where in most cases a death intoxication due to acute toxic effects of the drug is considered as 
an accident [12]. 
The voluntary drug intoxication is the most common method of attempted suicide in developed 
countries [45]. In fact, according to several studies, suicide by drug intoxication is more common 
in women than in men [45]. To be considered that a death by intoxication is a suicide, it requires 
evidence which indicates that the individual purposefully ended his/her life [12]. In these cases 
elevated levels of drugs (that are not typically used for recreational abuse purpose), or the 
presence of massive amounts of drugs are found within the stomach [12]. 
Homicidal poisonings are relatively rare, mainly due to the difficulties in their administration 
without the victim's knowledge [12,45]. However, in cases where the main goal is to diminish 
the strength of the victim in order to commit the crime itself, like sexual assault on liberty or 
property crimes, this usage turns to be very common [45]. 
 
 
2.2.1.1. INTOXICATIONS BY PSYCHOTROPIC DRUGS 
 
One of the most commonly used methods of self-injury worldwide is drug overdose [50].  A 
study was made to compare the Suicidal overdoses of PD between younger and adults in New 
York City, whose suicide was determined by the Office of the Medical Examiner to be the result 
of intentional poisoning or overdose from 1990 through 2006. It was demonstrated that victims 
of suicidal overdose aged 18–59 had significantly higher rates of death contributed by 
antidepressants, where female overdose victims had significantly higher rates. Here it can be 
concluded that antidepressants do not always prevent suicide and that some classes of 
antidepressants can cause or contribute to overdose death [51]. 
Fatalities have also been reported at therapeutic concentrations of the second-generation 
antipsychotic drugs, and as they are increasingly prescribed even among adolescents, they may 
play a significant role in many intoxications even though they are considered relatively safe [15]. 
According to the Annual Report of the American Association of Poison Control Centers, the 
antidepressants and antipsychotics are referred as the substances most frequently involved in 
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human exposures. The AP are the second and the antidepressants are the third Categories with 
largest numbers of deaths [52]. 
Also, in Portugal, the national institute of medical emergency (INEM) did a statistical analysis 
with incoming calls due to intoxications cases from 2011. It was concluded that in Portugal, the 
antidepressants and antipsychotics drugs are the second and third groups of drugs responsible 
for intoxication in adults (Table 2.3) [53]. 
 
Table 2.3- Intoxication in adults by drug groups in Portugal [53]. 
Drug group Number of cases Observed cases (%) 
Anxiolytics 2542 38.3 
Antidepressants 1092 16.5 
Antipsychotics 763 11.5 
NSAIDs
1
 552 8.3 
Antiepileptic 528 7.8 
Paracetamol 493 7.4 
ACE inhibitor
2
 436 6.6 
Beta blockers 239 3.6 
1
 Non-Steroidal Anti-Inflammatory; 
2
 Agents inhibitor - angiotensin-converting-enzyme inhibitor;
 
 
Another conclusion that can be drawn from the data, available on the website, is that 
intoxications are most frequent in females and the age ranges that have more prevalence is 40-
49 years. 
Finally, the leading cause of death in adults is intentional (corresponding to 43% of the 
intoxications) and accidental in children (corresponding to 83% of the intoxication), for the 
reasons which have been previously discussed. And the second cause is accidental in adults and 
therapeutic error in children (Table 2.4). 
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Table 2.4- Characterization of poisoning in adult and child [53]. 
Manner of death Adult (%) Child (%) 
Accidental 37.2 83.3 
Unknown 0.44 0.16 
Therapeutic error 
1
 16.3 11.5 
Intentional 42.7 4.47 
Professional 2.22 0.1 
Adverse reaction 1.11 0.46 
1 
Therapeutic error: refers to error (the dose or time of administration) in taking the 
prescribed medication 
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2.3. BIOLOGICAL MATRICES 
 
A drug may be detected in any body fluid or tissue with which it has been in contact. The 
primary choice of biological specimen for drug analysis depends on several issues: purpose of 
the sampling, time interval to study, ease of sampling, cost of sample preparation and analysis, 
drug concentrations in the sample, and drug stability [54]. 
Specimens available in post-mortem toxicology investigations can be numerous and variable. 
Generally, the specimens routinely collected at autopsy include fluids such as blood from 
peripheral sites and heart blood, urine, bile, cerebrospinal fluid, vitreous humor, gastric contents 
and organ tissues, particularly liver [55]. In addition to these, a variety of biological specimens 
are analyzed in forensic science [10]. Each biological matrix has advantages and disadvantages 
(Table 2.5) and may also be selected based on requests, legal aspects and availability in a given 
case [9,55].  
 
Table 2.5- Some advantages and disadvantages for different biological matrices. Adapted from [54]. 
 Blood Oral fluid Urine Hair 
Maximum drug detection period 
1
 1-2 days 1-2 days 2-4 days 3-6 months 
Intrusive sampling yes No Yes No 
Adulteration potential None Low High Medium 
3
 
Possibility for environmental contamination No No No Yes 
Potential for negative results after drug use Low Medium Low Medium to high 
On-site screening possible No Yes Yes No 
Analytical costs 
2
 Medium Medium Medium High 
1
 Approximate detection times after intake of a single dose varying from one substance to another; 
2 
Including confirmation testing; 
3
 Hair colouring and bleaching. 
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Of course one of the most important points to choose the biological matrix is the knowledge 
about the stability of analytes in biological material. This is crucial to ensure the reliability of 
analytical results, since there are gaps between sample collection, transport to the laboratory 
and the time of analysis [9]. 
Blood and urine are the most common specimens used for the analysis of drugs of abuse in post-
mortem cases [10,11].  But if a probable death by overdose or intoxication is identified, 
additional questions may arise such as the route of administration, a long-term or an exclusively 
recent use/exposure to a drug or poison. In these cases, additional and alternative specimens 
such as hair, nails or skin samples may be needed [55]. 
 
2.3.1. PLASMA 
 
Urine is the sample of choice for non-target comprehensive screening and for identification of 
unknown drugs. However, blood, plasma, or serum sometimes must be used for at least a 
limited screening especially for target analytes within multi-analyte procedures [56]. 
When plasma samples are used, care must be taken, for example, with anticoagulants because it 
can cause interference with some drugs and assay systems. However, in the absence of such 
effects, there are no clinically significant differences between serum and plasma, and either may 
be used [57]. Pharmacokinetic factors such as dose, volumes of distribution, and elimination 
half-life are also important when laboratory aspects of clinical toxicology are being considered. 
For example, if the volume of distribution is lower, the amount of drug available in the 
peripheral plasma for testing purposes is larger [57].  
Plasma is traditionally used in clinical settings because blood affords advanced handling in the 
laboratory procedures [55]. In vivo, the physiological effects of most drugs are directly 
correlated with their concentrations in blood, plasma and serum, a fact that serves as the basis 
for therapeutic drug monitoring [8,9].  
Drug concentrations provided in literature are usually determined from these fluids. And this is 
important since analytical results obtained from post-mortem blood are compared valuably with 
levels previously reported in therapeutic and toxic conditions [55]. Therefore, these matrices are 
preferred for quantitative analysis when interpretation of concentrations and effects are 
required [8,9]. 
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Multi-analyte procedures for screening and quantification of drugs in blood, plasma, or serum 
are relevant tools in these fields because they allow the analysis of several important 
compounds with a single sample extract injection, thus saving time and resources [56]. 
 
 
2.3.2. HAIR 
 
In the last decade, alternative or unconventional matrices have becoming more important in the 
field of toxicology, mainly because the advantages when compared with ‘conventional’ samples 
used in laboratorial routine analysis [58]. Urine and saliva sampling is non-invasive and has been 
widely used because of ease of collection, however the main disadvantage of these specimens is 
the short window of detection [10]. 
In recent years, remarkable advances in sensitive analytical techniques have enabled the analysis 
of drugs in unconventional samples such as hair [59]. This alternative matrix offers more several 
advantages like non-invasive collection, and good stability during storage at room temperature 
and transport conditions [54,58,60]. However, the most important advantage of hair analysis 
compared with other human matrices is the much larger detection window [58,61] (weeks to 
months, depending on the length of the hair shaft, against 2–4 days for most matrices), which 
allows the retrospective detection of chronic exposure to drugs up to years back [58,60,61]. 
In fact, hair grows at approximately 1 cm per month, and it is possible to associate the drug 
distribution pattern in the analyzed segments with a period in the past [58,62]. Segments of 
single hair may be downsized to 1 mm length if hair concentration and detection limits provide 
so [62]. 
The precise mechanisms involved in the incorporation of drugs into hair remain unclear 
requiring further investigation [63]. However, there are various incorporation models that are 
suggested for the incorporation of drugs (Figure 2.1).  
Beside the physiological characteristics of the individual, dose and time of intake, hair melanine, 
lipophilicity, chemical structure of drug content plays an important role for the interindividual 
variation of drug incorporation into the hair matrix [55,63-65].  
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Figure 2.1- Incorporation and elimination mechanisms of drugs in hair. The main mechanism 
that is typically assumed is the one where the drug enters in the hair by passive diffusion from 
blood capillaries. Besides incorporation from blood, drugs can be incorporated, with some time 
delay, from deep skin compartments during hair shaft formation. The other mechanism that is 
suggested and widely accepted is deposition by diffusion from sweat or sebum secretions into 
the completed hair shaft. The substances can also be deposited from the external environment, 
like pollution, smoke and dirty hands. However some losses may occur due to the use of hair 
cosmetics and ultraviolet radiation. Adapted from [63]. 
 
 
However, the hair analysis has some disadvantages, like low concentrations of some compounds 
and metabolites, and limited amount of sample supplied for testing [58]. And the most 
important disadvantage is the fact that substances can be deposited from the external 
contamination (Figure 2.1) [58,63]. So, if adequate measures are not taken, the risk of reporting 
false positive results increases, which is unacceptable, especially when there are legal 
implications of drug consumption. Therefore, to minimize this effect it is strongly recommended 
that hair analysis procedures include a washing step [58]. 
Hair analysis is becoming a routine practice in forensic toxicology laboratories [58,61].  Until 
now, most applications of hair testing have focused on forensic considerations [66], mainly for 
the detection of illicit drugs owing back to long-term drug consumption [61,64]. However, 
another exciting application of hair analysis is in the clinical cases, because hair analysis 
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complements blood and urine analyses by providing long-term information on an individual’s 
drug use [61,64-66]. 
In addition to the above applications, the hair drug analysis is employed in a wide range of 
situations, such as workplace drug testing, driving ability probation, doping control, chronic drug 
abuse intoxication, clarify cause of death, or discover drug use (violence, rape, prison cases, and 
social cases)[60,67]. In these cases, rapid and secure screening methods are therefore very 
important [67]. A drug screening in hair can also contribute to the identification of unknown 
corpses. In such cases, a systematic toxicological analysis, that means the general search for 
toxic substances in the hair sample, should be performed [61]. 
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3. ANALYTICAL METHODOLOGIES FOR PSYCHOTROPIC DRUG 
ANALYSIS 
 
 
3.1. ANALYTICAL METHODOLOGIES FOR SAMPLE PREPARATION 
 
The presence of interfering compounds in complex matrices is a challenge to accomplish reliable 
results [42,68]. Therefore, the main objective of sample preparation is to convert a real 
biological matrix into a form suitable for analysis by the desired analytical technique [69]. 
The pre-treatment of samples to separate drugs and metabolites from the matrices prior the 
analysis aims to reduce matrix effects via removal of potential interferences [70,71]. This is a 
fundamental part of the quantitative bioanalysis and is usually the most critical and time-
consuming step when using chromatography or affinity techniques for drug analysis in biological 
matrices [42,68,72]. 
The first aim of sample preparation is the removal of potential interferences such as proteins 
and lipids [69,71,72]. In chromatography, proteins increase the baseline, cause noise, and may 
even ruin chromatographic columns [69,71,72]. The presence of interferences can also influence 
the ionization efficiency in the mass spectrometers, may block the ion source and contribute to 
ion suppression for mass spectrometry (MS) assays [69,71-73].  
The second aim of sample preparation is to increase the concentration of analytes to achieve 
adequate signal intensities. The simplest form of enrichment is drying the sample and 
reconstituting it in a smaller solvent volume [69]. The enrichment is usually performed by 
extraction methods, protein precipitation (PP), liquid–liquid extraction (LLE), and solid-phase 
extraction (SPE) [68-70]. Each of these methods has advantages as well as disadvantages [68]. 
The optimum choice of one is specific for the respective analyte but also for the individual 
MS/MS system [71]. 
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3.1.1. SAMPLE PREPARATION OF PLASMA  
3.1.1.1. PROTEIN PRECIPITATION 
A simple work-up method for blood, plasma or serum samples is PP [80]. Probably this is the 
simplest way to separate proteins from small molecules in biological fluids [69] and it is clearly 
an attractive sample preparation technique because it’s fast and has a good recovery of polar 
analytes compared with some SPE and LLE procedures [70]. This technique may be used for 
‘cleaner’ matrices such as serum or plasma [16]. However, the precipitated proteins may bind 
various small molecules and remove them from the solution. This may influence quantification, 
which has to be taken into account [69]. 
The theoretical basis of PP is the interaction between the reagent and the protein (directly or 
indirectly) [73]. Either an organic solvent (typically acetonitrile, methanol or ethanol) or an acid 
(typically trichloroacetic acid or perchloric acid) is added to a sample to denature the proteins 
[68,69,71]. However, precipitation with miscible organic solvents is the most commonly used for 
plasma sample preparation method because of its low cost and minimal method development 
requirements [74]. 
The procedure generally begins with the addition of an internal standard (IS). Then a volume of 
protein precipitation reagent equal to three or four times the sample volume is added to each 
biological sample [68,73]. The mixture is agitated to increase the aggregation speed of the 
proteins. The supernatant, which contains the analyte, is then separated from the protein 
aggregate after centrifugation [69,71,73]. Protein precipitation may be performed alone or in 
conjunction with another extraction technique [68]. However, this technique does not allow 
concentration of the analytes; instead, typically a dilution of at least 1:2 is obtained [71].  
This method is applicable to a range of LC-MS methods relevant to toxicology [70,73] because it 
provides sufficient clean-up for most LC–MS analyses [74]. 
 
3.1.2. SAMPLE PREPARATION OF HAIR  
There is always the possibility that a drug in hair does not originate from consumption but has 
been incorporated from external sources [66]. And of course, contaminants of hair would be a 
problem if they were drugs of abuse and if they interfered with the analysis and interpretation 
of the test results [75].  
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Thus basically, cleaning the hair sample of external contamination is necessary for two reasons. 
First, residues of hair products (wax, shampoo, hair sprays) as well as sweat, sebum and dust 
typically present on hair lead to increased analytical noise/background. Second, drugs could 
adhere from the environment of the individual and potentially contribute to incorrect test 
results [63]. To minimize this effect it is strongly recommended that hair analysis procedures 
include a washing step [54,58]. This can, however, affect the extraction efficiencies of 
incorporated drugs and must be considered when interpreting quantitative results [54]. 
Although, basic and lipophilic drugs are well incorporated into hair and less susceptible to wash-
out effects [62]. 
One of the prerequisites of solvents used for hair decontamination is that this should remove 
external impurities as completely as possible, but not extract drugs from the hair matrix 
[63].There is no general consensus with respect to the hair washing procedure. For example, one 
washing sequence for post-mortem hair samples is composed of 0.1% sodium dodecylsulfate in 
water, distilled water and acetone. Another procedure that is very used includes one or two 
washes with dichloromethane [63,75]. Non-protic solvents such as dichloromethane or acetone 
are advantageous because they do not swell the hair thereby extracting materials from the hair 
[63].  
Another step prior to extraction is the cut of the hair typically between 1–3 mm lengths. 
Alternatively, hair may be processed by grinding. However, this latter approach generally results 
in loss of sample material and does not improve the extraction process [63].  
There are currently no direct methods for the detection of drugs in the hair matrix. Extractions 
with methanol, extraction by aqueous acids or buffer solutions, digestion of the hair with 
aqueous Sodium hydroxide are examples of extraction procedures that are more used 
[54,63,75]. 
The extraction yield depends on the drug’s structure, the state of the hair matrix, polarity of the 
solvent, duration and manner of extraction [66]. More precisely, in order to make the 
appropriate choice, the chemical structure of the drug and its sensitivity to agents used for 
sample preparation must be considered [63]. 
Clean-up methods used for this purpose are similar to those used in drug isolation from plasma 
or urine. Although procedures for liquid–liquid as well as solid phase extraction have been 
described, the latter method is normally used [63].  In this project the clean up of the hair 
samples was performed using OMIX Tip C18. This pipette tip contains a small bed of 
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functionalized monolithic sorbent (C18) and it can work as a miniaturized solid phase extraction 
bed for hydrophobic compounds clean up prior to MS. 
 
 
3.2. LIQUID CHROMATOGRAPHY COUPLED TO MASS SPECTROMETRY 
(LC-MS) 
 
Medical examiners determine the cause and manner of death, frequently requiring analysis of 
fluids and tissues for the presence of drugs and metabolites. In current practice, most medical 
examiner laboratories screen fluids using immunoassays. Despite being sensitive and capable of 
high specimen throughput, the matrix effects and substances similar in structure to analytes of 
interest often cause false positive results [76]. For this reason it is important that specimens with 
positive immunoassay results are confirmed by chromatographic methods [7,76]. 
Over the last twenty years there has been a growing interest in the development of 
methodologies for qualitative and quantitative analysis of several drugs in post-mortem matrices 
[42]. Liquid chromatography coupled to mass spectrometry is increasingly being used in clinical 
and forensic toxicology for the identification and quantification of a wide range of compounds in 
biological samples [60,67] and is often the method of choice because the sensitivity, selectivity 
and the relatively high throughput that can be achieved [77]. With this technique, the 
determination of multiple groups of compounds can be performed in a single method [60]. 
Usually it is used for compounds that are not volatile and are not suitable for gas 
chromatography [78]. Some of the advantages of this technique include easier sample 
preparation, derivatization procedures are avoided, and short analysis time [60,67].  
Because, the chromatography separation is not sufficient to allow unequivocal identification, 
further information is usually required from an auxiliary technique [79]. This can be achieve with 
the combination of high performance liquid chromatography (HPLC) with mass spectrometry 
that allows more definitive identification and the quantitative determination of compounds, that 
have similar retention characteristics but a different mass spectra  [79]. Mass spectrometer 
provides not only structural information from the molecule under investigation but it may also 
provide the molecular weight of the analyte [79]. 
Tandem mass spectrometry (MS/MS) in combination with Liquid chromatography (LC) now 
dominates the analytical field, providing a particularly convenient tool in the analysis of PD [16]. 
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Recent advances in this technology enabled the detection and quantification of these drugs 
present in biological matrices in exceptionally low concentrations [16,72]. The basic information 
of the procedures normally used for quantification of PD drugs by LC-MS in plasma and hair is 
summarized in Table 3.1 and Table 3.2, respectively. 
 
 
3.2.1. LIQUID CHROMATOGRAPHY 
 
In  liquid chromatography, the substances are separated based on differential solubilities in the 
mobile liquid and stationary solid phases, with identification based on retention times within a 
column [76]. The time required for an analyte to elute from a chromatographic column with a 
particular mobile phase is termed its retention time (RT) [79]. This interaction may be due to 
different  physical properties and one that is considered is the relative polarities of the species 
involved [79-81].  
High-performance liquid chromatography (HPLC) is the term used to describe LC in which the 
liquid mobile phase is mechanically pumped through a column that contains the stationary 
phase [82]. Thus, in an HPLC system, a liquid sample (or a solid sample dissolved in a suitable 
solvent) is introduced into a column which contains two immiscible phases: the stationary phase 
(contained in a column) and the liquid mobile phase (which flows through the column) 
[80,81,83]. 
The interaction of the analyte with the stationary phase may be adsorption, partition, size 
exclusion, affinity, and ion exchange [82]. In adsorption chromatography the solute molecules 
are in contact with both the stationary phase and the mobile phase, simultaneously [79-81,84]. 
When the analytes interact with the stationary phase, the polar solutes will be retained longest 
by polar stationary phases, and nonpolar solutes will be retained best by nonpolar stationary 
phases [82,84].  
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The widely used chromatographic mode to separate several classes of compounds, based on 
their hydrophobicity, is reversed-phase chromatography [79,80,84]. Here, the stationary phase is 
less polar than the mobile phase [69,79,80], the interaction between analyte and the stationary 
phase has a predominantly hydrophobic (apolar) character [69]. Thus, the more polar analytes 
elute more rapidly than the less polar ones [79,80] and a decrease in the polarity of the mobile 
phase results in a decrease in solute retention [82]. Reversed-phase chromatography typically 
refers to the use of chemically bonded stationary phases, such silica-based alkyl (C4, C8, C18), 
[69,79,80,84]. 
The mobile phases used in reversed-phase chromatography are mostly polar solvents such as 
water, acetonitrile, methanol, and isopropanol [69,82,84]. In LC-MS certain chemicals (ionic 
modifier) are often added to the mobile phase to influence analyte ionization. Small organic 
acids like formic and acetic acid are among the most commonly used additives. They improve 
ionization and resolution of a wide range of molecules [80]. 
The RT can be controlled by changing polarity of the mobile phase. For example, increasing the 
polarity of the mobile phase leads to longer retention times, whereas shorter retention times 
require a mobile phase of lower polarity [80].  
With the developed of an elution gradient, the RT also can be controlled. In this mode of elution 
the initial mobile-phase composition is relatively polar and as the separation progresses, the 
mobile phase’s composition is made less polar [80,84]. In the case of the isocratic, the solvent 
composition remains constant throughout the analysis [82,84]. 
 
 
3.2.2. MASS SPECTROMETRY 
 
The mass spectrometer provides the most definitive identification of all of the HPLC detectors. 
The molecular weight of the analyte together with the structural information that may be 
generated, allows an unequivocal identification [79]. 
The first step in the mass spectrometric analysis of compounds is the production of gas phase 
ions of the compound [78]. Thereby, the effluent from the HPLC column is directed to the 
ionization source of the mass spectrometer [81]. These ions are then introduced in several 
stages to the high vacuum region of the mass analyzer, where the ions are separated by mass to 
charge ratio and measured by the detector [76,78,81]. 
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The inlet system for LC, often termed the ‘interface’ between the two component techniques, 
must therefore remove as much of the unwanted mobile phase as possible while still passing the 
maximum amount of analyte into the mass spectrometer [79]. The essential components of a 
mass spectrometer are represented in the Figure 3.1. 
 
 
Figure 3.1- The essential components of a mass spectrometer. An inlet system transfers a sample 
into the ion source. There the neutral sample molecules are converted into gas-phase ions. The 
mass analyzer separates and analyzes the ionic species and the detector measures and amplifies the 
ion current of mass-resolved ions. For last, the data system records, processes, stores, and displays 
data. The mass analyser and detector are operated under high vacuum, which allows ions to move 
freely in space without colliding or interacting with other species. Adapted from [84]. 
 
 
3.2.2.1. MODES OF IONIZATION 
Liquid solutions are difficult to handle by the MS vacuum system and require some novel 
introduction and ionization systems [84]. Ionization of the analyte is the first step in the analysis 
of any class of compounds by MS [78,84].  
The choice of a particular method is dictated largely by the nature of the sample under 
investigation and the type of information desired [84]. In the field of toxicology, for analysis of 
smaller molecules and highly polar compounds associated with the higher sensitivity achieved 
makes ESI the most widely applied ionization technique [16,70]. The type of ionization that was 
used in this project was Electrospray Ionization (ESI). This ionization technique has become the 
most successful interface for LC/MS applications [84]. 
Inlet 
Ion 
Source 
Mass 
Analyser 
Detector 
Data 
System 
Mass Spectrum 
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Electrospray analysis can be performed in positive and negative ionization modes [84], which 
typically result in protonated molecular ions, [M+H]+, or deprotonated molecular ions, [M-H]-, 
respectively [78,81,92]. Because most toxicologically relevant compounds have basic properties, 
positive ionization mode is generally applied (Figure 3.2) [8]. 
 
 
Figure 3.2- A simplified mechanism of ion formation in the positive ESI mode. The analyte is 
introduced into the ESI source via a needle as an eluent flow from an LC chromatograph. The 
electrospray itself is formed as a result of a large electrostatic potential difference between the 
capillary and a cone electrode. Cations concentrate at the tip of the capillary and tend to migrate 
toward the cone electrode. The migration of the accumulated positive ions toward the cone 
electrode is counter balanced by the surface tension of the liquid, giving rise to a Taylor cone at 
the tip of the capillary. The air, which is passed continuously in the region spraying helps the 
evaporation of the solvent. As the size of the droplet reduces, the repulsive forces between 
charges on the surface of the droplets overcome the cohesive forces of surface tension and leads 
to the Coulomb explosion. The skimmer is used to retain these droplets and guide the ion to the 
analyzer region of the mass spectrometer [84]. 
 
 
In the positive-ion mode, the solution at the end of the needle is polarized and torn away from 
the needle [69]. The field accumulation of charge on the surface of the liquid emerging from the 
capillary produces a fine spray of highly charged droplet that are desolvated as they pass 
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through the atmospheric-pressure region of the source [78,81,92,93]. Because solvent contained 
in the droplets evaporates, this causes them to shrink, increasing their charge per unit volume 
[69,78,79,84,92,93]. At some point, the competing force of surface tension causes the droplets 
to disintegrate (Coulombic explosion) and gas phase ions of the analyte(s) are produced 
[79,81,92,93]. 
 
 
3.2.2.2. QUADRUPOLE ANALYZER 
Mass analyzers are used for ion separation, maximizing the transmission of all ions that enter 
from the ion source [69,84]. Once the gas-phase ions have been produced, they need to be 
separated according to their masses, which must be determined. The physical property of ions 
that is measured by a mass analyser is their mass-to-charge ratio (m/z)[78]. 
As there are a great variety of sources, several types of mass analysers have been developed 
[78,81]. All mass analysers use static or dynamic electric and magnetic fields that can be used 
alone or combined [78]. A quadrupole analyser was the type of mass analyser used in this 
project and is probably the most used type of mass analyser [84]. It is an ideal detector for 
chromatography as it is capable of fast scanning and uses low voltages which make it tolerant to 
relatively high operating pressures, such as those encountered in LC–MS [79].  
This device uses the stability of the trajectories in oscillating electric fields to separate ions 
according to their m/z ratios [78].The field is achieved by using four parallel rods ( Figure 3.3 ) 
[69,78,92,94] that are arranged symmetrically around a central axis that is the path of ion 
movement from ion source to ion detector [92]. 
Two opposite rods have the same voltage, while the perpendicular ones have a voltage with 
opposite sign ( + and -, respectively) [69,79,92]. The oscillating field applied to the rods 
alternately attracts and repels ions passing through the mass filter, inducing an ion motion that 
is exploited to differentiate ions on the basis of their mass [84,92]. Thus a mass spectrum is 
produced by changing both RF and DC voltages in a systematic way to bring ions of increasing or 
decreasing m/z ratios to the detector [79,84]. At a specific value of these voltages, only ions of a 
particular m/z follow a stable trajectory through the rods and reach the detector [69,79,92]. 
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Figure 3.3- Schematic representation of a quadrupole mass analyser and a voltage profile on the 
rods. One pair of rods receives a superimposed positive direct corrent (DC) potential  and a radio-
frequency potential. The other adjacent pair of rods receives a negative DC potential and an 
radio-frequency potential of the same magnitude. Adapted from [69]. 
 
The introduction of soft ionization techniques, like ESI, has trigged the rapid development of 
tandem mass spectrometry (MS/MS) techniques [69]. There are differences between MS mode 
and MS/MS mode (Figure 3.4). 
 
 
 
Figure 3.4- Diffrerences between single-stage MS and tandem MS/MS. In the MS mode, ions 
formed in the ionization source are separated by a single-stage mass analyzer. In tandem in space 
MS/MS there are three main steps in tandem mass spectrometry: (i) ion selection, (ii) ion 
activation (fragmentation), and (iii) analysis of the fragments of the selected ion. Adapted from 
[69]. 
 
 
Ionization Analysis 
MS: 
Ionization Selection Activation Analysis 
MS/MS: 
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In MS/MS, any individual ion can be selected and then activated to generate fragments of the 
selected ion. These fragments are characteristic for the precursor ion structure. The fragments 
originating exclusively from the precursor ion can then be analyzed separately with another 
mass analyzer [69]. In the Figure 3.5, the QqQ configuration indicates an instrument with three 
quadrupoles [78], called a triple quadrupole used for MS/MS experiments. 
 
 
 
Figure 3.5- General diagram of a triple quadrupole instrument. Q1 and Q3 are mass analyzers, 
where the Q1 acts as a mass filter and Q3 allows the passage of the fragment ions of the desired 
mass to charge ratio. The centre quadrupole, q2, is a collision cell made up of a quadrupole using 
RF only. Adapted from [78]. 
 
The first quadrupole (Q1), selects a ‘precursor’ ion with the desired mass to charge ratio from 
the ESI source [81,94]. The second quadrupole (q2) is the collision cell, [94] where collisions with 
a neutral gas such as N2 or Ar causes the ions to fragment through a process known as collision 
induced dissociation (CID) [81,94]. Ions are confined to the collision cell by a quadrupole, 
operated with only a radiofrequency voltage between the poles. The resulting fragment ions are 
transmitted to third quadrupole(Q3) [78,81,94], where only the fragment ions of the desired 
mass to charge ratio are allowed to pass and reach the detector [81].  
The mass spectrometer used in this project is a Hybrid Triple Quadrupole –Linear Ion Trap. With 
this mass spectrometer it is also possible to trap ions in between the quadrupole rods for a 
certain amount of time. In this instrument, the Q3 region can be operated as a normal triple 
quadrupole with all its scan modes or as a trap in various combinations with the use of the other 
quadrupoles [78]. This mass spectrometer has an additional quadrupole, Q0 which is a cell that 
works in high-pressure. Here the ions can be accumulated in the Q0 region of the system while 
the Q3 trap is scanning ions during MS/MS and scans MS3.  
Tandem mass spectrometry is used to determine ion structure and to detect and quantify 
targeted compounds in complex mixtures [94]. This improve the selectivity and sensitivity for 
quantitative assays, and greatly expand the capabilities for gaining qualitative information of 
unknown metabolites [81]. 
ESI 
Source 
Q1 q2 Q3 
Detector 
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3.2.2.3. MULTIPLE REACTION MONITORING (MRM) 
 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a triple quadrupole mass 
spectrometer operated in multiple reaction monitoring mode (MRM) is the method of choice for 
quantitative bioanalysis of small molecules (Figure 3.6) [81,84]. And this one was the mode that 
was used in this project. 
The two levels of selectivity in the MRM experiment, combined with the chromatographic 
separation, provided a very high level of selectivity [81]. Depending on the resolving power of 
the first mass analyzer, ions can be selected either monoisotopically or with multiple isotopes 
[69]. 
 
 
Figure 3.6- Schemating representation of Multiple reaction monitoring. Here a specific m/z value 
is selected in Q1 and is fragmented in q2. Q3 is set to transmit only ions of a selected m/z rather 
than scanning the entire fragment ion spectrum . Adapted from [78]. 
 
The Q1 (on QqQ scheme) is set to the m/z value of the precursor (first mass analysis step, MS1). 
Then is induced to dissociate (fragment) via CID in a collision region of the mass spectrometer 
(q2 on QqQ). Finally, a specific, structurally distinct fragment ion (product ion) is mass selected 
in Q3 (second mass analysis step, MS2) and detected [69,84,94,95]. Since higher sensitivity is 
desired, the Q3 is not scanned over a wide mass range of the fragments but, instead, it is set up 
to monitor only a selected fragment, or fragments [69,84,94]. 
The term MRM refers to the monitoring of more than one reaction, either from the same 
precursor or from more than one precursor [84]. This technique is very useful for quantitation 
[69] and provides enhanced selectivity in quantitative analysis, leading to increased confidence 
of the analyte of interest being monitored [95]. 
 
 
 
 
ESI 
Source 
Q1 q2 Q3 
Detector 
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3.2.2.4. ISOTOPIC ABUNDANCES 
Most elements appear in nature as isotope mixtures, each with fixed relative abundances 
[78,84]. Atoms with nuclei of the same atomic number differing in the number of neutrons are 
termed isotopes [96]. These isotopes are responsible for the peaks in the mass spectrum 
appearing as isotopic pattern that are characteristic of the elemental composition [78,84]. With 
a bar graph representations, it can be visualized the isotopic compositions and show how such a 
distribution would appear in a mass spectrum (Figure 3.7).  
 
 
Figure 3.7- Isotopic patterns of chlorine. The bar graph representations of the isotopic 
distributions have the same optical appearance as mass spectra. Adapted from [96]. 
 
Those peaks are isotopically shifted lines that appear at masses one or more units higher than 
the main peak M; the mass of M is calculated using the atomic masses of the most abundant 
isotopic species (i.e., the primary isotope). The pattern peaks, designated as M+1, M+2, and so 
on, reflect the differences in the natural abundances of the isotopes. [84]. 
Several elements exist naturally in two isotopes and within the context of MS it is useful to deal 
with them as a class of their own [96], because even without exact mass measurement, the 
possibilities for elemental composition determination can often be restricted by using isotopic 
abundance data [78]. 
So, it is essential to evaluate the compound structure to determine whether it contains any 
elements such as chlorine, bromine or boron, which would result in a unique isotope pattern 
[78].  
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3.3. ANALYTICAL METHOD VALIDATION 
 
 
Due to the increasing interdependence among the countries during the last years, it has become 
necessary for the results of many analytical methods to be acceptable internationally. 
Consequently, the need for and use of validated methods has increased [97]. The international 
scientific community needs published research results that are valid, reproducible and 
comparable. In addition, the ‘client of the laboratory’ will have the implicit expectation of 
correct results [98]. 
To ensure that an analytical method generates reliable information, it must be validated. The 
International Organization for Standardization (ISO) defines validation as the confirmation by 
examination and provision of objective evidence that the particular requirements for a specified 
intended use are fulfilled. By another words, method validation is the process of defining an 
analytical requirement, and confirming that the method under consideration has performance 
capabilities consistent with what the application requires [99]. 
Method validation is usually considered to be very closely tied to method development, indeed 
it is often not possible to determine exactly where method development finishes and validation 
begins [99]. 
Reliable analytical data are a prerequisite for correct interpretation of toxicological findings in 
the evaluation of scientific studies, as well as in daily routine work [100,101]. There are legal 
reasons, technical and commercial for the need of implementation of validation methods. The 
cost of carrying out the analyzes is high and additional costs arise from decisions made on the 
basis of the results [99]. The results are used by others for case report interpretation, by judicial 
authorities for implementation of legal measures and by medical doctors for patient treatment 
[98]. So, unreliable results might not only be contested in court, but could also lead to 
unjustified legal consequences for the defendant or to wrong treatment of the patient [101]. 
In several countries, judicial authorities impose proficiency testing and/or accreditation 
according to the ISO standards on laboratories performing analysis of certain samples in a 
forensic or clinical setting [98]. Therefore, quality management and accreditation have become 
matters of increasing importance in analytical toxicology in recent years [100,101]. 
However, all these guidelines not often provide a practical approach to how validation should 
occur in a particular laboratory setting [98]. 
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Owing to the importance of method validation in the whole field of analytical chemistry, a 
number of guidance documents about bioanalytical methods in which are definitions, 
procedures and parameters of validation, were published. This subject has been issued by 
papers, reviews and conferences [97,100-103]. However, there is no consensus on the extent of 
validation experiments and on acceptance criteria for validation parameters of bioanalytical 
methods in forensic and clinical toxicology [101]. 
International organizations such as ISO, IUPAC (International Union of Pure and Applied 
Chemistry), EMA (European Medicines Agency), FDA (Food and Drug Administration) and 
EUROCHEM group [99,104-106], also publish parameters and methodologies for analytical 
method validation. Guidance documents for analytical method validation differ between them, 
which creates confusion about the nomenclature and concepts. A single set of global guidelines 
and use of the same terminology still remains the ultimate goal for full method comparison [91]. 
Method validation includes all of the procedures required to demonstrate that a method to 
quantify the concentration of an analyte (or series of analytes) in a particular biological matrix is 
reliable for the intended application [107]. Any modification of an analytical method would 
require revalidation of the procedures [108]. 
It is essential to employ well-characterized and fully validated analytical methods to yield 
reliable results which can be satisfactorily interpreted [108]. In this way, all of the variables of 
the method should be considered, including sampling procedure, sample preparation, 
chromatographic separation, detection and data evaluation [107]. 
There is a general agreement that at least the following validation parameters should be 
evaluated for quantitative procedures: selectivity, calibration model (linearity), stability, 
accuracy, precision (repeatability, intermediate precision), limit of detection and limit of 
quantification. Additional parameters which might have to be evaluated include recovery, 
reproducibility and robustness [101,109]. 
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4. MATERIALS AND METHODS 
4.1. EQUIPMENTS  
 
 System of Liquid Chromatography coupled to a mass spectrometer, with the following 
components: 
 Liquid Chromatography, UltimateTM3000 (LC Packings, Dionex); 
 ESI source, turbo VTM; 
  Hybrid  triple quadrupole/linear ion trap mass spectrometer, 4000 QTRAP® 
(ABSciex); 
 Software Chromeleon® 6.80 (Dionex) for the LC system; 
 Software Analyst® 1.5.1 (ABSciex) for MS system. 
 Analytical balance CP 224S (Sartorius); 
 Bench-top Centrifuge (Minispin-Eppendorf®); 
 Concentrator Plus (Eppendorf®) - “speedvac”; 
 Quick spin, model QS 7000 (Edward Instrument Co); 
 Sonicator, model VibraCell - SonicsTM 75041 (Bioblock Scientific); 
 Thermomixer comfort (Eppendorf®);  
 Vortex, model MS3 basic (IKA®). 
 
4.2. MATERIAL 
 
 C18 OMIX Tip - 100µL (Agilent Technologies); 
 Eppendorf® CombipTip (w/ pre-cutted end); 
 Micropipettes® Research Plus (Eppendorf®); 
 Multipipette® Plus (Eppendorf®); 
 PS – Microplate 384 well, 128.0/85 mm (Greiner bio-one); 
 Microcentrifuge tubes (500µL, 1.5mL, 2mL) 
 Vials 500µL (VWR®). 
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4.3. STANDARDS AND REAGENTS 
 
Standards: 
 Citalopram hydrobromide, BIOTREND Chemicals AG (purity 99.8%); 
 Clozapine, BIOTREND Chemicals AG (purity 99.0%); 
 Haloperidol, BIOTREND Chemicals AG (purity 99.8%); 
 Desipramine hydrochloride, Sigma-Aldrich (purity ≥ 98%); 
 Haloperidol - D4, Cirilliant® (purity 99.2%); 
 Sulfamethazine-D4. 
Reagents: 
 Acetonitrile (LC Grade, Biosolve) - ACN; 
 Dichloromethano (Sigma ≥ 99.9%); 
 Formic Acid (LC Grade, Sigma Aldrich) - FA; 
 Methanol (LC Grade, Biosolve) – MeOH; 
 Water (LC Grade, VWR®). 
 
4.4. ANIMAL PROTOCOL 
4.4.1. ANIMALS AND DRUG ADMINISTRATION 
 
Young black male C57BL/6J mice were purchased from Charles River, Laboratories International, 
Inc (Spain). They were divided into four groups, 5 per group and each animal weighed around 20 
- 25 g with access to food and water ad libitum. 
After a 1 week habituation period to needle punctuation, the animals were injected, via 
intraperitoneal with clozapine, citalopram and haloperidol at a dose of 1 mg/kg, 20 mg/kg and 
10 mg/kg, respectively. An additional group was treated with vehicle (control group).  
The mice were injected daily for different periods: 1, 2, 4, 8, 15 and 30 days. It was also added a 
saline solution control (0.13% HCl at 5 M). Then, the animals were weighed and anesthetised 
with a mixture of ketamine and xylazine 24 hours after the final injection. 
Animals samples were kindly prepared in Dra. Graça Baltazar’s lab with the help of Sandra Rocha 
(University of Beira Interior, Covilhã). 
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4.4.2. PLASMA AND HAIR COLLECTION 
 
The blood was collected by cardiac puncture and placed in EDTA-coated tubes. Then the samples 
were centrifuged at 12000xg for 2 minutes and the plasma was recovered to another tubes. To 
each tube was added  protease and phosphatase inhibitors and stored at −80°C.  
The hair samples were pulled out with tweezers and placed into a centrifuge tube and were also 
stored at -80°C. 
Drug-free plasma and hair samples was courtesy of Professor Carlos Duarte’s group of Center for 
Neuroscience and Cell Biology (Coimbra, Portugal). The collection procedure of plasma and hair 
was similar. 
 
4.5. METHOD DEVELOPMENT 
 
The development of a LC-MS method requires the optimization of several parameters. This 
optimization refers to an adjustment of instrumental parameters in order to optimize 
performance characteristics of each compound. 
To set the conditions a direct injection into the mass spectrometer was performed by infusing a 
standard solution of each analyte with a syringe pump of 1mL, with a concentration of 0.453 μM 
for haloperidol, 1 μM for clozapine, 0.125 μM for citalopram, 1.14 μM for desipramine and 0.1 
μM for haloperidol-d4. Each solution was injected one by one with a flow rate of 9 μL/min. 
With this procedure, the conditions to the ESI source to apply to substances and the ideal 
collision energy (CE) for the fragmentation of each compound were optimized. It was also 
optimized the best value for declustering potential (DP) to minimize solvent cluster ions. 
Each compound fragmentation spectra was analysed with software Peak ViewTM 1.1.1.2 
(ABSciex). 
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4.6. INSTRUMENTAL CONDITIONS 
4.6.1. LIQUID CHROMATOGRAPHY 
 
The separation in the chromatography system was performed with a Gemini® C18 (3 µm, 110 Å, 
50 x 2 mm) column. Security Guard™ cartridges Gemini® C18 (4 x 2 mm ) was also used. 
To have an efficient separation an elution gradient was developed (Table 4.1) with a flow rate of 
250 μL/min and 9 min of running time for each sample. 
Between samples a blank was injected with a gradient that is also represented in the Table 4.1. 
Also between batchs three blanks were introduced (solution of 0.1%FA in ACN), with the same 
program and the same volume of injection that was used for the samples. The volume that was 
injected for hair samples was 1μL and for plasma samples was 20 μL. For the blanks between 
samples the injection volume was 10 μL. 
 
 
Table 4.1- Elution gradient used for chromatographic analysis. 
 
Running program Time (min) 
Mobile phase (% v/v) 
0.1% FA in H2O 0.1% FA in ACN 
Sample 
0 90 10 
0 90 10 
0.3 80 20 
6 70 30 
7 1 99 
9 1 99 
Blank 
0 100 0 
0 100 0 
1.9 100 0 
2 10 90 
8 10 90 
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4.6.2. MASS SPECTROMETRY 
 
 
The equipment and data acquisition were performed by the software with the Analyst® 1.5.1 
(ABSciex).   
The mass spectrometer is equipped with an ESI source, which was operated in positive ion 
mode.  All values of the source dependent parameters were optimazed: curtain gas (CUR), 30psi; 
ion source gas 1 (GS1), 30 psi; ion spray voltage, 5500V; source temperature, 450 οC. 
To monitor the precursor ions of each analyte and IS (haloperiodl-D4 and desipramine), the mass 
spectrometer was operated in MRM mode and the transitions monitored are in the Table 4.2. 
The haloperidol-D4 was used as IS of haloperidol and the desipramine was the IS used for 
citalopram and clozapine. 
All compound’s parameters were determined: Dwell time was 30 ms, entrance potential (EP) 
was 10eV and collision gas (CAD) was 8psi. The different values of declustering potential (DP), 
collision energy (CE), collision exit potential (CXP) for each transition are also represented in the 
Table 4.2. The analytical data were processed by the MultiquantTM 2.1.1 (ABSciex) software. 
 
Table 4.2- Mass spectrometer acquisition parameters: MRM transitions, collision energy (CE), collision 
exit potential (CXP) and declustering potential (DP), for each transition of all analytes and internal 
standards. 
 
 
Compound 
Transitions (m/z) 
CE (eV) CXP (eV) DP (eV) 
 Q1 Q3 
 
Citalopram 325.3 
109 39 8 
66 261.9 27 24 
83.1 91 4 
Clozapine 327.2 
269.9 35 18 
71 191.9 57 16 
163.8 95 10 
Haloperidol 376.0 
164.7 33 10 
61 122.9 55 8 
94.8 107 16 
In
te
rn
al
 s
ta
n
d
ar
d
s 
Desipramine 267.3 
72.2 27 4 
56 208 33 16 
190.8 83 14 
Haloperidol – D4 380.2 
127.1 61 8 
51 168.4 33 10 
98 99 6 
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4.7. EXTRACTION PROCEDURE FOR PLASMA SAMPLES 
4.7.1. PROTEIN PRECIPITATION 
 
 
To each microcentrifuge tube containing 70 μL of plasma, was added three volumes of methanol 
(210 μL). The samples were agitated by vortex and after by continuous agitation for 5 minutes at 
1000rpm’s in the thermomixer. To help the proteins to agregate, they were centrifuged at 
14,000×g for 10 minutes. 
The supernatant was collected to a new microcentrifuge tube and was placed on an evaporator 
at 60 °C, during approximately 1 hour. Subsequently, the sample was resuspended in 50μL of 2% 
ACN:0.1% FA. 
 
4.8. EXTRACTION PROCEDURE FOR HAIR SAMPLES 
 
4.8.1. DECONTAMINATION AND SEPARATION OF DRUGS FROM THE HAIR 
MATRIX 
 
Depending on the length, some hair samples were cut in the middle. Then the samples were 
weighed in amounts between 0.7 – 9.7 mg (see Appendix 8.1).  
First, the hair samples were decontaminated by adding 1mL of dichloromethane for 2 minutes at 
room temperature in the thermomixer. Then dichloromethane was removed, and this procedure 
was repeated twice. 
The hair was incubated overnight (17 hours)  in 1 ml of methanol  at 45 °C. Then methanol was 
evaporated to dryness in the speedvach at 60 °C, during approximately 1 hour. 
 
4.8.1.1. OMIX TIP C18 CLEAN UP 
 
OMIX Tip C18 contains a small bed of functionalized monolithic sorbent (C18) inserted inside a 
pipette tip, it can work as a miniaturized solid phase extraction bed to remove salts prior to mass 
spectrometry. This procedure was used as a clean up of the hair samples. 
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To performe the OMIX C18 SPE, three solution were prepared: 50% ACN, 2% ACN: 1% FA and 
70% ACN: 0.1% FA. 
To the evaporated sample 100µL of 2% ACN: 1% FA were added and were immediatly sonicated 
for 2min in the cuphorn (20% amplitude 1s on 1s off cycle). Then, to wet the tip, it was added, 
from the top, 200µL of 50% ACN and the pre-cutted CombipTip was used to push the solutions 
and sample through the tip. To equilibrate the tip, 300µL of 2% ACN: 1% FA were added. After, 
the sample was passed through the tip 5 times. To rinse the tip 100µL of 2% ACN: 1% FA were 
added and at last the analytes were eluted with 400µL of 70% ACN 0.1% FA. 
All samples were evaporated to dryness in the speedvac at 60 °C and then resuspended in 50μL 
of 2% ACN:0.1% FA and sonicated before being placed in the vials.  
 
4.9. ANALYTICAL METHOD VALIDATION 
 
Only validation can objectively demonstrate the inherent quality of an analytical method by 
fulfillment of minimum acceptance criteria and thus prove its applicability for a certain purpose 
[100]. Therefore, the validation of the method was performed and the parameters that were 
used for validation of analytical method for the identification and quantification of psychotropic 
drugs in plasma and hair samples by LC-MS evaluated are summarized in Table 4.3. 
 
Table 4.3- Parameters used for the analytical method validation for identification and 
quantification of psychotropic drugs in plasma and hair by LC-MS/MS. Adapted from [102,109].  
 
Parameter Qualitative method Quantitative method 
Selectivity     
Limit of detection     
Limit of quantification    
Linearity    
Working range    
Precision    
Accuracy    
Extraction efficiency    
Carry over     
Matrix effects     
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All the statistical tests and the acceptance criteria applied for each parameter will be explained 
exposed in the next pages. They were performed with the help of a Microsoft Excel® 
spreadsheet developed for the validation method, kindly provided by Margarida Coelho. 
 
4.9.1. SELECTIVITY 
 
Selectivity is the ability of an analytical method to differentiate the analyte(s) of interest in the 
presence of other components in the sample [105,106].  
To evaluate the selectivity, for plasma samples, six individual sources of blank plasma were 
selected and were divided in two aliquots with 70μL of plasma in each:  
 The first aliquot was fortified with 20μL of a solution (0.025 μM) containing the three 
compounds (citalopram, clozapine and haloperidol)  and the two IS (desipramine and 
haloperidol-D4) - positive samples; 
 The second aliquot was not fortified with any compound and only 20μL of 2% ACN: 0.1% 
FA were added, in order to have the same final volume - negative samples.  
Then, all samples were subjected to the analytical procedure developed for the extraction of 
drugs from plasma (see section 4.7). It was injected 20 μL of the sample into the LC–MS/MS 
system.  
In an analogous way, to evaluate the selectivity of hair samples, six individual sources of blank 
hair  were selected. The samples were cut and were placed in two different aliquots, each one 
with 3-4 mg: 
 The first aliquot was fortified with 20μL of a solution (0.5 μM) containing the three 
compounds (citalopram, clozapine and haloperidol)  and the two IS (desipramine and 
haloperidol-D4) - positive samples; 
 The second aliquot was not fortified with any compound and only 20μL of 2% ACN: 0.1% 
FA were added, in order to have the same final volume - negative samples.  
All hair samples were subjected to the analytical procedure developed for the extraction of 
drugs (see section 4.8). It was injected 1 μL of the sample into the LC–MS/MS system. 
In both cases the results obtained from positive samples were compared with the results 
obtained from negative samples. The criteria used were proposed by the World Anti-Doping 
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Agency (WADA) which required at least two precursor-product ion transitions should be 
monitored. The second criterion is monitoring the relative abundance of a diagnostic ion. This is 
expressed as a percentage of the intensity of the most intense fragment (base peak) and was 
calculated by dividing the area of the each ion trace by the area obtained from the peak 
corresponding to the m/z of the base peak ion (corresponding to 100%) [110].  The maximum 
tolerance range for relative ion intensities used for the identification of compounds are 
presented in the Table 4.4. The criteria used to calculate the ranges in this parameter are 
defined by data from the first positive sample. 
 
Table 4.4- Maximum Tolerance ranges for Relative Ion Intensities to Ensure Appropriate 
Confidence in Identification [110]. 
 
 
Relative Abundance 
(% of base peak) 
Maximum Tolerance Ranges (%) 
> 50 ± 10 (absolute range) 
25 to 50 ± 20 (relative range) 
5 to < 25 ± 5 (absolute range) 
< 5 ± 50 (relative range) 
 
 
 
It was also used as acceptance criterion the relative retention time (RTratio), which is expressed 
by the ratio between the RT of the interest compound and RT of the internal standard. Here, the 
∆RTRatio should not differ by more than ±1% (or ± 0.1%, if stable-isotope-labeled internal 
standard is used), when compared with the ∆RTRatio of the control sample. 
At last, the ratio between the signal of the least intense diagnostic ion and the signal of the noise 
of the baseline (S/N) shall be greater than 3:1. The determination of S/N was performed by the 
MultiquantTM 2.1.1. software. 
 
4.9.2. LINEARITY 
 
It is necessary to use a sufficient number of calibrators to define adequately the relationship 
between concentration and response [107]. Recommendations on how many concentration 
levels and how many replicates per concentration level should be studied, differ significantly. 
Most guidelines require a minimum of five to eight concentration levels [101,109,111]. 
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To study the linearity, it was prepared one calibration curve with a solution containing the three 
analytes (citalopram, clozapine ad haloperidol) with eleven calibrators, uniformly distributed in 
the working range: 0.05, 0.1, 0.15, 0.2, 0.25, 0.5, 1, 1.5, 2, 3 and 5 μM. At each calibrator a 
solution (0.5μM) containing the two IS (desipramine and haloperidol-D4) was added. 
The choice of an appropriate calibration model is necessary for reliable quantification. Then, if it 
is assumed that there is a linear relationship, the simplest regression model that is usually 
applied is the ordinary least squares model [97,109]. This model represents the relationship 
between two variables by a straight line, mathematically expressed by the equation (4.1), where 
  is the instrumental response and   is the concentration of the compound [112]. 
        (4.1) 
Where,    and    are the independent and dependent variable,   and   are the calibration 
parameters, the y-intercept and the slope, respectively. 
The linearity of the calibration process was first investigated by means coefficient of correlation 
(R) and coefficient of determination (R2), that should be above 0.99 in both cases. However, the 
evaluation of linearity should not rely only on those parameters. Therefore, the zero-value 
should be included within the confidence interval of 95% [113,114].  
Additionaly, the standard error of the linear regression (Sy/x) was used as a measure of the 
goodness of fit in order to exclude the residual values (response observed in relation with the 
response predicted) higher than 2 × ǀSy/xǀ. In addition, visual inspection of plots for residuals 
versus concentration was performed [101]. 
 
4.9.2.1. MANDEL TEST 
 
Spite of widespread practice of evaluating a calibration model via its coefficients of correlation 
or determination, this is not acceptable from a statistical point of view [101,115]. For example, 
calibration models with points not uniformly distributed along the calibration range may provide 
a good correlation coefficient [115]. Nevertheless, several researchers focused on the fact that R 
might not be a useful indicator of linearity and other statistical tests or quality parameters have 
been suggested to ascertain the goodness of fit of the calibration curve [116].  
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So, the Mandel’s fitting test was applied to ascertain which model (linear or quadratic) fitted 
better in calibration data [116,117]. 
First, it was calculated the differences between the variance of linear correlation and quadratic 
correlation (equation (4.2)) [115,117,118].  
 
 
 
 
Where,   
  
  is the variance of linear correlation calculated for the linear fit;   
  is the variance of 
quadratic correlation calculated for the quadratic fit and   is the number of calibration 
standards used to construct the curve. 
From this it is possible to calculate the significance of this difference (    ) through the equation 
(4.5) [115,118]. 
 
      
   
  
  
 
(4.5) 
 
Then, it was compared the value obtained for the calculated F value (      ) with the tabulated 
value         of the F distribution of Snedecor           at the confidence level of 95% (α = 
5%). The criteria for these results were:  
 If      ≤       - the differences between the variances are not statistically significant and 
therefore the linear adjustment is more appropriate; 
 If      >       - the differences between the variances are statistically significant and 
therefore the quadratic adjustment is more appropriate. 
 
 
 
 
 
             
  
            
  (4.2) 
  
  
  
        
 
   
 (4.3) 
  
  
        
 
   
 (4.4) 
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4.9.3. WORKING RANGE 
 
 
The working range of an analytical procedure can be defined as the interval between the upper 
and lower concentration of analyte for which suitable precision, accuracy and linearity have 
been demonstrated [119,120].  
In addition, the concentration range in bioanalytical methods is usually broad and therefore it 
might be expected that the variance of each standard point of the calibration curve might be 
different (heterocedastic data) [121]. Therefore, it is mandatory to evaluate the 
homoscedasticity assumption through the test of homogeneity of variances (or F test) and also 
by visual evaluation of residuals versus concentration plots [112,121]. Therefore, the study of 
the working range was performed simultaneous with the study of linearity and ten replicates of 
the lowest and the highest concentrations levels were performed, 0.1 and 5 μM respectively. To 
each calibrator it was added a solution (0.5μM) of the IS. 
It was calculated the variances of the first (  
 ) and the last calibrator (   
 ), according to the 
following equation (4.6) [118,121]. 
 
 
Where,   
  represents the variance;   is the calibration sample (i =1 and i=10);   is the number of 
replicates for each calibration sample (j=1 to 10 for each i);   is the number of results;    is the 
result obtained and    is the mean of results obtained. 
Then, it was obtained the calculated F value (    ) by the F-test, that uses the ratio between the 
variances obtained at the lowest (  
 ) and at the highest (   
 ) concentration level of the working 
range (equations (4.7) and (4.8)) [112,121,122]. 
 
 
 
 
 
 
 
 
  
  
          
  
   
     
 (4.6) 
     
   
 
  
 , if    
     
  (4.7) 
     
  
 
   
 , if   
      
  (4.8) 
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The value of      is compared with tabled value (     ) of F distribution of Snedecor        
   at the confidence level of 95% (α = 5%) [112]. The criteria used for these results were: 
 If      ≤       – the difference in variances is not statistically significant and thus the 
working range is adjusted; 
 If      >       – the difference in variances is statistically significant and so the working 
range is not adjusted. 
It was also performed a visual inspections of residuals versus concentration plots in order to 
check if residuals are randomly distribuited around the x-axis. If variance is constant over the 
working range, this condition is verified and also Fcal will be lower than Fcrit.  
On other hand, in the presence of heteroscedastic data different approaches could be followed, 
such as the reduction of the working range and repeat the verification for the homogeneity of 
variances by F-test, until obtain the      ≤       [118,121]. Another procedure which is used is the 
inverse of variance (1/S2) in each point of the calibration curve, which is impraticable in routine 
analysis since several replicates are nedeed to calculate the variance (S2). Therefore, the 
Weighted Least Squares Regression [112,120], choosing the approprieted weighting factor (  ) 
will overcome this problem [112]. 
 
4.9.3.1. WEIGHTED LEAST SQUARES LINEAR REGRESSION 
 
The constant variance over the whole range is not always observed. Larger deviations present at 
larger concentrations tend to influence (weight) the regression line. Thus if the data are 
heteroscedastic, the use of WLSLR is the simplest and the most effective way to harmonise the 
differences of variances of the line points [98,112,123].  
For this study calibration curves for all the analytes were prepared with eleven calibrators each. 
The calibrators were uniformly distributed in the working range: 0.05, 0.1, 0.15, 0.2, 0.25, 0.5, 1, 
1.5, 2, 3 and 5 μM. To each calibrator it was added the IS (0.5μM). This procedure was repeated 
in five different days. 
Taking into account the objective of WLSLR, appropriate weighting factors (  ) can be calculated 
from the inverse of the variances at the given concentration level [97,123]. However, as was 
mentioned before, it is not suitable to calculate the inverse of variance in laboratory routine, 
mainly because it requires several determinations for each calibration point and a fresh 
calibration line each time the method is used, so other empirical weights based on x-variable 
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(concentration) or y-variable (response) may provide a simplistic approximation of variance 
[112,124]. The empirical weights that should be study are:  
 
 
; 
 
  
; 
 
  
; 
 
 
; 
 
  
 and 
 
  
  [112,125]. 
Therefore, the   can be obtained by the equation (4.9) [124]. 
 
    
   
  
     
       
 (4.9) 
 
Where,   is the weighting factor;   
  is the appropriate empirical weight for the data (
 
 
; 
 
  
; 
 
  
; 
 
 
; 
 
  
 or 
 
  
) and  is the number of calibration standards. 
The effectiveness of the weighted regression can be assessed by calculating the percentage of 
the relative error (    ), which compares the estimated concentration of the sample, from the 
regression equation obtained for each   ,  with theoretical or nominal standard concentration 
of the sample (equation (4.10)) [112]. 
 
Where,      is the estimated concentration in the sample and      is the nominal standard 
concentration in the sample. 
Plots of %RE versus concentration were performed for the analytes in order to choose the best 
weighing  factor, along with the sum of  %RE (       The    more adequate will be the one 
which gives rise to a slight horizontal band of randomly distributed %RE around the x-axis and 
presents the smallest value of      across the whole concentration range [112,123]. 
In the simple linear regression model, the relationship between variables is established by a 
straight line, mathematically expressed by the equation (4.6), that is used to calculate the      
[112]. But, since it is used a WLSLR,  the model parameters (  and  ) of the weighted straight 
line equation need to be estimated using the term     according to the following equations, 
before being calculate the       [112,123]. 
   
                           
          
          
  (4.11) 
     
         
    
      (4.10) 
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  (4.12) 
 
Where,    and    is the i
th data pair of n total data pairs and   is the weighting factor chosen. 
Finally, the correlation coefficient ( ) of the weighted straight line equation, can be obtained by 
the following modified formula [112]. 
 
  
                         
           
                         
          
 
 
(4.13) 
 
 
4.9.4. LIMITS: LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
 
The limit of detection (LOD) is the lowest amount of analyte in a sample which can be detected 
but not necessarily quantified. And the limit of quantification (LOQ) is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable precision and accuracy 
[126]. 
The evaluation of LOD and LOQ was performed simultaneously with the study of linearity. For 
this study it was prepared one calibration curve with the three analytes with six calibrators, 
distributed at a lower range of the calibration curve: 0.01, 0.015, 0.025, 0.05, 0.1 and 0.15 μM. 
To each calibrator it was added IS solution (0.5μM). 
Several approaches for determining the detection limits are possible. The approache used to 
calculate LOD and LOQ was based on the standard error of the response (  
  
) and the slope, 
expressed by the following equations [109]: 
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(4.14) 
     
      
  
 
 
 (4.15) 
 
Where,   
  
 is the standard error of the response and  is the slope of the calibartion curve. 
The above mentioned equations use   
  
 for homocedastic data. In the presence of 
heterosceastic data some alterations must be performed and therefore the standard deviation 
of a predicted concentration is given by the following equation [122-124]. 
 
          
             
   
 (4.16) 
 
Where,         is the standard deviation of y-residuals of weighted regression line;    is the 
weight factor used in this study;    is the analytical signal measured and    is the analytical signal 
predicted. 
 
4.9.5. PRECISION 
 
 
The precision of an analytical procedure expresses the closeness of agreement between a series 
of measurements obtained from the same sample under the stipulated conditions 
[105,109,118]. Precision can be expressed as the variance (S2), standard deviation (S) or 
coefficient of variation (CV) of a series of measurements [109,119] and is considered at three 
levels: repeatability, intermediate precision and reproducibility [109]. 
Repeatability, also termed within-run or intra-day precision, expresses the precision of a 
determined sample by keeping constant the global factors (human, preparation, instrumental 
and geographical) over a short period of time [106,109,119]. 
The intermediate precision, also termed between-run or inter-day precision, expresses the 
precision of a determined sample by using the same procedure, despite the small changes 
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introduced that might occur during routine analysis (different analysts, lots of reagents, 
equipment among others) over an extended period of time (different days) [119]. 
The term reproducibility refers to reproduce the results by changing one or more of the global 
factors over a short or an extended period of time [119]. Usually it expresses the precision 
between laboratories (collaborative studies, usually applied to standardization of methodology) 
[109]. In this project, the reproducibility of the method was not study. 
The study of intermediate precision and the repeatability consisted of analysing a test sample in 
p different runs. Within each run, the sample was analysed n times under repeatability 
conditions. All the important sources of variation  were varied between each run [127]. Thus, it 
was prepared one calibration curve with the analytes. Eleven calibrators, uniformly distributed 
in the working range, were prepared: 0.05, 0.1, 0.15, 0.2, 0.25, 0.5, 1, 1.5, 2, 3 and 5 μM. 
Quality controls (QCs) were also prepared at three concentration levels: low, medium and high, 
respectively 0.075, 0.75 and 2.75 μM for citalopram and haloperidol. For clozapine, the 
concentrations levels were 0.075, 0.75 and 1.25 μM. Each QC was prepared in triplicate and at 
each sample it was added 50 μL of IS solution at 0.5μM. The procedure was repeated along five 
days. 
After choosing the best calibration model for each analyte, the calibration curves were obtained 
by the use of linear regression and the concentration of the QCs were calculated. The results 
obtained for the different levels of concentration for each compound were analysed by a one-
way analysis of variance (ANOVA) (Table 8.7 in Appendix 8.6) [127,128].  
Then, it were calculated the intermediate precision and the repeatability, expressed in terms of 
% CV [129], through the following equations [98,120]: 
 
       
  
  
     (4.17) 
 
Where,     is the coefficient of variation of repeatability;    is the standard deviation of 
repeatability;     is the coefficient of variation of intermediate precision;    is the standard 
deviation and   is the mean value of concentrations. 
       
  
  
     (4.18) 
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The limits of acceptable variability were set at 15% for all the concentrations, except at the LOQ, 
for which 20% was accepted [105,106]. 
 
 
4.9.6. ACCURACY 
 
The accuracy of an analytical procedure expresses the degree of agreement between the value 
measured by the procedure to the value accepted as reference value [126]. 
The experimental procedure to evaluate the accuracy was similar to the procedure used for the 
precision. Therefore, accuracy was evaluated in terms of percentage of mean relative error 
       [109,112,120,130]. 
Where,       is the mean of the estimated concentration in the sample and      is the nominal 
standard concentration in the sample. 
As acceptance criteria, the accuracy for each level of concentration should be within ±15% of the 
nominal concentration, except for the LOQ for which it should be within ±20% [105,106]. 
 
4.9.7. CARRY-OVER 
 
It is important to know how much analyte is retained or “carried over” from a preceding sample 
into the following sample, since it can affect the accuracy and precision of the method, 
especially when a low concentrated sample is injected after injections of samples at high levels 
of concentration. Thus, to evaluate the carry-over phenomena, five blank samples (2% ACN: 
0.1% FA) were injected after the injection of the highest level of concentration standard (5 μM). 
The procedure was repeated for the calibrators with 0.5 μM and 0.05 μM of concentration. This 
procedure was repeated in three different days. 
Therefore, the carry-over in the blank sample following the highest calibrator should not be 
greater than 20% of LOQ (equation (4.20))and 5% for the internal standard [105]. 
     
          
    
      (4.19) 
MATERIALS AND METHODS| 61 
 
 
                          (4.20) 
Where,                is the mean of peak areas of the blanks samples;       is the mean of peak 
area for LOQ. 
 
4.9.8. RECOVERY 
 
The recovery of a method can be measured comparing the response of analyte spiked in the 
sample before being processed with the response of the same quantity of analyte, spiked into 
matrix after the extraction procedure. This measure indicates if the method provides a response 
for the entire amount of analyte that is present in the sample [120,130,131]. 
To evaluate the recovery three levels of concentration were selected (low, medium and high), 
corresponding to 0.1, 0.5 and 3 μM, with plasma from 6 different sources. Each concentration 
was performed in triplicate. For each level two aliquots were prepared with 70μL each one of 
them: 
 One was spiked with 20 μL of a solution containing citalopram, clozapine, haloperidol, 
desipramine and haloperidol-D4 and then was subjected to the extraction procedure 
(see section 4.7); 
 The other was first subjected to the extraction procedure (see section 4.7) and at the 
end of the procedure (when the sample is reconstituted) was spiked with 20 μL of a 
solution containing citalopram, clozapine, haloperidol, desipramine and haloperidol-D4.  
In an analogous way, to evaluate the recovery in the hair three levels of concentration were 
selected (low, medium and high), corresponding to 0.1, 0.5 and 3 μM, with hair from 6 different 
sources. Each concentration was performed in triplicate. For each level two aliquots were 
prepared each one with hair weighing between 1.9 – 3.2 mg: 
 One was spiked with 20 μL of a solution containing citalopram, clozapine, haloperidol, 
desipramine and haloperidol-D4 and then was subjected to the extraction procedure 
(see section 4.8); 
 The other was first subjected to the extraction procedure (see section 4.8) and at the 
end of the procedure (when the sample is reconstituted) was spiked with 20 μL of a 
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solution containing citalopram, clozapine, haloperidol, desipramine and haloperidol-D4 
and then was subjected to the extraction procedure.  
To each sample, for plasma and hair, 10 μL of IS at 0.5μM were added, at the end of the 
procedure. The IS used in the study of recovery was Sulfamethazine-D4, since it was also 
evaluated the recovery of the two IS (desipramine and haloperidol-D4) used for the method that 
was being developed. 
The samples that were fortified after the extraction represent 100% recovery [120]. And it was 
calculated the recovery, in percentage, by the next equation (4.21) [120,131]. 
 
 
Where,     is the absolute area of the analyte fortified in the matrix before the extraction; 
     is the absolute area of the internal standard fortified in the matrix before the extraction;    
is the absolute area of the analyte fortified in the matrix after the extraction at the same level of 
concentration and     is the absolute area of the internal standard fortified in the matrix after 
the extraction at the same level of concentration. 
The acceptance value for the recovery of the analyte does not need to be 100%, but the extent 
of recovery of an analyte and of the IS should be consistent, precise, and reproducible [106]. The 
recovery of the IS should be within 15% of that determined for the analyte [120]. 
 
4.9.9. MATRIX EFFECTS 
 
The matrix effects (ME) can be defined as the difference between the mass spectrometric 
response for an analyte in standard solution and the response for the same analyte in a 
biological matrix [132].  
To evaluate the matrix effect three levels of concentration were selected (low, medium and 
high), corresponding to 0.1, 0.5 and 3 μM. For plasma, 70μL of blank plasma was subjected to 
the extraction procedure (see section 4.7). At the end of the procedure (when the sample is 
reconstituted) the sample was spiked with 20 μL of a solution containing citalopram, clozapine, 
           
   
    
 
  
   
 
     (4.21) 
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haloperidol, desipramine and haloperidol-D4. Each concentration level was prepared in 
triplicate. In addition it was prepared a standard solution with the five compounds with 
equivalent levels of concentration. 
The procedure to evaluate the matrix effect in hair samples was similar, with the exception to 
the amount of sample used (3-4 mg) and the extractive procedure (see section 4.8). 
To each sample type, plasma and hair, 10 μL of IS at 0.5μM were added, at the end of the 
procedure. And to prepare a standard solution (citalopram, clozapine, haloperidol, desipramine 
and haloperidol-D4) with equivalent levels of concentration, to 50 μL of this solution, it was 
added 50 μL of IS (Sulfamethazine-D4) at 0.5μM. 
The difference in response between the post-extraction sample and the standard solution 
divided by the                   response (4.22) determines the degree of matrix effect 
occurring to the analyte [131,133]. 
 
Where,    is the matrix effect;                               is the peak area of the analyte 
spiked in the sample after the extraction procedure and                     is the peak area of the 
analyte for the same concentration in standard solution 
For this equation, a negative result indicates suppression and a positive result indicates 
enhancement of the analyte signal. Thus, a calculated value of zero would represent no ME 
[131,133]. 
The assessment of the presence of a relative matrix effect, expressed as     , can be made 
based on direct comparison of the peak areas of an analyte spiked into extracts originating from 
different sources of a Blank matrix (equation (4.23)) [132]. 
  
        
 
  
     (4.23) 
Where,      is the coefficient of variation of relative  ;   is the sandard deviation and   is the 
mean value. 
    
                                                   
                   
 (4.22) 
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When the values of      are high this might indicate that the response originating from the 
same amount of an analyte is different in different sources of a Blank matrix [132]. 
 
 
4.10. APPLICATION OF THE ANALYTICAL METHOD DEVELOPED IN REAL 
SAMPLES 
 
The method that was developed was applied for the analysis in samples of hair and plasma 
collected from mice (five replicates per day) treated with different drugs: citalopram, clozapine, 
haloperidol, and saline solution (control samples) for different periods of time: 1, 2, 4, 8, 15 and 
30 days. 
In order to see if any differences statistically significant between the days a non-parametric test, 
Kruskal–Wallis test (or H test), was performed. 
The test proposed by Kruskal and Wallis evaluates whether two or more samples are from the 
same distribution [134,135]. The null hypothesis is that all the samples come from identical 
population distributions [134-136]. 
Given multiple samples (k) with ni observations in the ith sample, the H statistic tests the null 
hypothesis that the samples come from identical population distributions [136]. 
This hypothesis is tested by ranking the observations from 1 to N (giving each observation in a 
group of ties the mean of the ranks tied), finding the k sum of ranks, and computing an H 
statistic [134,136]. If there is no tie in all the values, the test statistic is: 
 
Where, N is the total number of values in all samples; ni is the number of values contained in the 
ith sample, and Ri is the sum of ranks in i
th sample. 
For ties in the scores, the tied observations are assigned the average of the ranks that would be 
assigned if there were no ties [136] and thus the calculation of the test statistic should be 
changed slightly [134].The correction factor for ties is: 
 
   
  
      
 
  
 
  
       
 
   
 (4.24) 
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 (4.25) 
 
Where, g is the number of groups of tied values, and ti is the number of tied values in the i
th 
group. 
Then it can compute H with these new ranks but first the H is divided by this correction 
[134,136]: 
 
   
 
 
 (4.26) 
 
Actually the equation (4.26) is the general solution that holds no matter there are ties or not. If 
there is no tie, C = 1 and thus,       [134]. 
This statistic is then compared with a tabled value for the H statistic. This comparison will 
determine whether the null hypothesis is accepted or rejected [136]. 
If there are more than five observations in each sample, the H statistic has been shown to be 
distributed approximately as a chi-square distribution (with degrees of freedom = C-1) and 
therefore chi-square tables are used for the comparison. If  the samples have fewer than five 
observations special approximations through exact tables, called the "critical values" for the H 
statistic [136]. 
If the computed value of the H statistic is larger than the tabled value of the H statistic, the 
results are significant and the null hypothesis is rejected and the probability that the null 
hypothesis is true is less than 0.05 [136]. 
When the obtained value of the H statistic is statistically significant, it indicates that at least one 
of the groups is different from the others. It does not indicate, however, which groups are 
different or whether the difference is meaningful, nor does it specify how many of the groups 
are different from each other [136]. 
In order to see where the differences are presented is used a procedure, called "multiple 
comparisons methods” that constructs pair-wise multiple comparisons to locate the source of 
significance [136]. They are also called post hoc or posteriori tests as they are only carried out 
after the fact, i.e., after a significant effect. 
An effective way of doing pairwise simultaneous inference was introduced by Dunn [137]. When 
sample sizes are unequal, or in the presence of tied ranks, it is recommended the Dunn’s test. 
Because it takes into account tied ranks, when group samples sizes are equal [135]. 
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First the data is combined and ranked. Second it is found the group mean ranks and then is 
calculated the standardized absolute differences of these average ranks by the next equations, 
which is the standard error that has a correction term for tied ranks[137,138]. 
         
 
, j=1,.., k and j≠i (4.27) 
    
  
  
, i=1,....,k (4.28) 
    
      
  
   
 
  
 
 
  
  (4.29) 
 
Where,    is the sum of the ranks for the i
th treatment (i=1,....,k and j=1,.., k); k is the number of 
samples (k > 2);    is the number of observations for the i
th treatment. 
A new α is computed for each multiple comparisons test based on the overall α level for the 
study and the number of comparison to be made. The new α is equal to α/C, where C is the 
number of post hoc tests to be performed [139]. 
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5. RESULTS AND DISCUSSION 
 
5.1. METHOD DEVELOPMENT  
 
The results obtained during method development, used to determine which parameters to use 
in the spectrometric conditions are presented in this section. 
The optimization of some parameters is necessary, as was mentioned in the section 4.6.2, to 
establish optimal conditions for each of the molecules. 
One of the important parameters that is optimized is the CE, which generate product ion scans 
at different collision energies (gradual increasing) to select the product ion candidate to monitor. 
This way it can be obtained the optimum CE for each product ion. As an example, the CE values 
corresponding to three different fragments of haloperidol are represented in the Figure 5.1, 
where for instance to obtain the lowest fragment (with m/z of 95) will need a higher CE than to 
obtain the largest fragment (with m/z of 164). They represent the amount of energy that the 
precursor ions receive as they accelerated into the collision cell, where they collide with gas 
molecules and fragments.  
 
 
 
Figure 5.1- Collision energy ramping values for three fragments of haloperidol. The fragments 
that each peak corresponds are indicated above the peak. 
 
Another parameter that is optimized in the development of the method is the DP. This 
parameter is used to minimize solvent cluster ions, which may attach to the analyte. If DP is too 
high, the analyte ion itself may fragment, so an appropriate value for each molecule is 
necessary. An example of optimization of this parameter is shown in Figure 5.2 for the 
haloperidol, where the maximum height of the peak corresponds to the best value of DP. 
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Figure 5.2- Declustering potential ramping for haloperidol. Results show a maximum intensity at 
61V for haloperidol. 
 
After these parameters are optimized, fragmentation mass spectra for each analyte of interest 
can be observed with all fragments of the analyte that is obtained in CID conditions. This 
parameter controls the pressure of collision gas in the collision cell during Q3 scan, helping to 
focus the ions as they pass through the collision cell (q2). With the fragmentation spectra it is 
possible to choose what transitions to monitor. The choice of product ions that are close in m/z 
to the precursor implies that the neutral loss fragment is of low molecular mass. For many 
reasons product ions of ‘low mass’ can be problematic for MRM detection. One of these reasons 
is due to the observation that ‘chemical noise’ (background) is considerably more intense at 
lower m/z values. The ideal product ion to use in MRM method would be the one that can be 
observed at good relative abundance in the spectrum. 
The fragmentation spectrum of haloperidol (Figure 5.3) shows a peak with m/z of 376 
corresponding to the intact molecule, and three most intense fragments, with m/z 123, with m/z 
165 and with m/z 95, which were chosen to monitor the haloperidol, for the reasons that were 
stated before. It can also be seen other peaks less intense with m/z of 113 and 75. 
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Figure 5.3- Averaged fragmentation mass spectra of haloperidol. A solution of 0.453 μM of 
haloperidol was infused at a flow rate of 9 μL/min and CE was ramped between 5 to 130 eV. 
 
 
These fragments are characteristic for haloperidol and they are due to loss of parts of the 
molecule that are illustrated in the Figure 5.4. The fragment that has the highest intensity, with 
m/z of 123, corresponds to F-C6H4-CO
+. The second more intense, with the m/z of 165, 
corresponds to F-C6H4-C(=O)-CH2CH2CH2
+. And lastly, the fragment with m/z of 95 corresponds to 
F-C6H4
+. 
 
 
 
 
Figure 5.4- Characteristic fragments observed in mass spectrometry for the molecule of 
haloperidol [M+H]
+
, with m/z of 376 [140]. 
 
 
 
The same approach was used for clozapine (Figure 5.5). Once again, the peak with m/z of 327 
corresponds to the m/z value of the intact molecule because here the value of CE applied was 
low. It can be observed in the spectra of clozapine, three more intense peaks. The fragments 
with m/z of 192, 270 and 164, were consequently chosen to monitor this molecule. 
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Figure 5.5- Averaged fragmentation mass spectra of clozapine. A solution of 1 μM of clozapine was 
infused at a flow rate of 9 μL/min and CE was ramped between 5 to 130 eV. 
 
 
The fragments characteristic for clozapine are illustrated in the Figure 5.6. The most intense 
peak, with m/z of 192, corresponds to C13H8N2.
 The second peak more intense, with m/z of 270, 
corresponds to C15H12ClN3.
 
 
 
 
Figure 5.6- Characteristic fragments observed in mass spectrometry for the molecule of clozapine 
[M+H]
+
, with m/z of 327 [140]. 
 
 
The same approach was used for citalopram (Figure 5.7).  The peak with m/z of 325 corresponds 
to the m/z value of the intact molecule. As it can be seen in the spectrum, the fragments with 
m/z of 262 and 109 are the most intense fragments so consequently these were chosen to 
monitor this molecule. 
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Figure 5.7- Averaged fragmentation mass spectra of citalopram. A solution of 0.125 μM of 
citalopram was infused at a flow rate of 9 μL/min and CE was ramped between 5 to 130 eV. 
 
 
The fragment 262 m/z corresponds to C18H13NF, probably is due to the loss of dimethylamine 
that corresponds to the fragment with m/z of 280. Another intense fragment with m/z of 116 
corresponds to the molecular structure NC-C6H4-CH2
+. And the most intense fragment, with m/z 
of 109, corresponds to F-C6H4-CH2
+ (Figure 5.8.) 
 
 
 
 
Figure 5.8- Characteristic fragments observed in mass spectrometry for the molecule of 
citalopram [M+H]
+
, with m/z of 325 [140]. 
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The fragmentation mass spectra for the two internal standards (Haloperidol-D4 and 
desipramine) are represented in the Figure 5.9.   
 
a) 
 
b) 
 
Figure 5.9- Averaged fragmentation mass spectra of haloperidol-D4 a) and of desipramine b). A 
solution of 0.100 μM for haloperidol-d4 and 1.14 μM for desipramine were infused at a flow rate of 
9 μL/min and CE was ramped between 5 to 130 eV. 
 
 
The fragmentation of the molecule of haloperidol-D4, used here as internal standard is very 
similar to the fragmentation spectrum of haloperidol, since the difference between them is the 
substitution of four hydrogens by four deuteriums, with m/z of 380.  The characteristic 
fragments are represents in Figure 5.9.a. 
The peak with m/z of 267 corresponds to intact molecule of desipramine. The most intense 
fragment, with m/z of 72, corresponds to CH2=CH–CH2–NH2CH3
+ and is represented in the Figure 
5.10. 
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a) 
 
b) 
 
 Figure 5.10- Characteristic fragments observed in a) the molecule of haloperidol-D4 [M+H]
+
, with 
m/z of 380 and b) the molecule of desipramine [M+H]
+
, with m/z of 267 [140]. 
 
 
5.1.1. ISOTOPIC IDENTIFICATION 
 
 
As it was demonstrated before, the compound structure was evaluated and this is important 
because it can be confirmed the molecule structured and if it contains any elements such as 
chlorine, bromine or boron, which would result in a unique isotope pattern.  
In this project two of the three compounds (haloperidol and clozapine) in their structures, 
besides carbon and others, have an element that appears as natural isotope, the chlorine. The 
natural chlorine is a mixture of 75.77% of isotope 35Cl and 24.23% of isotope 37Cl [78,96] .  
In the Figure 5.11, it can be observed the isotopic distribution for haloperidol and also for 
clozapine. For the haloperidol, the peak with m/z of 376 corresponds to the molecule with the 
isotope 35Cl and the peak with m/z of 378 corresponds to the molecule with the isotope 37Cl 
(Figure 5.11.a.). 
A similar analysis can be performed with the molecule of clozapine, where the peak with m/z of 
327 corresponds to the molecule with the isotope 35Cl and the peak with m/z of 329 corresponds 
to the molecule with the isotope 37Cl (Figure 5.11.b.) 
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a) 
 
b) 
 
Figure 5.11- Isotopic distribution for haloperidol a) and clozapine b). A solution of 0.08 μM for 
haloperidol and 1 μM for clozapine were infused at a flow rate of 9 μL/min and CE was ramped 
between 5 to 130 eV. 
 
 
Next, the chromatography was evaluated with the RT and the transitions of the isotopes being 
shown in Table 5.1. These fragments of chlorine 37 were monitorized only for confirmation that 
the present molecule is the molecule of interest because these transitions do not work so well, 
for the quantification, as the others transitions. However, this is one more way of confirming 
that we are in the presence of the molecule of interest. 
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Table 5.1- Mass/charge ratio (m/z) of the ionic fragments of the isotopic transition of clozapine 
and haloperidol monitorized in MRM mode and the retention time (RT) used for confirmation of 
the compounds. 
 
Compound 
Transitions (m/z) 
RT (min) 
Q1 Q3 
Clozapine 
(chloride 37) 
329.2 
84.1 4.05 
192.2 4.05 
Haloperidol 
(chloride 37) 
378.2 
164.8 6.43 
122.8 6.43 
95.2 6.43 
 
 
 
 
5.2. COMPOUND IDENTIFICATION 
 
The previous results allow the selection of the ionic transitions (m/z) to be monitored in MRM 
mode (Table 5.2) to each PD and also the IS used. 
 
 
Table 5.2- MRM transitions and retention time (RT) used for the identification of compounds. 
 
Compound 
Transitions (m/z) 
RT (min) 
Q1 Q3 
Citalopram 325.3 
109 6.06 
261.9 6.07 
83.1 6.06 
Clozapine 327.2 
269.9 4.07 
191.9 4.06 
163.8 4.05 
Haloperidol 376.0 
164.7 6.42 
122.9 6.43 
94.8 6.43 
Desipramine 267.3 
72.2 7.14 
208 7.16 
190.8 7.13 
Haloperidol – D4 380.2 
127.1 6.39 
168.4 6.41 
98 6.42 
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The criteria of WADA (section 5.9.) were applied and the results are presented and explained in 
the section related to the Selectivity (section 5.3.1). To apply the criteria for unequivocal 
identification of PD, mandatory the use of an IS for all analytes.  
Often, the choice of an appropriate internal standard lies on the following criteria: the IS should 
not be present in the samples to be analyzed and the IS also should be chemically and physically 
similar to the analyte (ideally, a stable-isotope-labeled IS), and should elute in a similar time to 
the analyte [79]. 
An isotope that is used extensively is deuterium, here the molecular weight of the compound is 
higher than the unlabelled precursor and this is often sufficient to ensure that the ions in the 
molecular ion region of the unlabelled compound do not occur at the same m/z ratios as those 
from the labelled molecule [79]. For these reasons, for the haloperidol it was used as IS the 
haloperidol-D4. 
Desipramine was the IS used for the citalopram and the clozapine, as already mentioned in 
literature [90,141].  
 
 
5.3. ANALYTICAL METHOD VALIDATION 
5.3.1.  SELECTIVITY 
 
Potential interfering substances in a biological matrix include endogenous matrix components, 
metabolites, decomposition products, concomitant medication and other exogenous 
compounds [106]. So it is very important to obtain a signal free from the influence of other 
species contained in the sample and this signal should be unequivocally assigned to the analyte 
of interest [142].  
One simple way to establish method selectivity in biological fluids, which is becoming state of 
the art in the procedures used in the majority in the published work related to the method 
validation, is to prove the lack of response in blank matrix. Normally is used at least six 
independent sources of the blank matrix [101,143]. However, interferences, present in small 
quantities, may adversely affect the quantification of unknown samples at concentrations 
approaching the limit of quantification [143]. Therefore, it is recommended that the selectivity 
of the method should be established with respect to endogenous substances, metabolite(s) and 
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known degradation products [143], spiking pure substance of interest with appropriate levels in 
a blank matrix and process the sample [144]. These results are compared with blank matrix 
processed without the analyte [119,120,145]. 
Thus, as was mentioned in the methodology (section 4.9.1) six individual sources of blank matrix 
(plasma and hair) were divided in two aliquots, each. One aliquot was spiked with the analytes 
and another aliquot was not spiked. It was considered that the negative samples were the 
aliquots without the analytes and the IS (citalopram, clozapine, haloperidol, desipramine and 
haloperidol-D4) and the aliquots that were spiked with the analytes were considered the 
positive samples. 
In the results for the hair, for instance, the selectivity of the method for haloperidol can be 
evaluated visually in the chromatogram, where one transition was selected, 376.0164.7 
(Figure 5.12). 
It can be observed in the negative samples (Figure 5.12 a-f) that only in sample 5 a small peak 
appears with the same RT of haloperidol. However, the peak was not integrated because the S/N 
was lower than 3. Still, in the positive samples (Figure 5.12 g-l), haloperidol was found in the 
expected retention time, with a good intensity signal and apparently with no more interferents. 
Selectivity results for plasma are presented in the Figure 5.13 also for the transition 376.0165 
of the haloperidol.  
In the negative samples (Figure 5.13. a-f)) some small peaks are observed in all samples at the 
same RT of the haloperidol. However, the S/N was lower than 3 for all samples. In the positive 
samples (Figure 5.13. g-l)) only the haloperidol appears with a higher intensity than the intensity 
of the interference which appeared in negative samples in the same RT. 
To confirm the selectivity, i.e., unequivocal identification of the analytes, was also used the 
WADA criteria [110] pre-establish in the section 4.9.1. by analyzing the data in the excel 
spreadsheet created for the analysis of analytical method validation data. Both positive and 
negative samples were also analyzed in the same excel spreadsheet and the criteria for the 
negatives were the reverse of the positive ones.  
In the WADA technical report, the RT and the RTRatio are presented as criterion for LC part and 
also it is stated that between RT and RTRatio it can be chosen whichever is smaller [110]. In this 
case it was chosen the RTRatio because better results were obtained with this one. 
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a) g) 
  
Figure 5.12- Chromatographic spectra of the haloperidol (376164.7) for the selectivity in hair. 
a-f) Six different sources of blank samples that were not fortified with the citalopram, clozapine, 
haloperidol, desipramine and haloperidol-D4 (negative samples). g-l) The same six blank samples 
that were fortified with citalopram, clozapine, haloperidol, desipramine and haloperidol-D4 
(positive samples). 
 
 
 
 
 
 
 
b) 
c) 
d) 
e) 
f) 
h) 
i) 
j) 
k) 
l) 
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a) g) 
  
Figure 5.13- Chromatographic spectra of the haloperidol (376164.7) for the selectivity in 
plasma. a-f) Six different sources of blank samples that were not fortified with the citalopram, 
clozapine, haloperidol, desipramine and haloperidol-D4 (negative samples). g-l) The same six blank 
samples that were fortified with citalopram, clozapine, haloperidol, desipramine and haloperidol-
D4 (positive samples). 
 
 
An example for one of the six hair samples that were used to study this parameter for 
haloperidol is presented in the Table 5.3. Through the analyses of the table, it can be seen that 
in the negative samples no chromatographic signal was detected and in the positives are within 
the values calculated according to WADA. 
 
 
b) h) 
c) i) 
d) j) 
e) k) 
f) l) 
82 |RESULTS AND DISCUSSION 
 
 
Table 5.3- Application of acceptance WADA criteria for unequivocal identification of the 
haloperidol in hair. 
Positive 1 
Transition Absolute area Relative area S/N RTA RTIS RTRatio 
376.0164.7 10716.280 55.225 37.544 6.625 6.591 1.005 
376.0122.9 19404.737 100.000 67.472 6.622 6.591 1.005 
376.094.8 9173.733 47.276 32.296 6.622 6.591 1.005 
Negative 1 
Transition Absolute area Relative area S/N RTA RTIS RTRatio 
376.0164.7 - - - - - - 
376.0122.9 - - - - - - 
376.094.8 - - - - - - 
Criteria 
Transition Relative Abundance range S/N 
 
ΔRTRatio  
376.0164.7 45.225 65.225 
>3 
0.995 1.015 
376.0122.9 90.000 110.000 0.995 1.015 
376.094.8 37.821 56.731 0.995 1.015 
 
In relation to the other five positive samples (see Appendix 8.2 in the Table 8.6) only one 
transition for two positives (positive 4, transition 376.094.8 and positive 5, transition 
376.0164.7) is outside the interval for the relative abundance. However the S/N was higher 
than three and the RTRatio was inside the interval pre-established. Therefore, it is expectable to 
unequivocally identify haloperidol. For the other 5 negatives, with the exception of negative 5, 
nothing was detected that interfere with the detection of haloperidol. 
In the case of citalopram (see Appendix 8.2 in the Table 8.4), with the exception of one transition 
(325.3261.9) for positive 3, all values for the positives samples are within the criteria. All the 
negative samples, in the first transition (325.3109.0), presented a chromatographic signal, but 
the S/N was lower than three.  Therefore the method is selective for this analyte. 
In the case of clozapine (see Appendix 8.2 in the Table 8.5), some values of RTRatio and also of 
relative abundance do not fit the criteria that was pre-establish for this analyte. Although in 
negatives no interference peaks were detected.  
The same approach was used for another matrix, plasma, and the results of one of the six blank 
samples that were used for haloperidol are represented in Table 5.4, where all values for all 
transitions in the positive sample are within the criteria and also for the negative sample. In 
relation to the other 5 positive samples all transitions are within the criteria proposed by WADA. 
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Also in negative samples no interferences were observed and therefore, the method is selective 
for haloperidol in plasma samples (see Appendix 8.2 in the Table 8.3). 
 
Table 5.4- Application of acceptance WADA criteria for unequivocal identification of the haloperidol in 
plasma. 
Positive 2 
Transition Absolute area Relative area S/N RTA RTIS RTRatio 
376.0164.7 41407.481 59.955 147.232 6.755 6.719 1.005 
376.0122.9 69064.705 100.000 256.026 6.754 6.719 1.005 
376.094.8 26602.638 38.518 97.336 6.754 6.719 1.005 
Negative 2 
Transition Absolute area Relative area S/N RTA RTIS RTRatio 
376.0164.7 - - - - 6.497 - 
376.0122.9 77.749 100.000 0.472 6.302 6.497 0.970 
376.094.8 - - - - 6.497 - 
Criteria 
Transition Relative Abundance S/N 
 
ΔRTRatio 
376.0164.7 47.874 67.874 
>3 
1.004 1.006 
376.0122.9 90.000 110.000 1.005 1.007 
376.094.8 29.723 44.585 1.004 1.006 
 
In the case of citalopram, the second transition (325.3261.9) of four positives (see Appendix 
8.2 in the Table 8.1), the value of relative area is outside the interval of criteria established but 
the S/N is greater than three. The RTRatio, only for one transition of one of positive (positive 2, 
transition 32583.1) is outside the criteria. In the negative samples, despite of have being 
detected chromatographic peaks, those were considered irrelevant since fulfilled the criteria for 
negative samples. The method has proved to be selective for this molecule. 
As in the case of hair, some values of RTRatio and also of relative abundance do not fit the criteria 
that was pre establish for clozapine (see Appendix 8.2 in the Table 8.2). Although in samples 
were not detected any interferences at the same retention time of clozapine.  
These results reinforce the importance to use multiple sources of blank matrix, since increases 
the heterogeneity of samples, allowing to check the variability between samples, which can give 
rise to different results.  In addition, the biological samples (hair and plasma) used for the 
method validation are from different species of mice from those used in the quantification. 
Furthermore, the WADA state that in ultimate analysis, the laboratory should establish its own 
criteria for identification of a compound [110]. 
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In this case, a value outside the criteria for more than two positive samples for the same 
transition was not observed for the citalopram and the haloperidol. So it can be said that no 
peaks were detected with significance enough that might interfere in the analysis of haloperidol 
and citalopram. For clozapine the selectivity only was proven to one transition, with m/z 
327192, that was used in the quantification. 
 
 
5.3.2. LINEARITY 
 
 
It is important to know the response of the instrument with regard to the concentration of 
analyte over a specified concentration range [101,105]. Thus, the linearity of an analytical 
procedure is its ability to obtain test results which are directly proportional to the concentration 
of the analyte in the sample [126]. This can be performed by the analysis of spiked calibration 
samples and plotting the resulting responses versus the corresponding concentrations [101]. 
To conduct this study, it was assumed that the results obtained obeyed a simple linear 
regression model. Then, to evaluate the linearity it was used a spreadsheet in excel developed in 
the laboratory. All data were subjected to this statistical analysis (see Appendix 8.3). 
The calibration curves of haloperidol, clozapine and citalopram are represented in Figure 5.14, 
Figure 5.15 and Figure 5.16, respectively.  
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Figure 5.14- Calibration curve for the transition 376.0164.7 of haloperidol. 
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Figure 5.15- Calibration curve for the transition 327.2191.9 for clozapine. 
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Figure 5.16- Calibration curve for the transition 325.3109.0 for citalopram. 
 
According to the results, the model appears to be linear for all the compounds, in the working 
range, through the analysis of the coefficient of correlation and determination (R>0.99 and R2 
>0.99). 
However, these parameters are not sufficient to prove the linearity of the calibration model. 
Indeed, a significant proportion of errors at the lower end of the calibration curve can coexist 
with acceptable R and R2 values. Therefore, other parameters, such as standard errors of the 
regression (Sy/x), confidence limits for the intercept at 95% confidence level with a zero-value 
included (Table 5.5) and also visual inspection of plots of residuals versus concentration 
(appendix 8.3) are needed to perform a complete evaluation of the linearity. 
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Therefore, the standard error of the linear regression allowed the exclusion of outliers (residual 
values > 2 × ǀSy/xǀ), which was necessary in citalopram and clozapine analysis. After outliers have 
been removed from the data, the linear regression model has been re-evaluated. The value of R 
and R2 were indeed higher than 0.99; for the intercept, the zero-value was included within the 
confidence interval of 95%, however the plots of residuals versus concentration (see Appendix 
8.3, Appendix 8.4 and Appendix 8.5) appear to show residuals not randomly distributed around 
the x-axis. In fact, the variances tend to increase as the concentration increases, which usually 
points to the hypothesis of others models of calibration beyond the simple linear regression. 
Therefore, the calibration curve was tested by the Mandel’s fitting test. 
 
Table 5.5- Results for the simple linear regression model. 
 
Compound Transition
1
 
Working 
range 
(pmol/μL) 
Calibration Curve R
2
 
Interval of confidence 
Lower 
limit 95% 
Upper 
limit 95% 
Citalopram 325.3109.0 0.05 - 3 y = 4.7068x - 0.0165 0.998 -0.215 0.182 
Clozapine 327.2191.9 0.05 - 2 y = 2.4692x - 0.0369 0.998 -0.122 0.049 
Haloperidol 376.0164.7 0.05 - 5 y = 1.3915x - 0.0223 0.998 -0.102 0.058 
1 
Transition used in the quantification 
 
 
5.3.2.1. MANDEL TEST 
 
To evaluate if the simple linear regression adequately fits in the data, visual evaluation, 
regression statistics and residuals evaluation are not enough [101,115,116]. Thus, it was 
performed a Mandel’s fitting test (see section 4.9.2.1) to determine if it is the linear or the 
quadratic regression model that better fits the data [116,117].  
It was demonstrated that linear adjustment is more appropriate for the calibration curves for all 
the compounds, since the      was lower than the       (Table 5.6). 
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Table 5.6- Results obtained in the Mandel test. 
 
Compound Transition
1
 Mandel test (    ) 
Criteria 
     ≤       (N-1; N-1; 0.95) 
Citalopram 325.3109.0            ≤ 3.179   (9; 9; 0.95) 
Clozapine 327.2191.9           ≤ 3.438   (8; 8; 0.95) 
Haloperidol 376.0164.7           ≤ 2.978   (10; 10; 0.95) 
1 
Transition used in the quantification. 
 
 
5.3.3. WORKING RANGE 
 
Linear regression assume that a constant variance of measured values occurs over the range 
(homoscedasticity) [97,101,121] and that the residuals are randomly distributed along the x-axis 
[97,112,113,116]. 
However, this situation is rare, especially in bioanalytical methods, so it is important to confirm if 
statically there is significant difference between variances within the limits of the working range 
[112,121]. Plots of residuals versus concentration were obtained and an example for haloperidol 
is show in the Figure 5.17. These plots clearly show an increase of variance as a function of 
concentration, which lead us to the hypothesis of heteroscedastic data. Therefore, it was 
performed a test of homogeneity of variances (F-test). 
 
 
 
Figure 5.17- Plot of residulals versus concentration in the limits of the working range. 
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With the test performed to verify the variances (equations (4.7) and (4.8) in section 1.5.3.), 
differences between the values of the variances within the limits of the working range (0.05 - 
5μM) were observed. 
Results of the homogeneity test (Table 5.7) show that values for       were above the tabled 
value of       ., consequently  there is a significant difference between the variances, which 
mean heteroscedastic data, for all compounds. 
 
 
Table 5.7- Results obtained in the test of homogeneity of variances. 
 
Compound Transition
1
 
Test of homogeneity of 
variances (    ) 
Criteria 
     ≤       (N-1; N-1; 0.95) 
Citalopram 325.3109.0 3373.9 
     ≤ 3.8   (9; 9; 0,95) 
 
Clozapine 327.2191.9 1311.6 
Haloperidol 376.0164.7 2104.0 
1 
Transition used in the quantification. 
 
 
 
5.3.3.1. WEIGHTED LEAST SQUARES LINEAR REGRESSION 
 
In presence of heteroscedastic data different approaches could be followed, as already 
mentioned. Therefore, it is possible to reduce the working range until homoscedasticity is 
observed (     ≤      ) [118,121], to use the inverse of variance (1/S
2) in each point of the 
calibration curve, or even to use the WLSLR [113,122], choosing the approprieted weighting 
factor,    [112]. In this project, it was used WLSLR and therefore it was necessary to choose an 
appropriate regression model for each compound, with the application of empirical weighting 
factors: 
 
 
; 
 
  
; 
 
  
; 
 
 
; 
 
  
 or 
 
  
 [112,125]. 
Plots of %RE versus concentration for unweighted (model 1) and weighted (models 2 – 7) of 
haloperidol obtained in intermediate precision study are shown in Figure 5.18. As it can be seen, 
the unweighted model overestimates the concentration, especially in lower ranges of the 
calibration curves, near LOQ. 
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As a measure to choose the weighting factor, it was used the percentage of the relative error 
(    ), which compares the estimated concentration, from the regression equation obtained 
for each  ,  with nominal standard concentration in the sample [112]. The best weighting factor 
is the one which presents the lowest value of the sum of the relative errors (       ) in the 
working range [112,123]. 
So, according to what was stated before, the         of the different weighting factors were 
compared and for haloperidol it was chosen the model 3 (     
  ), since the error associated 
to this model was lower compared to the others models. Additionally, the chosen model 
presents a better %RE distribution scatter (Figure 5.18.).  
For clozapine the model 4 (      ) was chosen and for citalopram was the model 5 
(     
  ) (Table 8.9 and Table 8.10 in the Appendix 8.7) for the same reasons presented for 
haloperidol. 
 
 
Table 5.8- Relative errors (%RE) and the respective sum of the relative errors (       ) generated 
by the use of simple linear regression and weighted linear regression for each weighting factor (  ) 
for haloperidol. 
 
Nominal 
concentration 
(μM) 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Unweighted 
(  =1) 
 
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
  
 
0.05 511.16 51.89 13.20 58.78 16.43 171.52 176.19 
0.1 259.97 47.08 38.70 47.68 38.71 100.68 102.06 
0.15 141.77 26.26 26.07 26.34 23.55 37.83 38.94 
0.2 104.25 30.07 28.64 30.86 29.40 46.35 47.41 
0.25 64.72 25.22 23.26 26.19 25.24 14.28 14.48 
0.5 20.75 21.62 15.05 22.01 15.17 18.65 18.60 
1 14.85 18.63 9.45 20.02 11.89 20.98 21.63 
1.5 33.67 30.20 24.13 31.29 26.49 33.12 33.55 
2 40.21 32.11 18.37 33.74 20.13 37.83 38.65 
3 29.47 20.10 21.46 22.05 22.02 25.19 26.14 
5 16.61 29.19 42.54 27.85 41.36 22.73 22.02 
        1237.43 332.36 260.87 346.81 270.39 529.16 539.67 
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Figure 5.18- Distribution of the %RE versus concentration for haloperidol (transition 376.0164.7) 
obtained for model 1 (  =1); model 2 (      ); model 3 (     
  ); model 4 (      ); model 5 
(     
  ); model 6 (        ) and model 7 (       ). 
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5.3.4. LIMITS: LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION 
 
As was mentioned before, there are different approaches for the determination of LOD and LOQ 
such as: the precision and accuracy of the data, the signal to noise ratio (S/N), and  the 
parameters of the analytical curve [115]. 
The first two methods are widely used due to their speed, but the first might give rise to higher 
values for LOQ and the second has the disadvantage of relying on qualitative parameters. 
The estimation method based on parameters of the analytical curve shows greater statistical 
reliability because it takes into account the confidence interval of the regression. Limit of 
detection in this case is defined as the minimum concentration of a substance that can be 
measured and reported with 95% confidence [115]. Therefore, using the equations (4.15) and 
(4.16) (section 4.10.4), with the appropriate transformation due to the weigh factor, can be 
calculated the LOD and LOQ. 
The results for LOD and LOQ, in the working range previously selected, of each molecule are 
present in the Table 5.9. 
 
Table 5.9- Results for LOD and LOQ of each molecule  
Compound Transition
1
 
LOD 
(pmol/μL) 
LOQ 
(pmol/μL) 
Citalopram 325.3109.0 0.012 0.037 
Clozapine 327.2191.9 0.014 0.044 
Haloperidol 376.0164.7 0.015 0.045 
1 
Transition used in the quantification. 
 
 
The values achieved for LOD and LOQ were determined using the calibration curve parameters 
(slope and standard error) and therefore these values are dynamic, since daily calibration curves 
originate different parameters. 
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5.3.5. PRECISION AND ACCURACY 
 
Results obtained during the study of precision and accuracy are show in (Table 5.10) and they 
were estimated through one-way ANOVA analysis and the equations (4.17) and (4.18) (section 
4.9.5). 
Precision (both repeatibility and intermediate precision) were characterized in terms of the 
percentage of coeficcient of variation (%CV). The limits of acceptable variability were set at 15% 
for all concentrations, except at the LOQ, for which 20% were accepted [105,106]. 
The results obtained for repeatability were within the acceptance criteria, except for the lowest 
concentration level of citalopram (%CV = 35.6). In the case of the intermediate precision the 
results obtained were not among the criteria pre-establish,presenting values between 17.69-
31.25 %. 
Accuracy was evaluated in terms of mean relative error (    ) between the measured and 
the nominal concentrations for the calibrators. The limits of acceptable variability were set to be 
± 15% of the accepted true value, except at the LOQ, where ±20% was accepted [130]. As it can 
be observed in Table 5.10, the results obtained show that the method is accurate for 
quantification of all the analytes. 
 
 
 
Table 5.10- Results of the precision and accuracy at three levels of concentration (n=15). 
 
Compound 
Nominal 
concentration 
(μM) 
Repeatability 
(%    ) 
Intermediate 
precision 
(%    ) 
     
Estimated 
concentration 
(μM) 
Citalopram 
0.075 35.69 29.72 0.55 0.075 
0.75 5.50 26.88 8.39 0.81 
2.75 5.71 31.25 9.27 3.0 
Clozapine 
0.075 12.56 17.69 -0.32 0.073 
0.75 7.62 24.92 7.87 0.81 
1.25 7.84 19.16 8.94 1.36 
Haloperidol 
0.075 14.05 22.35 13.51 0.08 
0.75 7.11 19.03 -2.42 0.73 
2.75 8.40 13.70 -2.00 2.69 
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5.3.6. CARRY-OVER 
 
As mentioned above, carry-over is the amount of the analyte retained in an LC system from a 
preceding sample that carries over into the next injected sample [146]. This phenomena can be 
measured by the response of the blank sample after the injection of a preceding sample at high 
concentration [146]. 
Usually, the procedure to evaluate carry-over is performed with the injection of blank samples 
after samples with an expected high concentration [105], but in this project it was also injected 
other levels of concentration, 0.5 μM and 0.05 μM (see section 4.9.8).  
So, a criterion that is accepted to evaluate if the phenomenon is relevant is proposed by EMA, 
where the peak area of the analyte in a blank sample that follows the high concentration 
standard must be less than 20% of the peak area of the limit of quantification and 5% for the IS 
[105]. 
Results for carry-over of citalopram and clozapine show that the criterion establish was fulfilled, 
as for the IS used, desipramine (Table 8.12 in the Appendix 8.8), thus no significant carry over 
was observed. In the clozapine, same occurs (Table 8.14 in the Appendix 8.8), so it can be said 
that with this molecule does not occur carry-over. 
For haloperidol, the signal detected in the first blank was intense and it was higher than 20% of 
the LOQ. However, the next blanks that were injected are in accordance to the criteria (Table 
8.16). 
These peaks that appear in the blank samples may be caused by analyte retention in previous 
injections [147], which can be absorbed in the autosampler or can be residues on columns  
[148].  Another cause may be the possibility of the inadvertent addition of the analyte in the 
sample blank (contamination), or non-analyte related peaks which can arise either from a 
previous injection (late eluters) or the current injection (interfering endogenous peaks) [147].  
Sample carry-over is a major problem that can influence the accuracy and precision of the 
method, with the consequences being more pronounced at lower concentrations [148]. 
Therefore, results that were obtained show that carry-over should be investigated and 
minimized, so it is important to inject blanks with the mobile phase, between samples, to reduce 
this phenomenon. In this project this phenomenon was minimized with a blank injected 
between samples and three blanks were introduced between batches. In this way, it was 
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ensured that the carry-over did not affect the analysis of samples, in particular in the 
quantification of real samples. 
 
 
5.3.7. RECOVERY 
 
Recovery is the amount of the substance of interest added to the blank matrix which is capable 
of being extracted and quantified [145]. This parameter basically evaluates the extraction 
efficiency of an analytical process of the biological samples [102,129]. 
Thus, recovery is best tested by comparing the response of blank matrix spiked before extraction 
with the response of extracted blank matrix to which analyte has been added at the same 
nominal concentration, just before injection [120,143]. This was the procedure that was 
performed in this project to study the recovery (see section 4.9.8) and additionally, it was also 
studied the recovery of the two IS (desipramine and haloperidol-D4), which is recommended to 
be determined independently [120]. 
Despite the recommendations related to values close to 100% recovery, Peters et al. [100,130], 
stated that the value for recovery is not important as long as precision, accuracy, LOQ and LOD 
are satisfactory. 
According to Ribani et al [145]., values between 70 to 120%, with a precision of ± 20%, are 
acceptable intervals for recovery. Also, depending on the analytical complexity and complexity 
of the sample, these values can be 50 to 120%, with a precision of ± 15%. 
Other authors state that it is unlikely that recoveries of 50% or less will compromise the integrity 
of the method [120] and it is not needed to provide good accuracy and precision if adequate 
detection can be attained [107]. 
Values of recovery for hair were between 8.9 to 45.5 % (Table 5.11). The dispersion of the 
results, measured by % CV, was higher for lower concentrations. Here, it is also important to 
take in count that the efficiency of the method varies depending on the concentration of the 
substance and in most cases the dispersion of results increases with the decrease in the 
concentration, so the recovery can differ substantially from the high and low concentrations 
[145].  
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Table 5.11- Recovery, in percentage, of the extraction of the hair for each compound at three 
concentration levels of concentration. 
 
 Recovery ± % CV 
Compound 0.1 μM 0.5 μM 3 μM 
Citalopram 34.0± 50.3 34.0± 27.8 38.9± 10.6 
Clozapine 10.7 ± 68.5 8.9 ± 14.4 12.4 ± 9.4 
Haloperidol 39.6 ± 36.4 36.5 ± 31.3 39.9 ± 20.2 
Desipramine 45.5 ± 36.3 36.6 ± 30.4 36.3 ± 18.6 
Haloperidol-D4 43.4 ± 39.7 34.6 ± 27.4 45.2 ± 14.4 
 
 
One explanation of the low values of recovery and high %CV can be compound degradation 
during extraction protocol due to the used high temperature and/or incubation time.  
Recovery results for plasma were between 68.9 to 115.5 % and the % CV were within the criteria 
with the exception of haloperidol-D4 and desipramine (Table 5.12). 
 
 
Table 5.12- Recovery, in percentage, of the extraction of the plasma for each compound at three 
concentration levels of concentration 
 Recovery ± % CV 
Compound 0.1 μM 0.5 μM 3 μM 
Citalopram 87.7 ± 7.4 90.9 ± 15.0 101.5 ± 17.4 
Clozapine 95.8± 23.0 116.1± 12.0 100.4± 15.5 
Haloperidol 89.1 ± 17.9 93.1 ± 19.4 115.5 ± 19.9 
Desipramine 69.9 ± 22.5 68.9 ± 10.0 92.2 ± 22.8 
Haloperidol-D4 82.9 ± 25.9 136.2 ± 52.1 102.1 ± 19.8 
 
 
The procedure of the plasma is simpler and with fewer steps where possible losses of the 
analyte may occur, which may explain better results for the recovery in plasma compared to the 
recovery of hair.  
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5.3.8. MATRIX EFFECTS 
 
One of the most important aspects is competition between an analyte and a co-eluting matrix 
component during ionization. As a result, depending on the environment in which the ionization 
and ion evaporation processes takes place, there is a decrease in analyte ionization (ion 
suppression) or an increase in this ionization (ion enhancement) [132,149]. Residual matrix 
components, endogenous phospholipids in particular, are a significant source of imprecision in 
quantitative analyses commonly conducted by LC-MS/MS [131,132]. 
Matrix effects cause a compound’s response to differ when analyzed in a biological matrix 
compared to a standard solution [150], therefore a methodology to compare these differences 
was developed (see section 4.9.9). Then, it was calculated the ME using the equation (4.22) 
where a negative result indicates ion supression. Otherwise, if a positive result is obtained this 
indicates analyte signal enhancement. Thus, a value of zero would represent no ME [131,133].  
The ME calculated in this manner may be referred as an absolute matrix effect, since the signal 
response of the compound present in the sample extract is compared to the response of a 
compound made directly in a pure mobile phase [132]. 
Results show that in hair matrix mostly of the analytes had positive results for the absolute ME, 
which indicates an enhancement of the signal response (Table 5.13). 
  
Table 5.13- Matrix effects for each compound at three levels of 
concentration in hair matrix 
 
 Matrix Effects  
Compound 0.1 μM 0.5 μM 3 μM 
Citalopram 0.182  -0.103  0.889  
Clozapine 0.126  -0.004  0.991  
Haloperidol -0.082  -0.383  0.464  
Desipramine 0.019  -0.362  0.803  
Haloperidol-D4 0.023  -0.307  0.618  
 
 
The variability in these responses, expressed as % CV can be used as a measure of the relative 
matrix effect for a given analyte (Table 5.14). The values were high and through the analysis of 
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the table it can be seen an additional variability of the peak areas for the analytes that were 
spiked after the extraction procedure than those observed in standard solution. This is an 
indicative of matrix effects since analytes at the same concentrations were spiked into plasma 
extracts. 
  
Table 5.14- Relative matrix effects (expressed as %CV) in hair for the standard solution 
and blank matrix samples spiked after extraction. 
 
 Relative Matrix Effects (% CV) 
 Spike after Standard solution 
Compound 0.1 μM 0.5 μM 3 μM 0.1 μM 0.5 μM 3 μM 
Citalopram 125.6 57.5 35.3 28.1 26.3 26.4 
Clozapine 56.1 50.1 26.4 15.6 26.0 23.9 
Haloperidol 75.9 53.5 25.7 11.3 16.0 18.3 
Desipramine 76.5 56.0 37.6 8.5 35.9 27.7 
Haloperidol-
D4 
72.5 58.9 34.4 3.3 16.3 25.8 
 
The absolute ME were also calculated for plasma and the values obtained were all negatives 
(Table 5.15) which indicates ion suppression. 
Table 5.15- Matrix effects for each compound at three levels of concentration in 
plasma matrix 
 
 Matrix Effects 
Compound 0.1 μM 0.5 μM 3 μM 
Citalopram -0.855 -0.875 -0.896 
Clozapine -0.951 -0.954 -0.951 
Haloperidol -0.863 -0.878 -0.904 
Desipramine -0.865 -0.856 -0.896 
Haloperidol-D4 -0.875 -0.916 -0.887 
 
 
It was also calculated the relative matrix effect and the results are in the Table 5.16. The values 
obtained were lower than those presented for the hair, but the variability of the peak areas for 
98 |RESULTS AND DISCUSSION 
 
 
the analytes that were spiked after the extraction procedure was higher in comparison to 
standard solution, indicating that there is matrix effect. 
 
Table 5.16- Relative matrix effects (expressed as %CV) in plasma for the standard 
solution and blank matrix samples spiked after extraction. 
 
 Matrix Effects (% CV) 
 Spike after Standard solution 
Compound 0.1 μM 0.5 μM 3 μM 0.1 μM 0.5 μM 3 μM 
Citalopram 30.4 8.7 21.9 17.5 6.7 4.1 
Clozapine 23.7 18.0 11.9 0.7 1.8 2.5 
Haloperidol 32.7 10.6 15.7 0.7 1.8 2.5 
Desipramine 23.3 7.3 24.4 11.9 5.1 3.8 
Haloperidol-
D4 
21.3 86.7 20.9 8.0 1.1 3.3 
 
 
 
5.4. APPLICATION OF THE DEVELOPED ANALYTICAL METHOD IN REAL 
SAMPLES 
 
In the previous section it was developed an analytical method for the determination of 
citalopram, haloperidol and clozapine in plasma and hair samples by LC-MS/MS. 
After this study, it is important the application of the method developed in samples which reflect 
reality, and where these drugs are indeed present. This application was made in samples that 
were collected from mice (five replicates per day) treated with different drugs, citalopram, 
clozapine, haloperidol, and saline solution (control samples) for different periods of time: 1, 2, 4, 
8, 15 and 30 days. 
Samples were processed according to the protocol defined for plasma and hair samples (see 
section 4.7 and 4.8) being analyzed on the LC-MS/MS system by a specific order: control 
samples, citalopram samples, clozapine samples and haloperidol samples. First, all samples of 
hair were analyzed and then plasma samples. 
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All compounds were detected in the control samples of plasma. The same was observed for 
samples which were supposed to contain only one of the compounds with the other two being 
present. This cross-contamination was more pronounced in plasma samples than hair samples. 
This fact might indicate an external contamination, for example in the collection procedure (See 
Appendix 8.9). 
The results for the quantification of citalopram, haloperidol and clozapine in hair samples are 
presented in Table 5.18. In some of the samples no signal was detected, especially in samples 
from days 1, 2 and 4. Few samples were quantified but below its limit of quantification, so it 
cannot be said with certainty that this value corresponds to reality. The higher values of 
quantification were obtained for citalopram. Clozapine was present only in few samples, and on 
the other hand, haloperidol was detected in almost samples. 
To visualize the data it was used a scatter plot, where each point represents a single data point 
(each replicate for each day). With this type of graph, depending on how tightly the points 
cluster together, it can be seen a clear trend in the data. Samples used in the graphical 
representation were samples where quantification of the drug was performed with reliably. 
The quantification of citalopram in hair which was collected from mice (5 independent replicates 
per day) that were administered with a solution of citalopram for different periods of time (1, 2, 
4, 8, 15 and 30 days) is summarized in the Table 5.17. 
 
 
Table 5.17- Summary of the citalopram quantification in hair samples. 
Different periods of 
treatment (days) 
Mean 
concentration 
(ng/mg) 
N 
1 0.8 3 
2 1.0 1 
4 1.2 3 
8 3.5 4 
15 4.6 3 
30 15.2 2 
N – sample size 
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Table 5.18- Quantification of citalopram, haloperidol and clozapine in hair samples. 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
01PECI1 ND 01PECL1 0.02* 01PEHA1 ND 
01PECI2 0.30 01PECL2 ND 01PEHA2 0.41 
01PECI3 0.00* 01PECL3 ND 01PEHA3 0.18 
01PECI4 1.82 01PECL4 ND 01PEHA4 0.17 
01PECI5 0.42 01PECL5 ND 01PEHA5 0.34 
02PECI1 1.03 02PECL1 0.58* 02PEHA1 1.48 
02PECI2 0.00* 02PECL2 ND 02PEHA2 0.20 
02PECI3 0.02* 02PECL3 ND 02PEHA3 0.61 
02PECI4 ND 02PECL4 0.19 02PEHA4 0.05* 
02PECI5 0.13* 02PECL5 x 02PEHA5 0.73 
04PECI1 2.16 04PECL1 ND 04PEHA1 0.20* 
04PECI2 0.17* 04PECL2 x 04PEHA2 0.13* 
04PECI3 0.87 04PECL3 ND 04PEHA3 0.20* 
04PECI4 0.06* 04PECL4 1.51 04PEHA4 0.10* 
04PECI5 0.70 04PECL5 ND 04PEHA5 0.18* 
08PECI1 5.76 08PECL1 ND 08PEHA1 0.61 
08PECI2 0.57* 08PECL2 1.26 08PEHA2 5.55 
08PECI3 2.13 08PECL3 0.75 08PEHA3 0.14* 
08PECI4 4.06 08PECL4 0.52 08PEHA4 2.78 
08PECI5 2.14 08PECL5 2.13 08PEHA5 ND 
15PECI1 0.37 15PECL1 x 15PEHA1 0.82 
15PECI2 7.97 15PECL2 0.07* 15PEHA2 7.56 
15PECI3 15.63* 15PECL3 5.05 15PEHA3 5.51 
15PECI4 15.41* 15PECL4 3.89 15PEHA4 0.13 
15PECI5 5.43 15PECL5 3.70 15PEHA5 5.96 
30PECI1 x 30PECL1 x 30PEHA1 x 
30PECI2 26.16* 30PECL2 4.65 30PEHA2 5.88 
30PECI3 21.59* 30PECL3 8.00 30PEHA3 3.23 
30PECI4 12.63 30PECL4 6.61 30PEHA4 5.26 
30PECI5 17.68 30PECL5 x 30PEHA5 4.19 
 
ND - Not detected; x – Insufficient sample or non-existent; *- out of calibration curve. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PE - hair; 
- the two second letters correspond to the drug: CI - Citalopram, CL - Clozapine and HA – Haloperidol; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
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Through the analysis of the scatter plot for the quantification of citalopram, it can be seen an 
increase in the concentration over the days (Figure 5.19). This suggests that higher amounts of 
drug can be quantified with increased hair growth. On days 1, 2 and 4, there is no significant 
increase, so the drug which was incorporate into the hair shaft can be minimal. 
To compare the days 4, 8 and 15 it was performed a nonparametric Kruskal-Wallis test. This 
method compares groups as a whole. In this case, the null hypothesis was accepted, so the 
difference in the overall data is not statistically significant. 
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Figure 5.19- Scatter plot for the quantification of citalopram in hair. Quantification of citalopram in 
hair which was collected from mice (5 independent replicates per day) that were administered with 
a solution of citalopram for different periods of time: 1, 2, 4, 8, 15 and 30 days. Each point 
corresponds to a replicate.  
 
 
The same approach was performed for clozapine. Thus, the quantification of clozapine in hair 
which was collected from mice (5 independent replicates per day) that were administered with a 
solution of clozapine for different periods of time (1, 2, 4, 8, 15 and 30 days) is summarized in 
Table 5.19. 
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Table 5.19- Summary of the clozapine quantification in hair samples. 
Different periods of 
treatment (days) 
Mean 
concentration 
(ng/mg) 
N 
1 - - 
2 0.4 2 
4 1.5 1 
8 1.2 4 
15 4.2 3 
30 6.4 3 
N – sample size 
 
Also, for clozapine, the analysis of the scatter plot for the quantification reveals an increase in 
the concentration over the days (Figure 5.20). Again, this suggests that higher amounts of drug 
can be quantified with increased hair growth. 
To compare the days 8, 15 and 30 it was performed a nonparametric Kruskal-Wallis test. This 
method compares groups as a whole. The difference in the overall data was proved to be 
statistically significant. In this sense it was performed a Dunn's post test to compare each pair of 
groups. It was revealed that only between day 8 and day 30 the differences are statistically 
significant (p value <0.05 - probability of accept the null hypothesis is less than 5 %). 
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Figure 5.20- Scatter plot for the quantification of clozapine in hair. Quantification of clozapine in 
hair which was collected from mice (5 independent replicates per day) that was administered with a 
solution of clozapine for different periods of time: 1, 2, 4, 8, 15 and 30 days. Each point corresponds 
to a replicate.  
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The same approach that was used for citalopram and clozapine was performed for haloperidol. 
The quantification of this compound in hair which was collected from mice (5 independent 
replicates per day) that were administered with a solution of haloperidol for different periods of 
time (1, 2, 4, 8, 15 and 30 days) is summarized in the Table 5.20. 
 
Table 5.20- Summary of the haloperidol quantification in hair samples. 
Different periods of 
treatment (days) 
Mean 
concentration 
(ng/mg) 
N 
1 0.3 4 
2 0.8 4 
4 - - 
8 3.0 3 
15 4.0 5 
30 4.6 4 
N - sample size 
 
Through the analysis of the scatter plot it can be seen a large dispersion of data (Figure 5.21). 
However, the analysis of the Table 5.20 for the quantification profile of haloperidol reveals an 
increase in the mean concentration over the days  
It was performed a nonparametric Kruskal-Wallis test between the days 8, 15 and 30. It was 
found no differences that were statistically significant in the overall data, so the Dunn's post test 
wasn't performed. However, there is a large dispersion of the data, as can be seen in Figure 5.21. 
Two explanations for a result that is not statistically significant can be provided. All data are 
identical, so there is no difference between them, or data really may be different, but no 
differences were found due to some combination of small sample size and high variability. 
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Figure 5.21- Scatter plot for the quantification of haloperidol in hair. Quantification of haloperidol in 
hair which was collected from mice (5 independent replicates per day) that were administered with 
a solution of haloperidol for different periods of time: 1, 2, 4, 8, 15 and 30 days. Each point 
corresponds to a replicate. 
 
Results for the quantification of citalopram, haloperidol and clozapine in plasma samples are 
presented in Table 5.22. The higher values of quantification were obtained for citalopram. 
The same procedure that was used to visualize the data in hair samples was performed in 
plasma samples. Again, samples used in the graphical representation were samples where 
quantification of the drug was performed with reliably. 
The quantification of citalopram in plasma which was collected from mice (5 independent 
replicates per day) that were administered with a solution of citalopram for different periods of 
time (1, 2, 4, 8, 15 and 30 days) is summarized in the Table 5.21. 
 
Table 5.21- Summary of the citalopram quantification in plasma samples. 
Different periods of 
treatment (days) 
Mean 
concentration 
(pg/μL) 
N 
1 3.9 3 
2 3.0 5 
4 5.2 5 
8 23.0 4 
15 7.0 5 
30 2.2 5 
N - sample size 
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Table 5.22- Quantification of citalopram, haloperidol and clozapine in plasma samples. 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
01PLCI1 x 01PLCL1 12.2 01PLHA1 0.6* 
01PLCI2 x 01PLCL2 11.6 01PLHA2 0.8 
01PLCI3 3.0 01PLCL3 9.1 01PLHA3 0.4* 
01PLCI4 5.0 01PLCL4 4.2 01PLHA4 x 
01PLCI5 3.8 01PLCL5 x 01PLHA5 0.3* 
02PLCI1 4.4 02PLCL1 x 02PLHA1 0.6* 
02PLCI2 2.2 02PLCL2 x 02PLHA2 0.6* 
02PLCI3 3.2 02PLCL3 11.3 02PLHA3 0.4* 
02PLCI4 2.8 02PLCL4 19.7 02PLHA4 0.7 
02PLCI5 2.3 02PLCL5 ND 02PLHA5 0.6* 
04PLCI1 4.8 04PLCL1 x 04PLHA1 0.6* 
04PLCI2 5.9 04PLCL2 1.9 04PLHA2 0.9 
04PLCI3 4.9 04PLCL3 1.5 04PLHA3 1.0 
04PLCI4 4.4 04PLCL4 ND 04PLHA4 1.1 
04PLCI5 6.0 04PLCL5 0.9 04PLHA5 x 
08PLCI1 21.0 08PLCL1 x 08PLHA1 x 
08PLCI2 x 08PLCL2 2.4 08PLHA2 1.1 
08PLCI3 22.4 08PLCL3 x 08PLHA3 x 
08PLCI4 20.8 08PLCL4 4.9 08PLHA4 0.8 
08PLCI5 28.0 08PLCL5 2.0 08PLHA5 1.0 
15PLCI1 7.5 15PLCL1 x 15PLHA1 0.5* 
15PLCI2 5.3 15PLCL2 ND 15PLHA2 0.5* 
15PLCI3 4.8 15PLCL3 1.8 15PLHA3 0.5* 
15PLCI4 6.7 15PLCL4 0.4* 15PLHA4 0.5* 
15PLCI5 10.6 15PLCL5 x 15PLHA5 x 
30PLCI1 1.1 30PLCL1 1.4 30PLHA1 0.9 
30PLCI2 1.5 30PLCL2 1.8 30PLHA2 0.6* 
30PLCI3 4.0 30PLCL3 6.0 30PLHA3 0.4* 
30PLCI4 2.2 30PLCL4 1.2 30PLHA4 0.8 
30PLCI5 2.1 30PLCL5 3.1 30PLHA5 0.7 
 
ND - Not detected; x - Sample insufficient or non-existent; *- out of calibration curve. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PL - plasma; 
- the two second letters correspond to the drug: CI - Citalopram, CL - Clozapine and HA – Haloperidol; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
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Visualization of the scatter plot for the quantification of citalopram shows a maximum peak in 
concentration on Day 8 (Figure 5.22). 
In order to compare days 2, 4, 8, 15 and 30, it was performed a Kruskal-Wallis test. The 
difference in the overall data was proved to be statistically significant. In this sense it was 
performed a Dunn's post test to compare each pair of groups. It was revealed that were 
differences statistically significant between days 2 and 8 (p value <0.05 - probability of accept 
the null hypothesis is less than 5 %), days 8 and 30 (p value <0.001 - probability of accept the null 
hypothesis is less than 0.1%) and days 15 and 30 (p value <0.05 - probability of accept the null 
hypothesis is less than 5 %). 
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Figure 5.22- Scatter plot for the quantification of citalopram in plasma. Quantification of citalopram 
in plasma which was collected from mice (5 independent replicates per day) that were administered 
with a solution of citalopram for different periods of time: 1, 2, 4, 8, 15 and 30 days. Each point 
corresponds to a replicate.  
 
 
The same approach was performed to evaluate the quantification of clozapine in plasma which 
was collected from mice (5 independent replicates per day) that were administered with a 
solution of clozapine for different periods of time (1, 2, 4, 8, 15 and 30 days) is summarized in 
the Table 5.23. 
 
 
RESULTS AND DISCUSSION| 107 
 
 
Table 5.23- Summary of the clozapine quantification in plasma samples. 
Different periods of 
treatment (days) 
Mean 
concentration 
(pg/μL) 
N 
1 9.3 4 
2 15.5 2 
4 1.4 3 
8 3.1 3 
15 1.8 1 
30 2.7 5 
N – sample size 
 
In the scatter plot for the quantification of clozapine, it can be seen that higher concentrations 
are reached on day 1 and day 2 (Figure 5.23). A nonparametric Kruskal-Wallis test was 
performed in order to compare days 1, 4, 8 and 30. Day 2 was not analyzed since sample sizes 
were too small. It was found that there are differences statistically significant between groups as 
a whole. Then, it was performed a Dunn's post test to compare each pair of groups and it was 
found that only between day 1 and day 4, the difference was statistically significant (p value 
<0.05 - probability of accept the null hypothesis is less than 5 %).. 
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Figure 5.23- Scatter plot for the quantification of clozapine in plasma. Quantification of clozapine 
in plasma which was collected from mice (5 independent replicates per day) that were administered 
with a solution of clozapine for different periods of time: 1, 2, 4, 8, 15 and 30 days. Each point 
corresponds to a replicate. 
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The same approach of the citalopram and clozapine was performed for haloperidol. The 
quantification of haloperidol in plasma which was collected from mice (5 independent replicates 
per day) that were administered with a solution of haloperidol for different periods of time (1, 2, 
4, 8, 15 and 30 days) is represented in Table 5.24. 
 
Table 5.24- Summary of the haloperidol quantification in plasma samples. 
Different periods of 
treatment (days) 
Mean 
concentration 
(pg/μL) 
N 
1 0.8 1 
2 0.7 1 
4 1.0 3 
8 1.0 3 
15 - - 
30 0.8 2 
N – sample size 
 
In the scatter plot for the quantification of haloperidol, it can be seen that higher concentrations 
are reached on day 4 and day 8. However no conclusion can be drawn since there is a large 
dispersion of data and also a small sample size.  
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Figure 5.24- Scatter plot for the quantification of haloperidol in plasma. Quantification of 
haloperidol in plasma which was collected from mice (5 independent replicates per day) that were 
administered with a solution of haloperidol for different periods of time: 1, 2, 4, 8, 15 and 30 days. 
Each point corresponds to a replicate. 
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6. CONCLUSION AND FUTURE PERSPECTIVES 
 
In this project a method was developed for the identification and quantification of psychotropic 
drugs (citalopram, clozapine and haloperidol) in plasma and hair from mice by LC-MS/MS. 
The chromatographic conditions were good, with an efficient separation and a running time for 
each sample of 9 min. The mass spectrometer was operated in MRM mode, allowing the 
selection of the transitions to be monitored for each PD and also the internal standards used. 
The application of the criteria proposed by WADA, allowed the unequivocal identification of 
these transitions. 
In order to obtain reliable analytical data, the method was validated by evaluation of various 
analytical parameters: selectivity, limits of detection and quantification, linearity, carry over, 
precision, accuracy, recovery and matrix effects. 
The method proved to be selective for citalopram, haloperidol and clozapine. 
This methodology was proved to be linear for all compounds over the concentration range 
studied, with R2 >0.99 and the residuals values were also evaluated (Residuals < 2x|  
  
|). The 
linearity of the method was demonstrated for the intervals: 0.05 to 5 pmol/μl for haloperidol, 
0.05 to 3 pmol/μl for citalopram and 0.05 to 2 pmol/μl for clozapine. However, it was observed a 
heteroscedastic distribution of the residuals, so it was used a weighted linear regression, with 
empirical weighting factors of 1 x2 , 1 y  and 1 y2  for haloperidol, clozapine and citalopram, 
respectively. 
The limits of detection were 0.012, 0.014 and 0.015 pmol/μL for citalopram, clozapine and 
haloperidol, respectively. These limits were good, since reduced amounts of samples were used 
for the extraction (70 μl of plasma and 1.2 mg for citalopram, 2.1mg for clozapina, 0.7mg for 
haloperidol of hair).  
The limits of quantification obtained were: 0.037, 0.044 and 0.045 pmol/μL for citalopram, 
clozapine and haloperidol, respectively. 
The precision was studied by analyzing the repeatability and intermediate precision. The results 
were good for the conditions of reapeatability (5.50 to 35.69 %), with high value in lowest 
concentration. For intermediate precision the results were slightly higher than the criteria (13.70 
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to 31.25 %). In future it is proposed to re-study this parameter to be able to get more precise 
values. The method was proved to be accurate with values within the criteria (-2.42 to 13.51 %).  
It was also evaluated the phenomenon of carry over and it was observed that citalopram, 
haloperidol and clozapine do not have significant values for this parameter. Nonetheless, in the 
analytical method developed, where multiple samples are analyzed, it was introduced wash 
injections (blanks with ACN: 0.1%FA) in order to avoid possible contamination between samples. 
The study of the recovery at different concentration levels, showed recoveries between 68.9 and 
115.5% for plasma, values quite acceptable and within the limits pre-establish. The recovery for 
hair showed lower values between 8.9 to 45.5%. For future it is proposed the study of different 
times of incubation for the hair and also different temperatures, in order to achieve the best 
recoveries for this matrix. 
The matrix effects were also studied, where negatives values were obtained for plasma, 
indicating ion suppression. In the matrix effects for hair were obtained positive values, indicating 
enhancement of the analyte signal and also the relative ME have high values.  
The developed method was applied in biological samples (plasma and hair) that were collected 
from mice (5 independent replicates per day) that were submitted to a treatment with 
psychotropic drugs (citalopram, clozapine and haloperidol) for different periods of time: 1, 2, 4, 
8, 15 and 30 days. 
The time evolution of quantification for the three compounds in hair reveals an increase in the 
concentration over the days with a marked increase on day 15. This could mean that higher 
amounts of drug can be quantified with increased hair growth. In the first days the amount of 
drug which was quantified is very low, so the drug that actually is incorporated into the hair 
shaft is also low. In these samples, the haloperidol was the compound more difficult to detect 
and quantified with more disperse values. Contrary to what was expected, since the validation 
results were in general very good for this compound. 
In plasma the time evolution of quantification for the citalopram, clozapine and haloperidol was 
different for each compound. For citalopram it can be seen a maximum peak in concentration on 
Day 8. For clozapine it can be seen an increase in the concentration reached on day 1 and day 2 
followed by a decrease to a steady state. And for haloperidol it can be seen that higher 
concentrations are reached on day 4 and day 8. Again, less satisfactory results were obtained 
with the haloperidol. Based on these data, it is suggested studies on the metabolism of this drug 
to address the absorption and elimination profiles. 
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All compounds were detected in the control samples and also for samples which were supposed 
to contain only one of the compounds with the other two being present. This was observed for 
plasma samples but not for the hair samples which might indicate a contamination in the plasma 
collection procedure. 
In the future it would be important to continue the study of clozapine with a purpose of creating 
a method more appropriated, since the validation parameters for this compound were less 
satisfactory. 
Due to the increased use of antidepressants and antipsychotics and their involvement in 
intoxications and suicide, the ability to reliably detect this class in biological specimens is very 
important. The biological specimens that were used are both relevant, where plasma is 
preferred in cases of therapeutic drug monitoring. And hair has become an important matrix, 
since it provides evidence of longer term exposure of drugs, complementing other specimens 
and also, it can be used in forensic cases, for example when there is decomposition of the body. 
Thus, by the foregoing, the methodology developed proves to be of great importance in clinical 
and forensic approaches. 
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8. APPENDIX 
 
Appendix 8.1: Weighing of the hair samples. 
Label Weight (mg) Label Weight (mg) Label Weight (mg) Label Weight (mg) 
01PECI1 3.4 01PECL1 6.4 01PEHA1 5.0 01PECT1 5.6 
01PECI2 4.1 01PECL2 5.4 01PEHA2 4.2 01PECT2 4.4 
01PECI3 4.8 01PECL3 5.9 01PEHA3 5.5 01PECT3 6.3 
01PECI4 7.1 01PECL4 3.7 01PEHA4 5.8 01PECT4 8.9 
01PECI5 6.6 01PECL5 4.4 01PEHA5 3.9 01PECT5 3.8 
02PECI1 8.7 02PECL1 7.7 02PEHA1 7.8 02PECT1 7.0 
02PECI2 6.8 02PECL2 4.6 02PEHA2 7.5 02PECT2 4.2 
02PECI3 9.7 02PECL3 4.9 02PEHA3 8.0 02PECT3 6.0 
02PECI4 7.7 02PECL4 5.5 02PEHA4 6.7 02PECT4 3.1 
02PECI5 5.2 02PECL5 x 02PEHA5 6.4 02PECT5 5.8 
04PECI1 1.8 04PECL1 1.0 04PEHA1 1.2 04PECT1 0.8 
04PECI2 2.1 04PECL2 x 04PEHA2 0.7 04PECT2 0.8 
04PECI3 2.4 04PECL3 1.0 04PEHA3 1.3 04PECT3 x 
04PECI4 2.0 04PECL4 6.2 04PEHA4 2.2 04PECT4 1.5 
04PECI5 2.7 04PECL5 1.1 04PEHA5 2.6 04PECT5 1.2 
08PECI1 2.5 08PECL1 1.7 08PEHA1 4 08PECT1 2.8 
08PECI2 1.2 08PECL2 2.3 08PEHA2 5.4 08PECT2 3.2 
08PECI3 2.8 08PECL3 2.1 08PEHA3 2.8 08PECT3 2.0 
08PECI4 3.2 08PECL4 2.9 08PEHA4 3.8 08PECT4 2.9 
08PECI5 2.6 08PECL5 3.0 08PEHA5 2.4 08PECT5 3.2 
15PECI1 5.9 15PECL1 x 15PEHA1 5.2 15PECT1 3.0 
15PECI2 4.5 15PECL2 2.9 15PEHA2 7.8 15PECT2 3.7 
15PECI3 7.7 15PECL3 4.4 15PEHA3 4.5 15PECT3 3.6 
15PECI4 6.8 15PECL4 3.4 15PEHA4 7.4 15PECT4 4.4 
15PECI5 4.7 15PECL5 4.1 15PEHA5 7.6 15PECT5 4.7 
30PECI1 x 30PECL1 x 30PEHA1 x 30PECT1 x 
30PECI2 2.9 30PECL2 4.6 30PEHA2 4.7 30PECT2 4.5 
30PECI3 3.4 30PECL3 5.0 30PEHA3 6.8 30PECT3 2.7 
30PECI4 3.3 30PECL4 5.7 30PEHA4 5.9 30PECT4 4.4 
30PECI5 2.9 30PECL5 x 30PEHA5 7.2 30PECT5 4.0 
x - sample insufficient or non-existent. 
Label:  
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PE - hair; 
- the two second letters correspond to the drug: CI - Citalopram, Cl - Clozapine and HA – Haloperidol; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
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Appendix 8.2: Data related to the study of selectivity 
 
Table 8.1- Application of acceptance WADA criteria for unequivocal identification of the 
citalopram in plasma. 
 Transition (m/z) Absolute area Relative area S/N RTA RTIS RTRatio 
Positive 1 
325.3109.0 8742.177 100.000 32.077 6.271 7.359 0.852 
325.3261.9 2450.138 28.027 8.611 6.266 7.359 0.851 
325.383.1 1800.696 20.598 7.230 6.266 7.359 0.851 
Negative 1 
325.3109.0 249.582 100.000 0.850 6.294 6.809 0.924 
325.3261.9 - - - - 6.809 - 
325.383.1 - - - - 6.809 - 
Positive 2 
325.3109.0 7587.675 100.000 25.649 6.404 7.445 0.860 
325.3261.9 1424.155 18.769 5.352 6.402 7.445 0.860 
325.383.1 1937.774 25.538 7.039 6.405 7.445 0.860 
Negative 2 
325.3109.0 93.434 100.000 0.315 6.055 6.633 0.913 
325.3261.9 - - - - 6.633 - 
325.383.1 - - - - 6.633 - 
Positive 3 
325.3109.0 7213.969 100.000 25.362 6.212 7.308 0.850 
325.3261.9 2101.156 29.126 7.286 6.207 7.308 0.849 
325.383.1 1657.643 22.978 6.026 6.209 7.308 0.850 
Negative 3 
325.3109.0 - - - - 6.844 - 
325.3261.9 - - - - 6.844 - 
325.383.1 - - - - 6.844 - 
Positive 4 
325.3109.0 7213.969 100.000 25.362 6.212 7.308 0.850 
325.3261.9 2101.156 29.126 7.286 6.207 7.308 0.849 
325.383.1 1657.643 22.978 6.026 6.209 7.308 0.850 
Negative 4 
325.3109.0 94.289 100.000 0.387 6.186 - - 
325.3261.9 - - - - - - 
325.383.1 - - - - - - 
Positive 5 
325.3109.0 7549.764 100.000 28.255 6.273 7.372 0.851 
325.3261.9 1354.053 17.935 4.516 6.283 7.372 0.852 
325.383.1 1680.863 22.264 6.620 6.262 7.372 0.849 
Negative 5 
325.3109.0 70.030 74.992 0.320 6.266 6.663 0.940 
325.3261.9 - - - - 6.663 - 
325.383.1 93.383 100.000 0.439 6.243 6.663 0.937 
Positive 6 
325.3109.0 9586.817 100.000 35.250 6.254 7.340 0.852 
325.3261.9 1937.547 20.211 6.108 6.258 7.340 0.853 
325.383.1 1657.569 17.290 6.078 6.256 7.340 0.852 
Negative 6 
325.3109.0 - - - - 6.758 - 
325.3261.9 - - - - 6.758 - 
325.383.1 - - - - 6.758 - 
Criteria 
Transition (m/z) Relative Abundance S/N 
 
ΔRTRatio 
325.3109 90 110 
>3 
0.844 0.861 
325.3261.9 22.421 33.632 0.843 0.860 
325.383.1 15.598 25.598 0.843 0.860 
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Table 8.2- Application of acceptance WADA criteria for unequivocal identification of the 
clozapine in plasma. 
 Transition (m/z) Absolute area Relative area S/N RTA RTIS RTRatio 
Positive 1 
327.2269.9 1073.920 80.706 4.146 4.094 7.359 0.556 
327.2191.9 1330.658 100.000 5.117 4.099 7.359 0.557 
327.2163.8 536.958 40.353 2.081 4.097 7.359 0.557 
Negative 1 
327.2269.9 656.442 84.205 2.922 4.066 6.809 0.597 
327.2191.9 779.572 100.000 3.662 4.056 6.809 0.596 
327.2163.8 93.381 11.979 0.419 4.084 6.809 0.600 
Positive 2 
327.2269.9 1005.915 68.590 3.684 4.366 7.445 0.586 
327.2191.9 1466.569 100.000 5.774 4.362 7.445 0.586 
327.2163.8 373.533 25.470 1.515 4.371 7.445 0.587 
Negative 2 
327.2269.9 - - - - 6.633 - 
327.2191.9 69.999 100.000 0.377 4.408 6.633 0.665 
327.2163.8 - - - - 6.633 - 
Positive 3 
327.2269.9 963.809 76.393 4.105 4.074 7.308 0.557 
327.2191.9 1261.645 100.000 4.997 4.073 7.308 0.557 
327.2163.8 326.841 25.906 1.384 4.096 7.308 0.560 
Negative 3 
327.2269.9 - - - - 6.844 - 
327.2191.9 - - - - 6.844 - 
327.2163.8 - - - - 6.844 - 
Positive 4 
327.2269.9 1587.527 73.916 6.761 4.091 7.356 0.556 
327.2191.9 2147.746 100.000 8.114 4.094 7.356 0.557 
327.2163.8 747.076 34.784 2.780 4.093 7.356 0.556 
Negative 4 
327.2269.9 - - - - - - 
327.2191.9 - - - - - - 
327.2163.8 - - - - - - 
Positive 5 
327.2269.9 1144.408 71.732 4.847 4.099 7.372 0.556 
327.2191.9 1595.394 100.000 6.181 4.098 7.372 0.556 
327.2163.8 723.736 45.364 3.212 4.102 7.372 0.556 
Negative 5 
327.2269.9 - - - - 6.663 - 
327.2191.9 - - - - 6.663 - 
327.2163.8 - - - - 6.663 - 
Positive 6 
327.2269.9 1143.923 62.848 4.575 4.093 7.340 0.558 
327.2191.9 1820.141 100.000 7.020 4.083 7.340 0.556 
327.2163.8 542.398 29.800 2.154 4.090 7.340 0.557 
Negative 6 
327.2269.9 140.078 100.000 0.724 4.076 6.758 0.602 
327.2191.9 140.076 99.999 0.525 4.068 6.758 0.602 
327.2163.8 - - - - 6.758 - 
Criteria 
Transition (m/z) Relative Abundance S/N 
 
ΔRTRatio 
327.2269.9 70.706 90.706 
>3 
0.551 0.562 
327.2191.9 90.000 110.000 0.551 0.563 
327.2163.8 32.282 48.423 0.551 0.562 
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Table 8.3- Application of acceptance WADA criteria for unequivocal identification of the 
haloperidol in plasma. 
 Transition (m/z) Absolute area Relative area S/N RTA RTIS RTRatio 
Positive 1 
376.0164.7 47778.286 57.874 172.756 6.635 6.600 1.005 
376.0122.9 82555.313 100.000 300.495 6.639 6.600 1.006 
376.094.8 30672.706 37.154 112.539 6.634 6.600 1.005 
Negative 1 
376.0164.7 162.229 100.000 0.872 6.592 6.230 1.058 
376.0122.9 138.565 85.414 0.436 6.254 6.230 1.004 
376.094.8 157.300 96.962 0.446 6.575 6.230 1.055 
Positive 2 
376.0164.7 41407.481 59.955 147.232 6.755 6.719 1.005 
376.0122.9 69064.705 100.000 256.026 6.754 6.719 1.005 
376.094.8 26602.638 38.518 97.336 6.754 6.719 1.005 
Negative 2 
376.0164.7 - - - - 6.497 - 
376.0122.9 77.749 100.000 0.472 6.302 6.497 0.970 
376.094.8 - - - - 6.497 - 
Positive 3 
376.0164.7 45566.235 63.522 163.777 6.585 6.548 1.006 
376.0122.9 71732.851 100.000 254.610 6.586 6.548 1.006 
376.094.8 31190.058 43.481 110.149 6.584 6.548 1.005 
Negative 3 
376.0164.7 210.114 100.000 0.746 6.508 6.140 1.060 
376.0122.9 73.158 34.818 0.341 6.274 6.140 1.022 
376.094.8 94.546 44.997 0.480 6.470 6.140 1.054 
Positive 4 
376.0164.7 31075.385 60.973 117.356 6.632 6.596 1.005 
376.0122.9 50966.167 100.000 182.164 6.631 6.596 1.005 
376.094.8 21352.538 41.896 75.102 6.630 6.596 1.005 
Negative 4 
376.0164.7 303.622 100.000 1.215 6.569 6.506 1.010 
376.0122.9 64.671 21.300 0.325 6.086 6.506 0.935 
376.094.8 69.928 23.031 0.313 5.822 6.506 0.895 
Positive 5 
376.0164.7 26276.164 57.210 94.598 6.657 6.620 1.006 
376.0122.9 45929.205 100.000 164.020 6.657 6.620 1.006 
376.094.8 19796.612 43.102 71.140 6.652 6.620 1.005 
Negative 5 
376.0164.7 116.779 87.326 0.483 6.599 6.581 1.003 
376.0122.9 133.727 100.000 0.430 5.971 6.581 0.907 
376.094.8 - - - - 6.581 - 
Positive 6 
376.0164.7 32008.587 67.184 115.245 6.630 6.594 1.006 
376.0122.9 47643.335 100.000 167.278 6.631 6.594 1.006 
376.094.8 18607.559 39.056 66.137 6.633 6.594 1.006 
Negative 6 
376.0164.7 116.736 47.689 0.423 6.573 - - 
376.0122.9 244.786 100.000 0.946 6.592 - - 
376.094.8 - - - - - - 
Criteria 
Transition (m/z) Relative Abundance S/N 
 
ΔRTRatio 
376.0164.7 47.874 67.874 
>3 
0.995 1.015 
376.0122.9 90.000 110.000 0.996 1.016 
376.094.8 29.723 44.585 0.995 1.015 
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Table 8.4- Application of acceptance WADA criteria for unequivocal identification of the 
citalopram in hair. 
 Transition (m/z) Absolute area Relative area S/N RTA RTIS RTRatio 
Positive 1 
325.3109.0 10831.351 100.000 37.960 6.290 7.330 0.858 
325.3261.9 2894.899 26.727 9.657 6.292 7.330 0.858 
325.383.1 1984.660 18.323 6.505 6.290 7.330 0.858 
Negative 1 
325.3109.0 132.599 100.000 0.656 6.126 - - 
325.3261.9 - - - - - - 
325.383.1 - - - - - - 
Positive 2 
325.3109.0 8469.233 100.000 28.450 6.091 7.133 0.854 
325.3261.9 2288.104 27.017 9.044 6.088 7.133 0.853 
325.383.1 1922.074 22.695 7.009 6.089 7.133 0.854 
Negative 2 
325.3109.0 296.179 100.000 0.773 6.345 - - 
325.3261.9 - - - - - - 
325.383.1 - - - - - - 
Positive 3 
325.3109.0 12350.847 100.000 42.149 6.181 7.261 0.851 
325.3261.9 2162.002 17.505 8.391 6.178 7.261 0.851 
325.383.1 2392.538 19.371 8.262 6.179 7.261 0.851 
Negative 3 
325.3109.0 116.730 100.000 0.500 6.255 - - 
325.3261.9 - - - - - - 
325.383.1 - - - - - - 
Positive 4 
325.3109.0 10781.131 100.000 38.682 6.136 7.192 0.853 
325.3261.9 2545.479 23.611 9.151 6.133 7.192 0.853 
325.383.1 1585.524 14.706 5.641 6.131 7.192 0.852 
Negative 4 
325.3109.0 273.367 100.000 0.907 6.113 - - 
325.3261.9 - - - - - - 
325.383.1 - - - - - - 
Positive 5 
325.3109.0 7037.525 100.000 25.665 6.473 7.477 0.866 
325.3261.9 1610.854 22.889 6.083 6.456 7.477 0.863 
325.383.1 1212.095 17.223 4.302 6.462 7.477 0.864 
Negative 5 
325.3109.0 439.462 100.000 1.607 6.112 - - 
325.3261.9 - - - - - - 
325.383.1 - - - - - - 
Positive 6 
325.3109.0 7162.747 100.000 23.736 6.200 7.268 0.853 
325.3261.9 2264.654 31.617 8.623 6.184 7.268 0.851 
325.383.1 1587.975 22.170 5.432 6.181 7.268 0.850 
Negative 6 
325.3109.0 184.775 100.000 0.869 6.215 - - 
325.3261.9 - - - - - - 
325.383.1 - - - - - - 
Criteria 
Transition (m/z) Relative Abundance S/N 
 
ΔRTRatio 
325.3109.0 90.000 110.000 
>3 
0.850 0.867 
325.3261.9 21.382 32.072 0.850 0.867 
325.383.1 13.323 23.323 0.850 0.867 
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Table 8.5- Application of acceptance WADA criteria for unequivocal identification of the 
clozapine in hair. 
Positive 1 
Transition (m/z) Absolute area Relative area S/N RTA RTIS RTRatio 
327.2269.9 1639.011 95.043 5.847 4.047 7.330 0.552 
327.2191.9 1724.491 100.000 6.015 4.038 7.330 0.551 
327.2163.8 585.835 33.971 2.081 4.040 7.330 0.551 
Negative 1 
327.2269.9 - - - - - - 
327.2191.9 - - - - - - 
327.2163.8 70.038 100.000 0.419 3.986 - - 
Positive 2 
327.2269.9 817.094 92.113 2.975 4.005 7.133 0.561 
327.2191.9 887.052 100.000 3.565 4.007 7.133 0.562 
327.2163.8 210.112 23.687 1.515 4.004 7.133 0.561 
Negative 2 
327.2269.9 - - - - - - 
327.2191.9 - - - - - - 
327.2163.8 - - - - - - 
Positive 3 
327.2269.9 770.384 63.390 3.235 4.019 7.261 0.554 
327.2191.9 1215.315 100.000 4.237 4.023 7.261 0.554 
327.2163.8 513.608 42.261 1.384 4.038 7.261 0.556 
Negative 3 
327.2269.9 - - - - - - 
327.2191.9 - - - - - - 
327.2163.8 - - - - - - 
Positive 4 
327.2269.9 1773.217 61.268 6.650 4.053 7.192 0.563 
327.2191.9 2894.188 100.000 9.519 4.050 7.192 0.563 
327.2163.8 910.486 31.459 2.780 4.054 7.192 0.564 
Negative 4 
327.2269.9 - - - - - - 
327.2191.9 - - - - - - 
327.2163.8 - - - - - - 
Positive 5 
327.2269.9 653.69 100.00 2.48 4.07 7.48 0.54 
327.2191.9 443.58 67.86 1.68 4.09 7.48 0.55 
327.2163.8 305.74 46.77 3.21 4.09 7.48 0.55 
Negative 5 
327.2269.9 - - - - - - 
327.2191.9 93.385 100.000 0.398 3.611 - - 
327.2163.8 - - - - - - 
Positive 6 
327.2269.9 327.884 70.224 1.537 4.026 7.268 0.554 
327.2191.9 466.913 100.000 1.422 4.056 7.268 0.558 
327.2163.8 210.117 45.001 2.154 4.037 7.268 0.556 
Negative 6 
327.2269.9 - - - - - - 
327.2191.9 - - - - - - 
327.2163.8 - - - - - - 
Criteria 
Transition (m/z) Relative Abundance S/N 
 
ΔRTRatio 
327.2269.9 85.043 105.043 
>3 
0.547 0.558 
327.2191.9 90.000 110.000 0.545 0.556 
327.2163.8 27.177 40.766 0.546 0.557 
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Table 8.6- Application of acceptance WADA criteria for unequivocal identification of the haloperidol in 
hair. 
Positive 1 
Transition (m/z) Absolute area Relative area S/N RTA RTIS RTRatio 
376.0164.7 10716.280 55.225 37.544 6.625 6.591 1.005 
376.0122.9 19404.737 100.000 67.472 6.622 6.591 1.005 
376.094.8 9173.733 47.276 32.296 6.622 6.591 1.005 
Negative 
1 
376.0164.7 - - - - - - 
376.0122.9 - - - - - - 
376.094.8 - - - - - - 
Positive 2 
376.0164.7 10873.386 63.211 37.926 6.405 6.376 1.005 
376.0122.9 17201.832 100.000 62.091 6.409 6.376 1.005 
376.094.8 6957.090 40.444 24.717 6.411 6.376 1.005 
Negative 
2 
376.0164.7 - - - - - - 
376.0122.9 - - - - - - 
376.094.8 - - - - - - 
Positive 3 
376.0164.7 15799.554 61.363 53.009 6.512 6.487 1.004 
376.0122.9 25747.751 100.000 96.379 6.518 6.487 1.005 
376.094.8 10482.686 40.713 39.603 6.515 6.487 1.004 
Negative 
3 
376.0164.7 - - - - - - 
376.0122.9 - - - - - - 
376.094.8 - - - - - - 
Positive 4 
376.0164.7 8907.074 46.722 31.581 6.464 6.428 1.006 
376.0122.9 19064.111 100.000 73.133 6.455 6.428 1.004 
376.094.8 6496.192 34.076 22.174 6.462 6.428 1.005 
Negative 
4 
376.0164.7 - - - - - - 
376.0122.9 - - - - - - 
376.094.8 - - - - - - 
Positive 5 
376.0164.7 6769.220 72.631 26.670 6.784 6.749 1.005 
376.0122.9 9319.994 100.000 33.391 6.784 6.749 1.005 
376.094.8 4943.972 53.047 17.638 6.788 6.749 1.006 
Negative 
5 
376.0164.7 257.399 52.430 0.871 6.445 - - 
376.0122.9 490.939 100.000 2.019 6.449 - - 
376.094.8 233.460 47.554 0.866 6.440 - - 
Positive 6 
376.0164.7 6319.393 54.834 23.209 6.527 6.493 1.005 
376.0122.9 11524.690 100.000 43.110 6.524 6.493 1.005 
376.094.8 4668.362 40.507 17.019 6.526 6.493 1.005 
Negative 
6 
376.0164.7 - - - - - - 
376.0122.9 - - - - - - 
376.094.8 - - - - - - 
Criteria 
Transition (m/z) Relative Abundance S/N 
 
ΔRTRatio 
376.0164.7 45.225 65.225 
>3 
0.995 1.015 
376.0122.9 90.000 110.000 0.995 1.015 
376.094.8 37.821 56.731 0.995 1.015 
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Appendix 8.3: Example of the linearity analysis for the transition 376.0164.7 of haloperidol. 
 
Concentration 
(pmol/μL) 
Peak Area Ratio S/N 
0.05 0.06 15.05 
0.1 0.13 22.52 
0.15 0.20 25.93 
0.2 0.25 37.13 
0.25 0.34 60.53 
0.5 0.64 120.58 
1.0 1.21 213.96 
1.5 2.07 302.20 
2.0 2.84 446.62 
3.0 4.32 663.66 
5.0 6.84 990.64 
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0.00
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0.000 1.000 2.000 3.000 4.000 5.000 6.000R
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Concentration (pmol/µL)
  
Regression Statistic 
m 1.39 
b -0.02 
R 0.999 
R
2
 0.999 
Sy/x 0.09 
2xSy/x 0.18 
Sb 0.04 
T-Student value 2.26 
Upper limit 95% 0.06 
Lower limit 95% -0.10 
Concentration 
(pmol/µL)  
Residuals 
0.05 0.012 
0.1 0.008 
0.15 0.009 
0.2 -0.002 
0.25 0.014 
0.5 -0.034 
1.0 -0.162 
1.5 0.005 
2.0 0.083 
3.0 0.167 
5.0 -0.101 
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Appendix 8.4: Example of the linearity analysis for the transition 327.2163.8 of clozapine. 
 
Concentration 
(pmol/μL) 
Peak Area 
Ratio 
S/N 
0.05 0.10 38.11 
0.1 0.24 79.27 
0.15 0.36 135.07 
0.2 0.48 178.84 
0.25 0.54 209.07 
0.5 1.16 439.08 
1.0 2.29 940.73 
1.5 3.79 1422.99 
2.0 4.89 1759.49 
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Regression Statistic 
m 2.469 
b -0.037 
R 0.999 
R
2
 0.998 
Sy/x 0.078 
2x Sy/x 0.157 
Sb 0.036 
T-Student value 2.360 
Upper limit 95% 0.049 
Lower limit 95% -0.122 
Concentration 
(pmol/µL) 
Residuals 
0.05 0.017 
0.1 0.034 
0.15 0.029 
0.2 0.026 
0.25 -0.037 
0.5 -0.033 
1.0 -0.146 
1.5 0.127 
2.0 -0.016 
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Appendix 8.5: Example of the linearity analysis for the transition 325.3109.0 of citalopram. 
 
Concentration 
(pmol/μL) 
Peak Area 
Ratio 
S/N 
0.05 0.25 80.13 
0.1 0.45 146.77 
0.15 0.74 246.29 
0.2 0.93 302.58 
0.25 1.16 377.00 
0.5 2.46 783.59 
1 4.31 1617.46 
1.5 6.95 2312.23 
2 9.77 2851.80 
3 14.00 4541.72 
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Regression Statistic 
m 4.707 
b -0.017 
R 0.9992 
R
2
 0.9984 
Sy/x 0.200 
2x Sy/x 0.400 
Sb 0.086 
T-Student value 2.310 
Upper limit 95% 0.182 
Lower limit 95% -0.215 
Concentration  Residuals 
0.1 0.030 
0.1 -0.009 
0.2 0.048 
0.2 0.007 
0.3 -0.004 
0.5 0.124 
1.0 -0.376 
1.5 -0.094 
2.0 0.375 
3.0 -0.101 
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Appendix 8.6: ANOVA analysis, repeatability and intermediate precision. 
 
Table 8.7- ANOVA table used for the study of repeatability and intermediate precision.  
Source Sums of Squares (SS) Degrees of freedom Mean Squares (MS) 
Between 
Groups (Run) 
            
 
   
                
            
 
   
 
   
 
Within Groups 
(Repeatability) 
                
 
 
   
 
   
             
            
  
   
 
   
       
 
Total                          
   
   
 
  - Number of runs on which the sample is analysed; 
  - Number of replicates performed at every run; 
    - Instrumental response of the sample analysed in the  th replicate and the  th run; 
    – Mean of the j replicates responses perform on run  ; 
   - Mean of the mean values obtained in the   different runs. 
 
 
 
Table 8.8- Calculation of variances used for the study of repeatability and intermediate precision. 
Variance Expression Degrees of freedom 
Repeatability variance (  
 )   
              
Between – run variance (    
 )     
  
         
 
  
Intermediate variance (  
     
     
       
   
Mean variance (  
 )   
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Appendix 8.7: Data of the study of weighted least squares linear regression. 
 
Table 8.9- Relative errors (RE%) and the respective sum of the relative errors (       ) generated 
by the use of simple linear regression and weighted linear regression for each weighting factor (  ) 
for citalopram 
 
Nominal 
concentration 
(μM) 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Unweighted 
(  =1) 
 
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
  
 
0.05 308.80 124.01 42.11 136.53 64.18 191.91 198.73 
0.10 121.78 34.23 39.68 24.02 27.06 51.13 53.59 
0.15 78.03 66.48 76.34 63.83 73.06 47.68 46.14 
0.20 37.52 37.92 38.28 37.35 39.45 25.03 24.52 
0.25 23.70 19.13 16.82 16.82 14.55 15.08 12.54 
0.50 15.55 23.27 11.24 23.87 13.31 21.78 21.95 
1.00 13.19 11.87 13.81 13.11 11.69 14.01 14.50 
1.50 47.87 41.77 43.58 43.25 42.54 45.31 46.02 
2.00 26.81 18.61 28.34 20.18 26.58 23.04 23.81 
3.00 20.70 29.75 46.08 28.35 38.26 25.18 24.51 
       693.95 407.04 356.28 407.32 350.68 460.17 466.30 
 
Table 8.10- Relative errors (RE%) and the respective sum of the relative errors (       ) generated 
by the use of simple linear regression and weighted linear regression for each weighting factor (  ) 
for clozapine. 
 
 
Nominal 
concentration 
(μM) 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Unweighted 
(  =1) 
 
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
  
 
0.05 198.15 115.11 51.78 138.13 99.85 156.26 165.49 
0.10 9.76 35.73 60.92 22.77 39.04 20.86 13.70 
0.15 77.85 82.34 90.74 74.21 77.39 77.67 73.70 
0.20 40.64 42.93 44.46 38.53 39.61 38.99 37.11 
0.25 32.49 38.40 34.30 35.87 34.22 34.81 33.78 
0.50 26.42 27.54 27.17 26.70 27.25 27.45 26.57 
1.00 28.21 28.22 47.54 26.96 40.84 27.84 27.46 
1.50 23.55 20.81 28.16 20.32 20.38 22.58 22.09 
2.00 14.18 18.72 40.76 19.43 36.71 16.17 16.68 
       451.25 409.78 425.83 402.91 415.29 422.64 416.59 
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Appendix 8.8: Data of the study of Carry-Over. 
 
Table 8.11- Area of LOQ of citalopram and desipramine used to calculate the criteria for carry-over. 
 
  
 
Table 8.12- Results of carry-over for citalopram and desipramine. Data obtained of the injections of blanks after 
sample that was fortified with 5, 0.5 and 0.05 μM with the compounds of the study. 
  Citalopram Desipramine 
Concentration (μM) Injection Area
1
 Area
1
 
5 
Sample 856213.45 48079.04 
Blank 1 1037.29 340.70 
Blank 2 540.03 69.02 
Blank 3 200.27 112.77 
Blank 4 188.09 205.41 
Blank 5 98.69 103.75 
0.5 
Sample 100896.00 68323.04 
Blank 1 274.44 108.36 
Blank 2 148.42 129.21 
Blank 3 100.75 222.56 
Blank 4 144.79 114.22 
Blank 5 103.01 140.25 
0.05 
Sample 9022.31 38356.54 
Blank 1 76.15 296.67 
Blank 2 133.71 235.05 
Blank 3 101.30 157.02 
Blank 4 128.20 96.34 
Blank 5 104.27 125.82 
1
 The value of the area presented is the average of the data obtained in the 3 days that the procedure was 
repeated 
 
 
 
 
  
Control LOQ 
Citalopram Desipramine 
Concentration 
(µM) Area 
Concentration 
(µM) Area 
0.05 11465.98 0.5 99834.11 
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Table 8.13- Area of LOQ of clozapine and desipramine used to calculate the criteria for carry-over. 
Control LOQ 
Clozapine Desipramine 
Concentration 
(µM) 
Area 
Concentration 
(µM) 
Area 
0.05 
1480.90 
0.5 99834.11 
 
 
Table 8.14- Results of carry-over for clozapine and desipramine. Data obtained of the injections of blanks after 
sample that was fortified with 5, 0.5 and 0.05 μM with the compounds of the study. 
  Clozapine Desipramine 
Concentration (μM) Injection Area
1
 Area
1
 
5 
Sample 177879.25 48079.04 
Blank 1 353.18 340.70 
Blank 2 97.63 69.02 
Blank 3 86.01 112.77 
Blank 4 ND 205.41 
Blank 5 45.82 103.75 
0.5 
Sample 22015.99 68323.04 
Blank 1 127.91 108.36 
Blank 2 70.58 129.21 
Blank 3 58.11 222.56 
Blank 4 ND 114.22 
Blank 5 46.44 140.25 
0.05 
Sample 2120.56 38356.54 
Blank 1 111.32 296.67 
Blank 2 116.72 235.05 
Blank 3 70.03 157.02 
Blank 4 ND 96.34 
Blank 5 46.11 125.82 
1
 The value of the area presented is the average of the data obtained in the 3 days that the procedure was 
repeated; 
ND – Not Detected. 
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Table 8.15- Area of LOQ of haloperidol and haloperidol-D4 used to calculate the criteria for carry-over. 
Control LOQ 
Haloperidol Haloperidol-D4 
Concentration 
(µM) 
Area 
Concentration 
(µM) 
Area 
0.05 
9691.26 
0.5 
210345.35 
 
 
Table 8.16- Results of carry-over for haloperidol and haloperidol-D4. Data obtained of the injections of blanks after 
sample that was fortified with 5, 0.5 and 0.05 μM with the compounds of the study. 
  Haloperidol Haloperidol-D4 
Concentration (μM) Injection Area
1
 Area
1
 
5 
Sample 887658.99 166663.54 
Blank 1 5123.66 1416.41 
Blank 2 1594.62 542.83 
Blank 3 910.34 214.88 
Blank 4 467.47 163.70 
Blank 5 426.84 122.07 
0.5 
Sample 108201.71 199866.04 
Blank 1 940.34 1664.06 
Blank 2 296.29 376.27 
Blank 3 307.68 197.21 
Blank 4 244.01 157.89 
Blank 5 129.08 79.69 
0.05 
Sample 10226.17 174195.86 
Blank 1 214.52 1240.46 
Blank 2 77.35 414.63 
Blank 3 131.49 223.01 
Blank 4 103.58 144.09 
Blank 5 83.58 125.42 
1
 The value of the area presented is the average of the data obtained in the 3 days that the procedure was 
repeated 
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Appendix 8.9: Data related of the contamination of plasma samples. 
 
Table 8.17- Contamination of citalopram in plasma samples. Citalopram quantification in plasma samples 
of clozapine, haloperidol and control. 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
01PLCL1 0.58 01PLHA1 1.87 01PLCT1 0.54* 
01PLCL2 0.79 01PLHA2 1.82 01PLCT2 0.34* 
01PLCL3 0.83 01PLHA3 1.38 01PLCT3 0.58 
01PLCL4 0.40* 01PLHA4 x 01PLCT4 0.43* 
01PLCL5 x 01PLHA5 1.98 01PLCT5 0.58 
02PLCL1 x 02PLHA1 0.77* 02PLCT1 1.00 
02PLCL2 x 02PLHA2 0.48* 02PLCT2 0.78 
02PLCL3 1.55 02PLHA3 1.00 02PLCT3 0.73 
02PLCL4 1.32 02PLHA4 0.68 02PLCT4 1.10 
02PLCL5 0.70* 02PLHA5 0.49* 02PLCT5 x 
04PLCL1 x 04PLHA1 4.16 04PLCT1 x 
04PLCL2 1.26 04PLHA2 3.25 04PLCT2 0.18* 
04PLCL3 1.36 04PLHA3 4.29 04PLCT3 0.05* 
04PLCL4 0.76 04PLHA4 3.88 04PLCT4 0.05* 
04PLCL5 0.88 04PLHA5 x 04PLCT5 0.06* 
08PLCL1 x 08PLHA1 x 08PLCT1 17.69 
08PLCL2 23.77 08PLHA2 34.83 08PLCT2 7.80 
08PLCL3 x 08PLHA3 x 08PLCT3 22.38 
08PLCL4 31.30 08PLHA4 35.76* 08PLCT4 14.49 
08PLCL5 21.20 08PLHA5 27.78 08PLCT5 16.48 
15PLCL1 x 15PLHA1 4.39 15PLCT1 3.73 
15PLCL2 3.31 15PLHA2 5.72 15PLCT2 4.12 
15PLCL3 6.07 15PLHA3 6.95 15PLCT3 4.58 
15PLCL4 4.96 15PLHA4 7.00 15PLCT4 3.84 
15PLCL5 x 15PLHA5 x 15PLCT5 3.60 
30PLCL1 0.30* 30PLHA1 0.51* 30PLCT1 0.23* 
30PLCL2 0.52* 30PLHA2 0.52* 30PLCT2 0.25* 
30PLCL3 0.28* 30PLHA3 0.28* 30PLCT3 0.17* 
30PLCL4 0.38* 30PLHA4 0.27* 30PLCT4 0.20* 
30PLCL5 0.51* 30PLHA5 0.44* 30PLCT5 0.20* 
 
x - Sample insufficient or non-existent; *- out of calibration curve. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PL - plasma; 
- the two second letters correspond to the drug: CL – Clozapine, HA – Haloperidol and CT - Control; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
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Table 8.18- Contamination of clozapine in plasma samples. Clozapine quantification in plasma samples of 
clozapine, haloperidol and control. 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
01PLCI1 x 01PLHA1 * 01PLCT1 * 
01PLCI2 x 01PLHA2 * 01PLCT2 * 
01PLCI3 * 01PLHA3 * 01PLCT3 * 
01PLCI4 * 01PLHA4 x 01PLCT4 * 
01PLCI5 * 01PLHA5 0.50* 01PLCT5 * 
02PLCI1 * 02PLHA1 0.21* 02PLCT1 * 
02PLCI2 * 02PLHA2 * 02PLCT2 * 
02PLCI3 * 02PLHA3 0.32* 02PLCT3 * 
02PLCI4 * 02PLHA4 0.22* 02PLCT4 * 
02PLCI5 * 02PLHA5 * 02PLCT5 x 
04PLCI1 * 04PLHA1 0.01* 04PLCT1 x 
04PLCI2 * 04PLHA2 * 04PLCT2 * 
04PLCI3 * 04PLHA3 * 04PLCT3 * 
04PLCI4 * 04PLHA4 * 04PLCT4 * 
04PLCI5 * 04PLHA5 x 04PLCT5 * 
08PLCI1 0.95 08PLHA1 x 08PLCT1 0.77* 
08PLCI2 x 08PLHA2 1.96 08PLCT2 * 
08PLCI3 1.46 08PLHA3 x 08PLCT3 0.72* 
08PLCI4 0.66* 08PLHA4 2.27 08PLCT4 0.38* 
08PLCI5 1.34 08PLHA5 1.59 08PLCT5 0.21* 
15PLCI1 0.20 15PLHA1 0.10* 15PLCT1 * 
15PLCI2 0.12 15PLHA2 * 15PLCT2 * 
15PLCI3 * 15PLHA3 0.48* 15PLCT3 * 
15PLCI4 * 15PLHA4 0.89 15PLCT4 * 
15PLCI5 * 15PLHA5 x 15PLCT5 * 
30PLCI1 * 30PLHA1 1.34 30PLCT1 0.82 
30PLCI2 * 30PLHA2 0.45* 30PLCT2 0.08* 
30PLCI3 0.20* 30PLHA3 1.08 30PLCT3 * 
30PLCI4 0.02* 30PLHA4 0.03* 30PLCT4 0.25* 
30PLCI5 0.24* 30PLHA5 0.29* 30PLCT5 0.08* 
 
x - Sample insufficient or non-existent; *- out of calibration curve. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PL - plasma; 
- the two second letters correspond to the drug: CI – Citalopram, HA – Haloperidol and CT - Control; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
 
 
 
142 |APPENDIX 
 
Table 8.19- Contamination of haloperidol in plasma samples. Haloperidol quantification in plasma 
samples of citalopram, clozapine and control. 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
Label 
Concentration 
(pg/μL) 
01PLCI1 x 01PLCL1 0.07* 01PLCT1 0.13* 
01PLCI2 x 01PLCL2 0.04* 01PLCT2 0.04* 
01PLCI3 0.04* 01PLCL3 ND 01PLCT3 0.06* 
01PLCI4 ND 01PLCL4 ND 01PLCT4 0.05* 
01PLCI5 0.05* 01PLCL5 x 01PLCT5 0.06* 
02PLCI1 ND 02PLCL1 x 02PLCT1 0.05* 
02PLCI2 ND 02PLCL2 x 02PLCT2 0.04* 
02PLCI3 0.04* 02PLCL3 0.05* 02PLCT3 0.02* 
02PLCI4 ND 02PLCL4 ND 02PLCT4 0.06* 
02PLCI5 ND 02PLCL5 ND 02PLCT5 x 
04PLCI1 0.05* 04PLCL1 x 04PLCT1 x 
04PLCI2 0.06* 04PLCL2 ND 04PLCT2 0.04* 
04PLCI3 ND 04PLCL3 ND 04PLCT3 0.03* 
04PLCI4 0.04* 04PLCL4 ND 04PLCT4 0.09* 
04PLCI5 0.05* 04PLCL5 ND 04PLCT5 0.02* 
08PLCI1 0.55* 08PLCL1 x 08PLCT1 0.37* 
08PLCI2 x 08PLCL2 0.40* 08PLCT2 0.16* 
08PLCI3 0.58* 08PLCL3 x 08PLCT3 0.57* 
08PLCI4 0.52* 08PLCL4 0.24* 08PLCT4 0.31* 
08PLCI5 0.68 08PLCL5 0.34* 08PLCT5 0.34* 
15PLCI1 0.09* 15PLCL1 x 15PLCT1 0.10* 
15PLCI2 0.12* 15PLCL2 0.14* 15PLCT2 0.07* 
15PLCI3 0.17* 15PLCL3 0.07* 15PLCT3 0.14* 
15PLCI4 0.10* 15PLCL4 ND 15PLCT4 0.08* 
15PLCI5 0.13* 15PLCL5 x 15PLCT5 0.11* 
30PLCI1 ND 30PLCL1 ND 30PLCT1 ND 
30PLCI2 ND 30PLCL2 ND 30PLCT2 ND 
30PLCI3 ND 30PLCL3 ND 30PLCT3 0.03* 
30PLCI4 ND 30PLCL4 ND 30PLCT4 ND 
30PLCI5 ND 30PLCL5 ND 30PLCT5 ND 
 
ND - Not detected; x - Sample insufficient or non-existent; *- out of calibration curve. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PL - plasma; 
- the two second letters correspond to the drug: CI - Citalopram, CL – Clozapine and CT - Control; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
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Appendix 8.10: Data related of the contamination of hair samples. 
 
Table 8.20- Contamination of citalopram in hair samples. Citalopram quantification in hair samples of 
clozapine, haloperidol and control. 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
01PECL1 ND 01PEHA1 ND 01PECT1 ND 
01PECL2 ND 01PEHA2 ND 01PECT2 ND 
01PECL3 ND 01PEHA3 ND 01PECT3 ND 
01PECL4 ND 01PEHA4 ND 01PECT4 ND 
01PECL5 ND 01PEHA5 ND 01PECT5 ND 
02PECL1 ND 02PEHA1 ND 02PECT1 ND 
02PECL2 ND 02PEHA2 ND 02PECT2 ND 
02PECL3 ND 02PEHA3 ND 02PECT3 ND 
02PECL4 ND 02PEHA4 ND 02PECT4 ND 
02PECL5 x 02PEHA5 ND 02PECT5 ND 
04PECL1 * 04PEHA1 ND 04PECT1 ND 
04PECL2 x 04PEHA2 ND 04PECT2 0.27* 
04PECL3 0.01* 04PEHA3 ND 04PECT3 x 
04PECL4 ND 04PEHA4 ND 04PECT4 ND 
04PECL5 ND 04PEHA5 ND 04PECT5 ND 
08PECL1 0.01* 08PEHA1 ND 08PECT1 ND 
08PECL2 #VALOR! 08PEHA2 ND 08PECT2 * 
08PECL3 0.01* 08PEHA3 ND 08PECT3 * 
08PECL4 0.04* 08PEHA4 ND 08PECT4 ND 
08PECL5 0.12* 08PEHA5 ND 08PECT5 0.01* 
15PECL1 x 15PEHA1 NQ 15PECT1 0.02* 
15PECL2 ND 15PEHA2 NQ 15PECT2 ND 
15PECL3 0.016* 15PEHA3 ND 15PECT3 ND 
15PECL4 ND 15PEHA4 ND 15PECT4 ND 
15PECL5 ND 15PEHA5 0.016
#
 15PECT5 ND 
30PECL1 x 30PEHA1 x 30PECT1 x 
30PECL2 0.011* 30PEHA2 NQ 30PECT2 ND 
30PECL3 0.036* 30PEHA3 ND 30PECT3 ND 
30PECL4 0.024* 30PEHA4 ND 30PECT4 ND 
30PECL5 x 30PEHA5 ND 30PECT5 ND 
 
ND - Not detected; x - Sample insufficient or non-existent; *- out of calibration curve. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PE - hair; 
- the two second letters correspond to the drug: CL – Clozapine, HA – Haloperidol and CT - Control; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
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Table 8.21- Contamination of clozapine in hair samples. Clozapine quantification in hair samples of 
citalopram, haloperidol and control. 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
01PECI1 ND 01PEHA1 ND 01PECT1 ND 
01PECI2 ND 01PEHA2 ND 01PECT2 ND 
01PECI3 ND 01PEHA3 ND 01PECT3 ND 
01PECI4 ND 01PEHA4 ND 01PECT4 ND 
01PECI5 ND 01PEHA5 ND 01PECT5 ND 
02PECI1 ND 02PEHA1 ND 02PECT1 ND 
02PECI2 ND 02PEHA2 ND 02PECT2 ND 
02PECI3 ND 02PEHA3 ND 02PECT3 ND 
02PECI4 ND 02PEHA4 ND 02PECT4 ND 
02PECI5 ND 02PEHA5 ND 02PECT5 ND 
04PECI1 ND 04PEHA1 ND 04PECT1 ND 
04PECI2 ND 04PEHA2 ND 04PECT2 NQ 
04PECI3 ND 04PEHA3 ND 04PECT3 x 
04PECI4 ND 04PEHA4 ND 04PECT4 ND 
04PECI5 ND 04PEHA5 ND 04PECT5 ND 
08PECI1 ND 08PEHA1 ND 08PECT1 ND 
08PECI2 ND 08PEHA2 ND 08PECT2 ND 
08PECI3 ND 08PEHA3 ND 08PECT3 ND 
08PECI4 ND 08PEHA4 ND 08PECT4 ND 
08PECI5 ND 08PEHA5 ND 08PECT5 ND 
15PECI1 ND 15PEHA1 ND 15PECT1 ND 
15PECI2 ND 15PEHA2 ND 15PECT2 ND 
15PECI3 ND 15PEHA3 ND 15PECT3 ND 
15PECI4 ND 15PEHA4 ND 15PECT4 ND 
15PECI5 ND 15PEHA5 ND 15PECT5 ND 
30PECI1 x 30PEHA1 x 30PECT1 x 
30PECI2 ND 30PEHA2 NQ 30PECT2 ND 
30PECI3 ND 30PEHA3 NQ 30PECT3 ND 
30PECI4 ND 30PEHA4 ND 30PECT4 ND 
30PECI5 ND 30PEHA5 ND 30PECT5 ND 
 
ND - Not detected; NQ - Detected but not quantified; x - Sample insufficient or non-existent. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PE - hair; 
- the two second letters correspond to the drug: CI – Citalopram, HA – Haloperidol and CT - Control; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
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Table 8.22- Contamination of haloperidol in hair samples. Haloperidol quantification in hair samples of 
citalopram, clozapine and control. 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
Label 
Concentration 
(ng/mg) 
01PECI1 ND 01PECL1 ND 01PECT1 ND 
01PECI2 ND 01PECL2 ND 01PECT2 ND 
01PECI3 ND 01PECL3 ND 01PECT3 ND 
01PECI4 ND 01PECL4 ND 01PECT4 ND 
01PECI5 ND 01PECL5 ND 01PECT5 ND 
02PECI1 ND 02PECL1 ND 02PECT1 ND 
02PECI2 ND 02PECL2 ND 02PECT2 0.01* 
02PECI3 ND 02PECL3 ND 02PECT3 ND 
02PECI4 ND 02PECL4 ND 02PECT4 ND 
02PECI5 ND 02PECL5 x 02PECT5 ND 
04PECI1 ND 04PECL1 ND 04PECT1 ND 
04PECI2 ND 04PECL2 x 04PECT2 0.18* 
04PECI3 ND 04PECL3 ND 04PECT3 x 
04PECI4 ND 04PECL4 ND 04PECT4 0.06* 
04PECI5 ND 04PECL5 ND 04PECT5 0.02* 
08PECI1 ND 08PECL1 ND 08PECT1 ND 
08PECI2 ND 08PECL2 ND 08PECT2 0.02* 
08PECI3 ND 08PECL3 ND 08PECT3 0.03* 
08PECI4 ND 08PECL4 ND 08PECT4 0.41 
08PECI5 ND 08PECL5 ND 08PECT5 0.03* 
15PECI1 ND 15PECL1 x 15PECT1 ND 
15PECI2 ND 15PECL2 ND 15PECT2 ND 
15PECI3 ND 15PECL3 ND 15PECT3 ND 
15PECI4 ND 15PECL4 ND 15PECT4 ND 
15PECI5 ND 15PECL5 ND 15PECT5 ND 
30PECI1 x 30PECL1 x 30PECT1 x 
30PECI2 0.03* 30PECL2 ND 30PECT2 ND 
30PECI3 0.04* 30PECL3 ND 30PECT3 ND 
30PECI4 0.04* 30PECL4 ND 30PECT4 ND 
30PECI5 ND 30PECL5 x 30PECT5 ND 
 
ND - Not detected; NQ - Detected but not quantified; x - Sample insufficient or non-existent. 
Label: 
- the two first numbers correspond to the different days: 1, 2, 4, 8, 15,30; 
- the two first letters correspond to the matrix: PE - hair; 
- the two second letters correspond to the drug: CI – Citalopram, CL – Clozapine and CT – Control; 
- the last number correspond to the animal replicate: 1, 2, 3, 4 and 5. 
 
 
 
